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Definitions/Abbreviations 
 
11β-HSD  11 β-hydroxysteroid dehydrogenase 
24h QP  24h quantified total proteinuria 
ACE  Angiotensin converting enzyme 
ACEi  Angiotensin converting enzyme inhibitor 
ACR  Albumin to creatinine ratio 
ACTH  Adrenocorticotrophic hormone 
AIx  Augmentation index 
AIx@75bpm  Augmentation index normalised to 75bpm 
Aldo  Aldosterone 
ANOVA  Analysis of variance 
APKD  Adult polycystic kidney disease 
ARB  Angiotensin receptor blocker 
ARR  Aldosterone to renin ratio 
BBl  Beta blocker therapy 
BMI  Body mass index 
BNP  Brain natriuretic peptide 
BSA  Body surface area 
C&G  Cockcroft and Gault 
C1  Collagen 1 
CCB  Calcium channel blocker 
Chol:HDL  Cholesterol to high density lipoprotein ratio 
CKD  Chronic kidney disease 
CMR  Cardiac magnetic resonance imaging 
Cort metab  Cortisol metabolites 
Cr  Creatinine   
CrCl  Creatinine clearance 
CRH  Corticotrophin releasing hormone 
CRP  C-reactive protein 
CT  Threshold cycle 
CV  Cardiovascular 
DBP  Diastolic blood pressure 
DMN  Diabetic nephropathy 
DOC  Deoxycorticosterone 
DOCA  Deoxycorticosterone acetate  
E  Cortisone 
ECG  Electrocardiogram 
Echo  Echocardiogram 
ED  End diastole  17 
EDV  End diastolic volume 
eGFR  Estimated glomerular filtration rate 
EH  Essential hypertension 
ELISA  Enzyme linked immunosorbent assay 
ENaC  Epithelial sodium channel 
ERK  Extracellular signal-related kinases 
ESRD  End stage renal disease 
ESV  End systolic volume 
F  Cortisol   
FBS  Fetal bovine serum 
FENa  Fractional excretion of sodium 
FMD  Flow mediated dilatation 
GM-CSF  Granulocyte macrophage colony stimulating factor 
GN  Glomerulonephritis 
Hb  Haemoglobin 
HDL  High density lipoprotein 
HK-2  Human kidney 2 cells 
HLA  Horizontal long axis 
HR  Heart rate 
Ig  Immunoglobulin 
IgAN  IgA nephropathy 
IHD  Ischaemic heart disease 
IL  Interleukin 
K  Potassium 
LDL  Low density lipoprotein 
LPS  Lipopolysaccharide 
LV   Left ventricle  
LVMI  Left ventricular mass index 
LVOT  Left ventricular outflow tract 
LVSD  Left ventricular systolic dysfunction 
MAP  Mean arterial pressure 
MC  Mineralocorticoid 
MC  Myocardial 
MDRD  Modification of diet in renal disease  
MGN  Membranous nephropathy 
mmHg  Millimetres of mercury 
MR  Mineralocorticoid receptor 
MRB  Mineralocorticoid receptor blocker 
MRI  Magnetic resonance imaging  
NO  Nitric oxide 
PAC  Plasma aldosterone concentration 18 
PAT  Peripheral artery tone 
PCR  Polymerase chain reaction 
PO4  Phosphate 
PP  Pulse pressure 
PRC  Plasma renin concentration 
PTH  Parathyroid hormone 
PWA  Pulse wave analysis 
PWV  Pulse wave velocity 
RAAS  Renin-angiotensin-aldosterone system 
REC  Research ethics committee 
RF  Radiofrequency 
RHI  Reactive hyperaemia index 
RIA  Radioimmunoassay 
ROMK  Renal outer medullary potassium channel 
RRT  Renal replacement therapy 
SA  Short axis 
SBP  Systolic blood pressure 
Statin  HMG Co-A reductase inhibitor 
TG   Triglyceride 
TGFβ  Transforming growth factor beta 
THAldo  Tetrahydroaldosterone 
THDOC  Tetrahydrodeoxycorticosterone 
UNa  24h Urinary sodium excretion 
UNa:Cr  Urinary sodium to creatinine ratio 
uPCR  Urinary protein to creatinine ratio  
UPot  Urinary potassium excretion  
UPr   Urinary protein excretion 
VLA  Vertical long axis 
WNK  With-no-K[Lys] protein kinases  
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Summary  
Chronic kidney disease is common and associated with an elevated cardiovascular risk, as 
well as the long-term risk of renal failure. At present, therapeutic approaches to managing 
chronic kidney disease (CKD) do not fully reverse these risks. This has led to study of the 
determinants of pathological outcomes in these patients, with the hope of further 
therapeutic interventions to reduce these risks.  
Mineralocorticoids, predominantly aldosterone, are produced by the adrenal cortex and 
have a vital role in maintaining sodium status and blood pressure. However, high levels of 
aldosterone in humans are known to produce an adverse phenotype of hypertension and a 
disproportionately elevated cardiovascular risk. Furthermore, in animal models of renal 
failure, elevated aldosterone levels stimulate renal damage, in the presence of a high 
sodium milieu. These laboratory findings have been translated to provide a basis for 
several short-term follow-up clinical trials looking at the impact of non-genomic non-
natriuretic doses of mineralocorticoid receptor inhibition in patients with chronic kidney 
disease. These studies have shown a reduction in proteinuria, often independent of decline 
in blood pressure. However, there is a paucity of baseline physiological data relating to the 
normal regulation of mineralocorticoid synthesis and action in chronic kidney disease. The 
response of the adrenal cortex to renal failure is not understood. Is mineralocorticoid 
synthesis regulated in the usual way? Are the stimulators of mineralocorticoid production 
and release affected by uraemia? Is dietary sodium intake associated with steroid status and 
adverse outcomes in humans?  
The hypothesis of this thesis was that the renin-angiotensin-aldosterone system is 
inappropriately activated in patients with chronic kidney disease. Secondly, that high levels 
of mineralocorticoids are associated with adverse end-organ damage including proteinuria 
excretion, left ventricular hypertrophy, endothelial dysfunction, elevated pulse wave 
velocity and markers of renal fibrosis. Furthermore, that these deleterious effects are 
associated with sodium status and that an elevated dietary sodium intake is independently 
associated with increased renal and cardiovascular risk. In order to test these hypotheses, 
70 patients with CKD and 30 patients with essential hypertension (EH) were recruited and 
underwent detailed clinical and biochemical phenotyping. This included 24 hour urinary 
steroid metabolite analysis, plasma renin and aldosterone measurement, cardiac magnetic 
resonance imaging, carotid-femoral pulse wave velocity and assessment of endothelial 
function.  20 
It was shown that levels of the main mineralocorticoids (MC) (aldosterone and 
deoxycorticosterone) are not elevated in patients with CKD, as compared with patients 
with essential hypertension (EH). However, the determinants of levels of MC excretion 
differed between the two conditions. In CKD, excretion of MC metabolites was directly 
proportional to excretion of urinary sodium. A high urinary sodium (a marker of dietary 
sodium intake) was associated with a higher excretion of tetrahydroaldosterone (THALDO 
- the main aldosterone metabolite). In patients with EH, no relationship was seen between 
urinary steroid excretion and urinary sodium excretion. This is a novel relationship 
between the kidney and adrenal gland which questions the conventional wisdom that the 
adrenal cortex is unaffected by uraemia and prompts further study into the regulation of 
steroid synthesis in CKD.  
Furthermore, it was shown for the first time that 24h excretion of 
tetrahydrodeoxycorticosterone (THDOC) is an independent predictor of left ventricular 
mass index and that THALDO is an independent predictor of proteinuria excretion – 
demonstrating a relationship between mineralocorticoids and two of the main predictors of 
mortality in CKD. An interaction between sodium, MCs and these two features was also 
demonstrated.  
No association between levels of mineralocorticoids and vascular function was seen. 
Urinary 24 hour excretion of sodium was significantly associated with endothelial 
dysfunction in patients with CKD and pulse wave velocity in patients with essential 
hypertension.   
Retrospective data analysis further confirmed an association between a high dietary 
sodium intake and adverse outcomes. In a study of 498 patients with CKD and a median 
follow-up of 7 years, an elevated 24h urinary sodium to creatinine ratio was shown to be 
associated with an increased risk of death. There was however no independent association 
with renal progression or requirement for renal replacement therapy. This is the first time 
that sodium intake has been clearly linked to adverse outcomes in patients with CKD. 
Lastly, laboratory work demonstrated that steroid stimulation (aldosterone or cortisol) of 
human proximal tubular cells resulted in increased collagen 1 gene expression, but only in 
the context of a high sodium environment. Collagen 1 is deposited in renal interstitial 
fibrosis. This effect was inhibited by MR blockade, further expanding on the potential role 21 
of steroids in the progression of CKD and again confirming the relationship between salt 
and steroids. 
In conclusion, in this thesis it has been demonstrated that production of MCs in patients 
with CKD is closely associated with urinary sodium excretion (a surrogate for dietary 
sodium intake). This relationship is novel and not seen in patients with essential 
hypertension. It suggests that the response of the adrenal cortex in the context of uraemia is 
altered.  Moreover, levels of mineralocorticoids are independently associated with left 
ventricular mass index and proteinuria excretion, both significant predictors of mortality, 
in patients with CKD. Dietary sodium intake has been shown to be an independent 
predictor of mortality and laboratory studies have demonstrated that mineralocorticoid 
receptor binding in a high sodium environment is associated with collagen 1 gene 
upreguation. These findings have important implications for the role of adequate renin-
angiotensin-aldosterone blockade in patients with CKD and suggest that the addition of a 
mineralocorticoid receptor blocker and dietary sodium restriction should be advocated. 
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1  Chapter One - Introduction 23 
1.1  General introduction 
In this thesis, hypotheses relating to adrenal steroid metabolism and function in the context 
of chronic kidney disease will be addressed. The relationship between steroid levels and 
negative prognostic features including left ventricular hypertrophy, proteinuria, pulse wave 
velocity, endothelial dysfunction and inflammatory marker production will be examined. 
The role of sodium in pathophysiological outcomes, both as an independent feature and in 
the context of steroid levels will also be discussed. 
In this introduction, the burden of chronic kidney disease and current therapeutic 
approaches will be discussed in section 1.2. Sodium homeostasis and the role of sodium in 
blood pressure control are discussed in section 1.3, in conjunction with evidence that a 
high sodium intake has adverse consequences. Adrenal steroid production (section 1.4) and 
consequences of mineralocorticoid excess in humans (section 1.5); in vivo (section 1.6) 
and in vitro (section 1.7) are further discussed. Section 1.8 describes left ventricular 
abnormalities in CKD- measurement and determinants; whilst section 1.9 describes 
abnormalities in the vasculature. Section 1.10 describes the aims of the thesis and section 
1.11 summarises the hypotheses generated. 
The influences of many systems on the body’s electrolyte (sodium and potassium) status 
results in equilibrium, the disturbance of which would alter electrolyte and blood pressure 
homeostasis, often with clinically significant consequences. Prominent among these 
regulating systems are a number of aspects of corticosteroid metabolism.  
1.  Aldosterone is a product of the adrenal zona glomerulosa. It acts on 
sodium/potassium transporting epithelia via a nuclear receptor (the mineralocorticoid 
receptor: MR) and promotes sodium ion excretion in exchange for potassium and 
hydrogen ions, as well as having direct actions on other tissues. Excess secretion results 
in hypokalaemia, increased exchangeable sodium, metabolic alkalosis and hypertension. 
This is further discussed in sections 1.4 to 1.7. 
2.  Deoxycorticosterone (DOC) is principally a product of the adrenal zona fasciculata 
and is capable of acting as a mineralocorticoid. In normal human subjects, its secretion 
rate and plasma concentration are very low and little is known of its role, although it can 
become more abundant in some rare genetic diseases. It has frequently been used 
experimentally to model mineralocorticoid hypertension. New information on its 24 
metabolism may alter assessment of its role. This is expanded upon in sections 1.4 and 
1.6.3. 
3.  Cortisol exerts a potent influence on blood pressure by a variety of mechanisms 
Most relevant to this study, it is potentially a potent mineralocorticoid, binding with 
high affinity to the MR. This is normally prevented by the enzyme, 11β-hydroxysteroid 
dehydrogenase type 2 (11βHSD2) which oxidises cortisol to inactive cortisone. Genetic 
disruption of the gene for the enzyme leads to a severe mineralocorticoid hypertension. 
Other important indices used in this study are the levels of cortisol, cortisone, their 
respective metabolites and the relation between them (see sections 1.4.7, 1.4.8, 1.4.11). 
1.2  CKD   
1.2.1  Chronic kidney disease: risk, prevalence and consequence 
Chronic kidney disease (CKD) is common, being present in 5-10% of the population(1;2) 
(Figure 1a), increasing markedly with age.  Patients with CKD are at risk of progression to 
end stage renal disease (ESRD), requiring dialysis or kidney transplantation. Once patients 
have developed ESRD, their cardiovascular mortality is increased by 20-100 fold that of 
age matched individuals from the general population(3) (Figure 1b). Furthermore, 
provision of dialysis treatment costs approximately £30-35,000 per patient annually(4). 
Renal transplantation is a successful treatment of ESRD but requires a suitable kidney 
donor and only one third of patients with ESRD will be fit enough to undergo the renal 
transplant operation. There is a shortage of cadaveric organs with each patient waiting 
approximately 3 years prior to receiving a suitable organ. Therefore prevention of 
progression of CKD is desirable for individuals as well as for society.   25 
 
Figure 1-1: Chronic kidney disease prevalence and association with cardiovascular events. 
A - Population prevalence of chronic kidney disease by stage. Data derived from Northern Europe and 
North America (2).  B - Age standardised rate of cardiovascular events according to stage of chronic 
kidney disease (5). 26 
The increased cardiovascular risk associated with CKD, not yet treated with dialysis, may 
reflect a clustering of cardiovascular risk factors (smoking, hypertension, hyperlipidaemia) 
but likely also relates to factors specific to kidney disease such as endothelial dysfunction, 
hyperhomocysteinaemia and oxidative stress(6). The presence of proteinuria is an 
additional independent risk factor for cardiovascular disease(7), even within the normal 
range(8). It may reflect glomerular dysfunction or endothelial dysfunction at the 
glomerular basement membrane.   
1.2.2  Staging of chronic kidney disease 
The stages of CKD are based on the glomerular filtration rate (measured or estimated). 
There are five stages, with stage 1 patients having normal excretory function and stage 5 
being severely impaired renal function or the requirement for renal replacement therapy. 
The addition of a p suffix relates to the presence of significant proteinuria (>1g/d)(9). 
1.2.3  Proteinuria 
Proteinuria and level of renal function at presentation are the two best independent 
predictors of outcome in patients with chronic kidney disease (CKD)(10-13). This is true in 
patients with primary renal disease(14;15) and also in patients with diabetic 
nephropathy(16;17). Proteinuria is also a predictor of mortality in the general population 
(18) as well as in patients with CKD(7). Reducing proteinuria retards progression of renal 
disease(14;19). 
Proteinuria is a largely a reflection of increased glomerular permeability secondary to 
disease, but can also be directly nephrotoxic. The toxic effects of proteinuria are mediated 
at the glomerulus and in the proximal tubule. In vitro, proximal tubular cells stimulated 
with serum proteins (albumin, IgG, transferrin) produce a number of profibrotic and pro-
inflammatory markers at the basolateral membrane including endothelin and IL-8 (20). 
Furthermore, local tubular cells may be overloaded with filtered plasma proteins and signal 
for the recruitment of local macrophages. High molecular weight proteinuria has also been 
associated with proximal tubular cell apoptosis(21).  
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1.2.4  Blood pressure as a risk factor for progression in CKD 
Multiple studies have demonstrated that control of blood pressure is an important 
prognostic indicator in terms of risk of progression of CKD(22). These findings have been 
shown in patients with diabetic nephropathy(23) and in patients with primary renal 
diseases(24). The optimal level of blood pressure control varies depending on the severity 
of proteinuria excretion. Effects are likely to be mediated via a limitation of glomerular 
barotrauma and endothelial dysfunction. 
 
1.2.5  Interstitial fibrosis 
The degree of interstitial fibrosis is the best histological correlate of risk of progressive 
renal disease(25). Whether it arises as a consequence of proteinuria being toxic to the 
proximal tubule, triggering inflammation and fibrosis, or more generalised renal ischaemia 
and glomerular hyperfiltration remains unclear(26).  
 
1.2.6  General management 
Management of patients with renal disease is multi-faceted (27). Treatments include 
symptomatic therapies such as diuretics; dietary interventions such as restricting sodium 
intake; management of secondary complications such as anaemia with erythropoeisis 
stimulating agents; treatment of secondary hyperparathyroidism; management of 
cardiovascular risk with lifestyle advice, anti-platelet therapy and statin treatment and 
treatments with the aim of retarding renal progression. 
Current drug treatments employed in the management of CKD with the aim of retarding 
progression have one of three approaches – blood pressure reduction, inhibition of the 
renin-angiotensin-aldosterone system (RAAS) or immunosuppression. Immunosuppression 
is utilised in a targeted fashion in conditions thought to be primarily immune-mediated 
such as vasculitis. Secondly, antihypertensive agents are utilised with a target blood 
pressure of 140/90mmHg, falling to 130/80mmHg in the presence of more than 1g/day of 
proteinuria(27).  
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1.2.7  RAAS inhibition 
Inhibition of the renin-angiotensin-aldosterone system with inhibitors of the angiotensin 
converting enzyme (ACEi) or blockers of the angiotensin II type 1 receptor (ARB) has 
revolutionised treatment of CKD(28). Beneficial effects on blood pressure do not 
adequately explain the significant benefits seen with these drugs in terms of reduction of 
proteinuria and retardation of progression of kidney disease. (29) The benefits of RAAS 
blockade are most marked in the context of dietary sodium restriction, since relative 
volume depletion results in greater angiotensin II dependence of the glomerular 
microcirculation (30). Other mechanisms of benefit include reduction of inflammation and 
fibrosis via alteration of podocyte behaviour and reduction in TGFβ1(31). 
These agents are primarily indicated in patients with proteinuric renal disease either 
diabetic in origin (RENAAL study – losartan in type 2 DM)(19) (IDNT study – Irbesartan 
in diabetic nephropathy)(32) or non-diabetic (REIN study – ramipril)(33;34). There has 
however been a consistent failure to demonstrate a reduction in cardiovascular risk with 
these agents, despite limiting renal progression, suggesting alternative mechanisms of 
increasing cardiovascular risk are not being addressed via this therapeutic approach, 
leading to the pursuit of novel factors, such as mineralocorticoid blockade.  
 
1.2.8  Mineralocorticoid receptor antagonism 
This will be discussed in-depth in section 4.3. 
 
1.2.9  Diabetic nephropathy 
Diabetic nephropathy, progressive proteinuric kidney disease in the context of type 1 or 
type 2 diabetes, is characterised on light microscopy (Figure 1-2) by nodular 
glomerulosclerosis comprising mesangial expansion, nodule formation, mesangial 
hypercellularity and thickening of the glomerular basement membrane, which stains for 
IgG. (35) Initial pathological changes include a reduction in podocyte number per 
glomerulus, which is predictive of subsequent proteinuria (36), however these changes 
occur prior to the clinical phase of the disease and there are no therapies or investigations 
which are targeted at this.  29 
Known risk factors for developing diabetic nephropathy include hypertension, poor 
glycaemic control, poor lipid control and smoking (37). UKPDS, a randomised trial of 
glycaemic therapy in type 2 diabetes, demonstrated the importance of optimising 
glycaemic control and managing hypertension in delaying onset of diabetic complications, 
including nephropathy(38). There is however evidence that there is genetic clustering of 
diabetic nephropathy in families(39), supporting a multi-factorial basis for the disease. 
Diabetic nephropathy is one of the commonest causes of end stage renal disease in 
Scotland and the incidence is increasing (40). 
 
1.2.10   IgA nephropathy 
IgA nephropathy is a primary glomerular disease whereby there is expansion of the 
mesangium (Figure 1-2) which stains positive for IgA antibody on immunofluorescence. It 
is associated with microscopic haematuria and proteinuria and has a variable progression 
rate, largely determined by blood pressure and levels of proteinuria(24). It is more 
common in men and studies suggest geographical variation in incidence, although this may 
simply reflect biopsy policy(41). It is the commonest primary glomerulopathy in 
Scotland(41). 30 
 
   
   
Figure 1-2: Renal biopsy specimens. 
Upper left panel demonstrates IgA nephropathy with mesangial expansion and hypercellularity. Upper 
right panel demonstrates diabetic nephropathy with nodular glomerulosclerosis. Lower left panel shows 
electron microscopy of a glomerulus with membranous nephropathy and subendothelial immune complex 
deposition. Lower right panel, normal glomerulus seen under light microscopy. 
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1.2.11  Membranous nephropathy 
Membranous nephropathy is the second most common primary glomerulopathy diagnosed 
on native renal biopsy and the commonest primary cause of nephrotic syndrome in 
Scotland(41;42). It is a condition characterised by subendothelial immune complex 
deposition resulting in significant levels of proteinuria. Recent evidence implicates the 
phospholipase A2 receptor in the disease pathogenesis(43). Membranous nephropathy can 
be seen secondary to recognised conditions but after excluding these, the majority of 
patients are found to have idiopathic disease. 
1.3  Sodium 
1.3.1  Normal homeostatic control of sodium excretion 
Sodium is freely filtered at the glomerulus, with filtration depending upon three main 
factors. Firstly, the balance of hydraulic and oncotic pressures, secondly the ultrafiltration 
coefficient (determined by glomerular permeability and total filtration area of glomerular 
capillaries) and lastly the rate of plasma flow through the glomeruli (myogenic 
autoregulation). 
The majority of sodium (70%) is reabsorbed in the proximal tubule via co-transport with 
organic molecules (urea, glucose, amino acids) and via the sodium-hydrogen ion 
exchanger. Active reabsorption occurs in the thick ascending limb via the NKCC2 channel 
(dysfunctional in Bartter’s syndrome) where around 20% is reabsorbed. Five percent is 
reabsorbed in the proximal part of the distal convoluted tubule via the NCC channel 
(dysfunctional in Gitelman’s syndrome) and fine tuning occurs in the collecting ducts via 
the epithelial sodium channel (ENaC) (2-4%). 
Tubuloglomerular feedback is the mechanism whereby increased sodium delivery to the 
macula densa causes a reduction in renin secretion and AgII formation, with an increase in 
afferent arteriolar resistance and reduction in GFR. Changes in arteriolar tone are also 
mediated by vasodilatory factors (e.g. prostaglandins, atrial natriuretic peptide, nitric 
oxide) and vasoconstrictor factors (adenosine, ATP, vasopressin, angiotensin II, 
endothelins and adrenergic factors). Tubular sodium reabsorption is more important than 
GFR in regulating amount of sodium reabsorbed from the nephron, with angiotensin II 
enhancing proximal tubular sodium reabsorption and aldosterone promoting distal tubular 32 
reabsorption(44). When patients are in steady state, urinary sodium excretion reflects 
dietary sodium intake. 
 
1.3.2  Evidence for the role of sodium in blood pressure and kidney disease 
1.3.2.1  Pressure natriuresis curve 
Sodium has a key role in maintaining blood pressure. This is demonstrated by the pressure-
natriuresis relationship, described by Guyton. Equilibrium pressure is the blood pressure 
obtained when the urinary sodium intake equals urinary sodium output (Figure 1-3). If the 
patient’s blood pressure exceeds the equilibrium pressure, urinary sodium excretion is 
enhanced above sodium intake thus normalising blood pressure. This relationship is altered 
in renal failure, where the slope of the renal output curve is steeper due to the reduced renal 
mass, meaning that hypertension in these patients is traditionally salt sensitive i.e. blood 
pressure responds more closely to dietary sodium intake. 33 
 
 
Figure 1-3: The pressure-natriuresis curve.  
Between the mean arterial pressure on the X axis and the urinary sodium excretion rate on the Y axis, 
there is an approximately linear relationship (the renal output curve). When sodium intake is plotted, the 
blood pressure value at the intercept of the two lines is the equilibrium pressure at which the amount of 
sodium excreted in the urine becomes equal to the sodium intake, resulting in net sodium balance(45). 
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1.3.3 Measurement of total body sodium 
Over time various measures have been used to assess sodium intake and total body sodium 
content. Urinary sodium excretion accurately reflects dietary sodium intake. Sodium is the 
predominant extracellular cation and 90% of body sodium is in this compartment. 
Measurement of total body sodium is difficult but a number of physiological studies were 
performed 30-40 years ago using a radioisotope method described by Davies et al to look 
at exchangeable body sodium utilising the 
24Na (T1/2 15h) radioisotope(46). By injecting a 
known quantity of isotope and then sampling the amount of isotope in the blood at 22h, 
adjusting for the amount excreted in the urine, exchangeable sodium can be calculated.  
NaE = (
24Na injected - 
24Na excreted) / (serum 
24Na / serum sodium)  
Muscle, skin, kidney and liver equilibriate with the isotope within an hour. Bone, brain and 
CSF take up to 20h to equilibriate and it is estimated that only around 40% of bone sodium 
equilibriates(47), therefore this method only estimates the amount of metabolically active 
sodium present. 
Newer data, predominantly from Titze et al(48), supports a role for the non-osmotic 
storage of sodium in the skin and lymphatic system, via glycosaminoglycan binding. These 
data have come predominantly from animal studies but also from studying humans. The 
use of MR-spectroscopy to assess body sodium using 
23Na is non-invasive and attractive. 
Titze has validated this method in amputee muscle specimens and it is likely to be 
increasingly utilised, although still as a research tool(49).  
1.3.4 Renin, angiotensin and exchangeable sodium in CKD 
Historical studies demonstrate altered relationships between sodium, renin and blood 
pressure. In normal patients, a highly significant inverse relationship exists between 
exchangeable sodium and plasma renin concentration – a higher sodium is associated with 
a lower PRC. In patients with EH (50;51) a relationship between BP and level of 
exchangeable or plasma sodium was not consistently demonstrated. Furthermore, no 
relationship was consistently demonstrated between BP and renin or angiotensin levels in 
patients with EH.  
In uraemia, total body sodium has been shown to be increased(52). Despite the presence of 
sodium retention and increased exchangeable sodium, plasma renin levels and angiotensin 35 
II have been shown to be inappropriately high and renin failed to suppress normally with 
sodium retention in patients with uraemia (53). 
1.3.5 Population blood pressure / sodium studies 
Previous population studies have established dietary sodium intake to be a key mediator of 
blood pressure(54), with sodium reduction strategies demonstrated to result in a reduction 
in systolic blood pressure of 3 to 5 mmHg(55;56). Subsequent to this, long-term follow-up 
of these cohorts has demonstrated a 25% cardiovascular risk reduction in patients receiving 
a low sodium diet during preceding trial conditions(57). Further population extrapolations 
have suggested that salt-related blood pressure elevation accounts for 14% of strokes and 
9% of myocardial infarctions(58). Damaging effects of dietary sodium on end-organs have 
also been shown in patients with hypertension, including increasing left ventricular mass 
and albuminuria (59) (60;61).  
In patients with non-diabetic nephropathy, reduction in dietary sodium intake (mean 
urinary sodium excretion 106mmol/d versus 184 mmol/d) in addition to ACE inhibition 
reduced proteinuria and blood pressure more effectively than the combination of ACEi and 
ARB (62). As previously noted, inhibition of the RAAS is more effective in the presence 
of sodium reduction. 
1.3.6 Sodium and CKD progression 
Sodium intake is widely believed to influence progression of CKD, independent of effects 
on blood pressure(63). Certainly, a dietary approach to limiting progression would be 
attractive. There is experimental evidence to suggest a direct pathogenic role in renal 
failure(64). Clinical outcome data from cohorts of patients with CKD are sparse. A small 
cohort study from Italy(65) addressed the impact of sodium intake on progression of renal 
disease. They found patients with low urinary sodium excretion to have a lower creatinine 
clearance at baseline, but a slower loss in renal function. In patients with proteinuric 
nephropathy and stable CKD3, a low sodium diet resulted in a reduction in proteinuria 
over a 6 week period, independent of blood pressure which also reduced significantly. 
Aldosterone and renin levels increased during salt restriction(66).  
The potential pathogenic mechanisms explaining sodium mediated vascular and renal 
damage are multiple. Haemodynamic effects mediated via volume retention, resulting in 
increased intraglomerular pressure and increased glomerular filtration are plausible; non-36 
haemodynamic factors such as oxidative stress via superoxide production(67) and 
inflammatory mediators have been widely studied in rat models (68) (69;70).  
Increased expression of the pro-fibrogenic molecule TGF-β1 was seen in Sprague-Dawley 
rats treated for 4 weeks with a high salt diet (8.0% NaCl) compared with those treated with 
a low salt diet (0.3% NaCl)(68), with similar findings in aortic rings subjected to similar 
conditions (71;72). Modulating these effects is eNOS, with a parallel increased expression 
by the endothelium, which inhibits TGF-β1 expression (63). Normotensive and 
hypertensive rats fed a high salt diet developed vascular, glomerular and interstitial 
fibrosis(73). These studies suggest a directly nephrotoxic effect of dietary sodium. 
In the rat anti-Thy 1 model of glomerulonephritis, sodium retention was seen, with reduced 
urinary sodium excretion mediated via a reduction of the sodium hydrogen exchanger type 
3 (NHE3) in the proximal tubule and thick ascending limb of the loop of Henle and 
increased epithelial sodium channel (ENaC) expression in the collecting duct(74). 
1.4  Aldosterone and other adrenal steroids – Humans 
1.4.1  Aldosterone production 
Aldosterone is produced in the zona glomerulosa of the adrenal cortex. It is produced from 
cholesterol which is translocated to the inner mitochondrial membrane by the steroidogenic 
acute regulatory protein (StAR), which is the rate limiting step in steroid hormone 
production. There then follows a series of enzymatic reactions (Figure 1-6) performed by 
dehydrogenases and cytochrome p450 oxidases. The final steps of converting 
deoxycorticosterone to aldosterone are performed by aldosterone synthase, which is 
encoded by the CYP11B2 gene. This enzyme is responsible for 11β-hydroxylation, 18-
hydroxylation and 18-methyloxidation producing corticosterone, 18-hydroxycorticosterone 
and finally aldosterone. 
There has been historical interest in extra-adrenal production of aldosterone in the central 
nervous system, heart and kidney but recent evidence suggests this is unlikely to occur and 
if it does may have little physiological relevance (75). 37 
1.4.2  Physiological effects of aldosterone 
Aldosterone is synthesised by the zona glomerulosa in response to a number of trophins – 
primarily angiotensin II, increased extracellular potassium concentration and adreno-
corticotrophic hormone (76). Intracellular binding of aldosterone (Aldo) to the 
mineralocorticoid receptor (MR) in the distal tubular epithelium of the kidney results in  
translocation of the hormone:receptor complex to the nucleus and transcription of 
aldosterone inducible proteins e.g. serine threonine kinase (SGK1)(77). These in turn result 
in synthesis and translocation of the epithelial sodium channel (ENaC), promoting sodium 
reabsorption, and activation of the renal outer medullary potassium (ROMK) channels, 
extruding potassium into the lumen to maintain electrochemical neutrality. Sodium 
retention promotes water reabsorption and an increase in blood pressure(78). 
1.4.3  Genetic control of aldosterone production  
Aldo production has a heritable component, commonly reported to represent about 30% of 
variability. The C-344T polymorphism in the aldosterone synthase gene (CYP11B2)(79)  
is the most widely studied, with the T allele being associated with increased plasma Aldo 
and THAldo excretion rates. A further polymorphic variation, the intron 2 conversion, 
where intron 2 of the CYP11B2 gene is replaced with the corresponding region of 
CYP11B1, is in tight linkage disequilibrium with C-344T (Figure 1-4). The C-344T and 
intron 2 conversion are more frequent in patients with essential hypertension(80). The 
fundamental effects of these polymorphisms remain incompletely understood. This is 
explored by Connell et al(81). 38 
 
Figure 1-4: The CYP11B2 and CYP11B1 gene orientation (upper panel) and common polymorphisms 
of the CYP11B1 gene (lower panel). 
Reproduced from Kupari et al(82).  39 
1.4.4  Non-traditional role of aldosterone 
Recent findings have widened the understood effects of Aldo to include so called non-
genomic effects, which occur in response to Aldo but are too rapid to be accounted for by 
gene transcription, such as alterations in heart rate or vasoconstriction in response to blood 
loss or postural change (83). 
In classic aldosterone target tissues, aldosterone has non-genomic effects where binding to 
the MR is followed by a rapid increase in intracellular calcium, followed by activation of 
the sodium-hydrogen ion exchanger, alkalinisation of the cell, extrusion of potassium and 
reabsorption of sodium. This process relies on protein kinase C, MAP kinases ERK 1/2 and 
epidermal growth factor(84). Inhibition of ERK 1/2 phosphorylation prevents the rise in 
intracellular calcium and activation of NHE(85). It is generally acceped that non-genomic 
effects of aldosterone often involve the MR and support genomic effects. 
Similarly, aldosterone synthase, the main regulatory enzyme of aldosterone synthesis, has 
been located in tissues out with the adrenal cortex, particularly the vascular endothelium, 
brain and renal cortex, with synthesis occurring mainly in response to tissue damage(86). 
The MR additionally has been localized to the preglomerular vasculature, mesangial cells, 
fibroblasts as well as the distal tubular cells of the nephron(87). Therefore the roles of Aldo 
and the MR are likely to be more far reaching than initially understood. 
1.4.5  Deoxycorticosterone 
Deoxycorticosterone (DOC) is the Aldo precursor and substrate for aldosterone synthase. It 
is produced predominantly by the zona fasciculata of the adrenal gland, but only DOC 
produced in the zona glomerulosa can be used for aldosterone production. It is also formed 
extra-adrenally by 21-hydroxylation of plasma-borne progesterone(88), a mechanism 
which is not subject to negative feedback regulation. It is a weak mineralocorticoid which 
binds the MR with equal affinity to aldosterone but has a twentieth of the power of Aldo in 
terms of retaining sodium (77). Elevated levels of DOC can however be pathogenic(89;90), 
for example in rare patients with congenital adrenal hyperplasia and 11-βhydroxylase 
deficiency, where the DOC measured is predominantly under ACTH control and produced 
in the zona fasciculata. In these patients effects of mineralocorticoid excess (hypertension, 
sodium retention and volume expansion) are seen. Recent studies have also identified a 
DOC specific enzyme (AKR1C3) which converts DOC to an inactive metabolite (20ʱ –
hydroxyl-DOC) to allow MR binding to be restricted to aldosterone in the kidney and 40 
colon(91). It has been postulated that variations in the expression of this enzyme may 
account for differing responses to DOC. 
1.4.6  Adrenocorticotrophic hormone 
The corticotrophin releasing hormone (CRH) – adrenocorticotrophic hormone (ACTH) 
axis has been studied in patients with CKD, with conflicting findings, largely due to 
problems with cortisol assays in renal failure(92). The most recent studies showed that 
baseline cortisol levels did not differ in patients requiring RRT compared with controls but 
there was a trend towards higher ACTH levels. ACTH responded normally to CRH but the 
cortisol response was blunted. The adrenals responded normally to synthetic ACTH 
(synacthen) stimulation(93;94). This suggests that the adrenal cortex responds near 
normally to ACTH stimulation. 
1.4.7  Cortisol 
Cortisol is the major human glucocorticoid. The production of cortisol by the zona 
fasciculata of the adrenal gland is largely controlled by ACTH which binds the promoter 
region of the CYP11B1 gene, altering production of the 11β-hydroxylase enzyme, 
catalysing production of cortisol from 11-deoxycortisol (Figure 1-6). The CYP11B1 and 
CYP11B2 genes are highly homologous, although the promoter regions differ(75). The 
major roles of cortisol are maintaining blood sugar levels, regulating the immune system 
and maintaining blood pressure during physiological stress.  Cortisol and aldosterone have 
equal affinity for the mineralocorticoid receptor but specificity of the MR in the renal 
tubules is maintained by the 11β-HSD2 enzyme which converts cortisol to inactive 
cortisone.    
1.4.8  11-β hydroxysteroid dehydrogenase 
The 11-β hydroxysteroid dehydrogenase enzyme occurs in two main isoforms – type 1 and 
type 2. Type 1 converts inactive cortisone to active cortisol in the liver and adipose tissue 
and is assessed using the ratio of THF (tetrahydrocortisone) to THE (tetrahydrocortisol). It 
is inhibited by carbenoxolone. Type 2 is the enzyme predominantly found in the renal 
collecting tubules and converts active cortisol to inactive cortisone, protecting the 
aldosterone selectivity of the MR (Figure 1-5). The efficiency of this enzyme is assessed 
by measuring the ratio of free cortisone (F) to free cortisol (E). The ratio should measure 
between 2 and 3.  41 
Studies have assessed activity of the 11-beta hydroxysteroid dehydrogenase (11-βHSD) 
enzyme in patients with CKD. In patients on HD, plasma cortisol:cortisone (F:E) and 
THF:THE ratios were increased, compared with controls, suggesting impaired enzyme 
activity(95). Similarly, in nephrotic patients the plasma THF:THE ratio was found to be 
higher than in controls(96). The enzyme of predominant interest in terms of CKD is the 
11βHSD-2 isoform and the urinary F:E ratio is a more accurate measurement of this than 
the THF:THE ratio, which predominantly measures 11BHSD-1 activity(97). When the 
urinary F:E ratio was assessed in 8 nephrotic patients compared with 8 healthy controls 
there was no evidence of impaired enzyme activity(98). Quinkler et al however found that 
the urinary free F:E ratio correlated with level of renal function in patients with CKD(99). 
Sufficient ambiguity therefore exists relating to the function of this enzyme in the context 
of loss of renal function.  42 
 
 
Figure 1-5: Diagramatic illustration of the opposite roles of 11-beta hydroxysteroid dehydrogenase 
isoforms.  
Reproduced from Odermatt(100). 43 
1.4.9  Metabolism and measurement of adrenal steroids 
Metabolism of Aldo is predominantly hepatic, with 35-40% of Aldo in the urine being 
tetrahydroaldosterone (3-ʱ, 5-β -tetrahydroaldosterone) (THAldo), due to metabolism with 
3β-hydroxysteroid dehydrogenase and 3-alpha-hydroxysteroid dehydrogenase, followed by 
conjugation to glucuronic acid. 0.5% of secreted Aldo is free (unconjugated) aldosterone. 
Aldosterone-18-glucuronide is produced by direct conjugation of Aldo, largely in the 
kidney, accounting for 5-10% of Aldo metabolites in urine(101). 
Measurement of urinary metabolites of Aldo over 24h has been shown to provide a more 
accurate representation of Aldo production, as it averages out short term fluctuations 
associated with timing and posture(101). Urinary metabolites of cortisol (THE, THF and 
aTHF) are recorded as a measure of cortisol production. Urinary free cortisol (F) and 
cortisone (E) are considered and the ratio between them as a measure of 11β-HSD2 
enzyme activity. The ratio of 11-deoxycortisol (S) or it’s principal metabolite (THS) to 
cortisol is another index of potential mineralocorticoid activity. 44 
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Figure 1-6: Adrenal steroid synthesis and pathway with dominant urinary metabolites in yellow, 
enzymes in italics and genes in red.  
Metabolites: THDOC = tetrahydrodeoxycorticosterone; THALDO = tetrahydroaldosterone; THS = 
Tetrahydrodeoxycortisol; THF = Tetrahydrocortisol; aTHF = Allotetrahydrocortisol; THE = 
Tetrahydrocortisone. AgII = Angiotensin II; K = Potassium; ACTH = adrenocorticotrophic hormone. 
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1.4.10   Drug and obesity effects on aldosterone levels 
The levels of aldosterone and renin are directly affected by drugs used to treat hypertension 
(Table 1-1). This should be borne in mind when interpreting results. Plasma aldosterone 
concentration (PAC) levels have also been shown to be increased in patients who are 
obese(102), with oxidized fatty acids being thought to stimulate aldosteronogenesis(103). 
Levels are also higher in patients of black origin(104). 
Multiple questions therefore remain relating to the control of mineralocorticoid synthesis 
in the uraemic milieu. Data which inform our understanding of this situation are largely 
historical and relate to patients with significantly impaired renal function. Similarly, 
current clinical practice is greatly influenced by the prescription of medications known to 
interfere with normal levels of mineralocorticoids, and how to understand and interpret this 
in patients with CKD has not been studied. 
 46 
 
Medication class  Aldosterone  Renin 
ACE-inhibitor     
ARB     
Beta-blocker     
Potassium sparing 
diuretic 
   
Potassium wasting 
diuretic 
   
NSAID     
Dihydropyridine calcium 
channel blocker 
   
 
Table 1-1: Effects of medication on measurement of plasma aldosterone and renin(105). 
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1.4.11  Steroid related genetic effects causing hypertension 
A number of rare genetic mutations have been associated with steroid related hypertension. 
These are detailed in Table 1-2. 48 
 
Condition  Mutation  Effect  Treatment 
Liddle’s syndrome  Autosomal 
dominant ENaC 
subunit mutation 
Impaired ENaC 
degradation with 
enhanced Na 
reabsorption, 
hypertension, low PRC, 
low PAC, hypokalaemia, 
metabolic alkalosis 
Amiloride 
Glucocorticoid-
remediable 
aldosteronism 
Chimeric gene 
formed from 
CYP11B1 and 
CYP11B2 – 
autosomal 
dominant 
Hyperaldosteronism 
secondary to ACTH 
sensitive aldosterone 
production in the zona 
fasciculata 
Dexamethasone 
Syndrome of 
apparent 
mineralocorticoid 
excess (SAME) 
11ʱ-hydroxysteroid 
dehydrogenase 
type 2 mutation 
Cortisol:MR binding and 
clinical mineralocorticoid 
excess 
Carbenoxolone 
and liquorice 
Congenital adrenal 
hyperplasia 
11β-hydroxylase 
deficiency due to 
CYP11B1 mutation 
Impaired cortisol 
production, androgen 
excess, ACTH and DOC 
excess 
Replacement 
Congenital adrenal 
hyperplasia 
17ʱ-hydroxylase 
deficiency - CYP17 
mutation 
Hyporeninaemia, 
hypoaldosteronism, 
hypokalaemia, 
hypocortisolaemia, absent 
secondary sexual 
characteristics. DOC 
excess. 
Replacement 
Gordon’s 
syndrome 
Autosomal 
dominant WNK 
gene mutation 
Pseudohypoaldosteronism 
type 2 – hypertension, 
hyperkalaemia and 
acidosis. Increased NCC 
activity 
Thiazide diuretic 
Table 1-2: Steroid biosynthesis defects associated with hypertension. 
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1.5  Role of aldosterone in hypertension and kidney disease 
1.5.1  Aldosterone and hypertension 
Hypertension is a key determinant of cardiovascular risk and progression of renal 
dysfunction(87;106;107). Aldo contributes to the development of hypertension in the 
general population. In the Framingham offspring study(108), variation in Aldo levels 
across the normal physiological range accounted for change in blood pressure over a five 
year period and development of hypertension. Additionally, in up to 15% of hypertensive 
patients, excessive Aldo levels, in relation to renin, defined by a raised ratio of aldosterone 
to renin (ARR) is described(109). Evidence of excessive Aldo production is found in up to 
20% of patients with resistant hypertension(110). However, although high blood pressure 
is very common in patients with CKD, the role of Aldo in these patients in raising blood 
pressure and contributing to progression of renal dysfunction is unknown.  
1.5.2  Risks associated with hyperaldosteronism 
Patients with primary aldosteronism have significantly worse cardiovascular outcomes 
than matched essential hypertensive subjects(111). Additionally, Aldo levels are directly 
correlated with adverse outcomes after myocardial infarction(112). There is also evidence 
that higher Aldo levels within the normal range, as well as proven hyperaldosteronism, in 
the context of hypertension, are associated with microalbuminuria(113). Whether this 
reflects endothelial dysfunction secondary to oxidative stress, or a consequence of 
hyperfiltration due to direct Aldo effects on the pre and post glomerular arterioles is 
controversial(114). Patients with hypertension secondary to hyperaldosteronism initially 
demonstrate a sharp decline in glomerular filtration rate with treatment, which stabilises 
after 6 months and thereafter renal decline does not differ between patients with 
hyperaldosteronism and essential hypertensives(114;115). The initial sharp reduction is 
thought to represent a reversal of hyperfiltration.  
Isolated hyperaldosteronism does not appear to be pathogenic in itself, in the context of a 
low dietary sodium intake and high potassium intake. This is exemplified by studies on 
Yanomamo Indians, where their primitive lifestyle and rudimentary diet results in high 
aldosterone production but low blood pressure and minimal cardiovascular disease(116). 50 
1.5.3  Aldosterone and the kidney – adverse effects in humans  
One recent study, in hypertensive humans with normal kidney function, demonstrated a 
relationship between Aldo, sodium excretion and urinary protein excretion, with 
proteinuria being greatest in subjects with both high Aldo levels and high urinary sodium 
excretion(117). An analysis of the Framingham cohort(118) demonstrated an association 
between high urinary sodium and urinary protein excretion and high serum Aldo and 
protein excretion, but no interaction between the two. Bianchi demonstrated a relationship 
between plasma aldosterone concentration and proteinuria excretion(119). However, there 
are no studies in man that have examined the relationship between Aldo and sodium status 
and proteinuria in patients with CKD. 
1.5.4  Mineralocorticoid levels and the adrenal axis in chronic kidney 
disease 
Traditionally it has been accepted that the plasma Aldo concentration rises in renal failure. 
Findings from a small historical cohort showed that once creatinine clearance falls below 
60ml/min(120) the aldosterone : renin ratio (ARR) rises (Figure 1-7). The main statistically 
significant increase in plasma Aldo concentration (PAC) was however seen in patients with 
a creatinine clearance between 3-10ml/min and the wide scatter at this level suggests the 
effect is not uniform. 51 
 
 
Figure 1-7 Relationship between the aldosterone:renin ratio and creatinine clearance(120). 
Aldosterone : renin ratio derived from upright early morning samples in patients with CKD and controls.  52 
Berl et al in 1978 assessed 8 patients with CrCl <15ml/min and found PAC to be above the 
reference range for the assay in 5 out of the 8. They also found that  patients responded 
normally to alterations in posture and sodium restriction(121), suggesting the cortex 
responds appropriately. In patients on haemodialysis, one study showed 50% of patients 
had an elevated PAC but this was not associated with a worse mortality(122).  
Previous studies predominantly utilise plasma measures, but a more recent study assessed 
plasma and urinary Aldo levels in patients with CKD 3 and low levels of proteinuria on 
ACEi / ARB therapy. They found PAC correlated negatively with eGFR but found no 
association between eGFR and THAldo excretion. As metabolism of Aldo is 
predominantly hepatic, with principal circulating metabolites being inactive, increased 
PAC or THALDO levels should not relate to reduced renal function. 
1.5.5  Mineralocorticoid receptor blockade in humans – delaying 
progression of renal disease 
Evidence that existing therapies delay progression or prevent cardiovascular complications 
in renal disease is limited. In patients with diabetic nephropathy and primary 
glomerulopathies, agents which block the RAAS reduce the rate of progression to end 
stage renal disease(19). However, there are patients in whom this treatment has no effect, 
or the effect of ACE inhibition or ARBs is not complete and patients continue to progress. 
The addition of one drug to the other has additional antiproteinuric effects; however 
whether the failure of monotherapy to be effective is due to insufficient drug dose, to non-
angiotensin converting enzyme generation of angiotensin II or breakthrough of Aldo 
production is unclear (123). ‘Aldosterone breakthrough’, i.e. inappropriate elevation of 
serum Aldo levels in the context of blockade of the renin-angiotensin system, has been 
estimated to occur in up to 40% of patients and has been associated with more rapid 
decline in renal function in patients with nephropathy(124). This has contributed to interest 
in MR blockade as a potential target for inhibiting renal progression. 
Mineralocorticoid receptor blockers (MRBs) include spironolactone and eplerenone. 
Spironolactone is a synthetic steroid which competitively inhibits intracellular MR:Aldo 
binding in the distal convoluted tubule. It also has anti-androgen activity by binding the 
androgen receptor, leading to gynaecomastia in men. Eplerenone is similar to 
spironolactone but is more selective and does not have the anti-androgen effects. 53 
MRBs have been shown to significantly reduce mortality in patients with heart failure or 
post-myocardial infarction(125;126). In proteinuric CKD patients, there have been a 
number of studies demonstrating beneficial effects of MRBs both in terms of proteinuria 
reduction(127;128) and slowing of decline in GFR(119;129). However, the studies are 
small, diverse and have short follow-up. A recent Cochrane review supported the 
conclusion that MRBs contribute to the reduction in proteinuria in patients with CKD 
prescribed ACEi or ARB but are associated with an increase in hyperkalaemia(130). One 
study has examined the cardiovascular effects of spironolactone on LV mass in patients 
with CKD and demonstrated a significant reduction, independent of blood pressure(131). 
That cohort was studied further and shown to have improved LV systolic function and 
reduced pro-BNP levels(132). Carotid intimal media thickness(133) and aortic pulse wave 
velocity(131) have both also been shown to be favourably reduced in HD and CKD 
patients respectively with MR blockade. 
Whilst these studies are intriguing, none provide definitive information on the role of Aldo, 
and on the dependency of an interaction with sodium status, in determining renal risk and 
cardiac and vascular function in CKD patients. Similarly, clinical studies have failed to 
demonstrate whether the beneficial effects of MR blockade relate to a generic effect, or 
specific inhibition of Aldo, the traditional MR ligand.  
1.6  The relationship between aldosterone levels and sodium 
intake - in vivo studies 
A number of historical studies underpin current physiological understanding of the 
relationship between sodium and aldosterone. The primary physiological role of Aldo is 
sodium reabsorption, thus maintaining intravascular volume and pressure. In the situation 
of a high sodium load, renin and Aldo production are suppressed(134). Similarly, Aldo is 
important for potassium extrusion and levels increase in a linear fashion with potassium 
loading(135). Sodium depletion results in a steepening of the aldosterone dose response 
curve to angiotensin II(136) – i.e. the adrenal cortex is more sensitive in sodium depletion. 
In renin-dependent hypertension, the AgII-Aldo response relationship is also 
steepened(50). 
Similarly, angiotensin II levels increase with sodium deprivation(53) and in normotensive 
subjects, exchangeable sodium is inversely correlated with AgII levels and plasma renin 
concentration(137). 54 
In the context of hyperaldosteronism, the usual feedback mechanisms are lost with the 
excess Aldo producing deleterious effects. The negative effects have been most 
comprehensively studied in animals. 
1.6.1  Excess aldosterone and the heart - in vivo studies 
Studies in animal models have shown that Aldo exerts major pro-inflammatory and fibrotic 
effects in the heart and kidney via the MCR, mainly seen in the context of a high sodium 
intake(87;138). In 1993 Brilla et al(139) demonstrated that the uninephrectomized rat, fed 
a high salt diet and infused with Aldo, developed cardiac perivascular and interstitial 
fibrosis. These effects were blocked with spironolactone but not captopril. The results were 
confirmed by Young et al (140). The cardiac fibrosis was demonstrated equally in both 
ventricles, suggesting a direct humoral effect, rather than being related to altered 
haemodynamics. Coadministering spironolactone(141) or canrenoate(142) blocked the 
hypertrophy and fibrosis, at doses which had minimal effects on blood pressure. The 
timescale for these effects to be seen was of the order of 4 weeks (143).  
Similarly, in a rat model where the rats were treated with AgII, L-NAME (a NOS 
inhibitor) and saline, significant vascular damage, proteinuria and renal arteriopathy was 
seen at 14 days(144). These effects were not seen in rats treated with adrenalectomy or 
eplerenone, suggesting mineralocortioids had a central role in the process. The effect of 
eplerenone was more marked in the heart than the kidney and the protective effects of 
adrenalectomy were lost when Aldo was infused. Notably, the rats did not develop fibrosis, 
leading the authors to hypothesise that this occurs at a later stage as a consequence of the 
vasculopathy. 
Extrapolating these findings to humans with long-term mineralocorticoid excess may be 
difficult, but it may be possible to compare the situation to acute myocardial infarction, 
where there is some evidence of AgII stimulated local Aldo synthesis in rats and 
inappropriate MCR activation, which is blocked by spironolactone, limiting cardiac 
remodelling(145). Recent evidence however questions the significance or indeed existence 
of cardiac aldosterone synthesis(75). 
1.6.2  Excess aldosterone and the kidney - in vivo studies 
In 1996, Hostetter demonstrated that in the 5/6 nephrectomy rat model, rats treated with an 
ACE inhibitor (enalapril) and angiotensin receptor blocker (losartan), infused with Aldo 55 
and fed a normal salt diet developed hypertension and glomerulosclerosis(146). Rocha 
confirmed these findings using the stroke prone spontaneously hypertensive rat fed a high 
salt diet, finding that the rats developed severe glomerular injury with vascular fibrinoid 
necrosis and thrombotic microangiopathy, leading to renal fibrosis(147;148). Figure 1-8 
illustrates some of these findings. 
Uninephrectomised rats treated with Aldo and salt also produce an inflammatory response, 
whereby there is increased expression of a number of inflammatory molecules including 
ICAM-1(149), IL-1β, IL-6 and osteopontin(150); which in turn leads to hypertension and 
glomerulosclerosis. Adrenalectomised spontaneously hypertensive stroke prone (SHRSP) 
rats infused with Aldo produce profibrotic factors including TGF-B1 and PAI-1 resulting 
in renal injury. This pro-inflammatory effect was not seen in similar animals infused with 
angiotensin II(151). Aldo has also been shown to increase NADPH and oxidative stress in 
rats with Aldo/high salt induced renal injury(138). 
It was previously thought that these proinflammatory and profibrotic effects were not seen 
in normal, normotensive rats. However it has been shown that adrenalectomised mice 
maintained on 0.9% saline and infused with Aldo exhibit renal collagen 1 accumulation 
prior to the development of hypertension(152), demonstrating that these changes can occur 
without prior renal injury or hypertension. The effect was not seen with corticosterone. 
Transgenic mice with hyperaldosteronism but normotension do not however develop 
cardiac hypertrophy or fibrosis(153). This is consistent with findings in Yanomamo 
Indians who have chronically elevated aldosterone levels secondary to a low sodium high 
potassium diet, but normotension and excellent vascular health(116). 
Spironolactone has been shown to inhibit acute tubular necrosis in the ischaemia 
reperfusion model(154) and induce regression of existing glomerulosclerosis(155). 
Subsequently Aldo has also been shown to have a role in acute and chronic(156) 
calcineurin nephrotoxicity.  56 
 
 
Figure 1-8: Aldo/1% NaCl-treated rats exhibit damaged glomeruli characterized by mesangial matrix 
expansion and cell proliferation, which is blocked by the addition of eplerenone (Reproduced from 
Nishiyama et al (138) ). 
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1.6.3  The DOCA salt rat 
Aldosterone is not the only mineralocorticoid demonstrated to have negative effects. The 
DOCA-salt rat is a model of hyperaldosteronism in humans, whereby administration of a 
high concentration of deoxycorticosterone acetate, a high salt diet and often 
uninephrectomy causes hypertension within 3 weeks(90), with DOCA treatment causing a 
30-fold increase in sodium absorption(157) secondary to increased sodium channel 
activity. The initial sodium and fluid retention seen results in hypertension, with enhanced 
sympathetic activity and elevated levels of endothelin-1, increasing vascular resistance. In 
humans, deficiency of 11β-hydroxylase or 17ʱ-hydroxylase results in elevated circulating 
DOC concentrations leading to mineralocorticoid hypertension in the majority of patients. 
1.7  In vitro studies of renal fibrosis: inflammatory mediators, 
aldosterone and sodium 
Renal fibrosis is the pathological hallmark of chronic kidney disease. Aldo has been shown 
to have significant pro-inflammatory and pro-fibrotic effects on cultures of renal, vascular 
and cardiac cells. No studies have looked directly at the combined effects of aldosterone 
and sodium on cell culture, out with the heart, despite evidence that the negative effects of 
mineralocorticoids are predominantly seen in a high sodium environment.  
1.7.1  Transforming growth factor beta 
TGFβ1 is a key mediator in the development of renal fibrosis. It has a number of 
physiological functions including regulating proliferation and differentiation of cells, tissue 
repair and angiogenesis(158), with effects depending on the target cell(159). TGF-β 
downregulates the matrix metalloproteinase collagenase, promotes fibroblast proliferation 
and upregulates collagen synthesis(160).  Virtually every cell in the body produces TGFβ 
and has receptors for it. TGFβ1 is expressed in endothelial, haematopoietic and connective 
tissue cells, TGFβ2 in epithelial and neuronal cells and TGFβ3 in mesenchymal cells. In 
normal rat kidney TGFβ1 expression was localised to the afferent and efferent arterioles, 
particularly the cytoplasm of smooth muscle cells rather than the endothelium. TGFβ2 
stained strongly in the basolateral aspect of distal tubules and weakly in the proximal 
tubules. TGFβ3 was strongly expressed in tubules, especially the brush border of proximal 
tubules of the other cortex of the kidney.(161)  58 
TGF β1 impacts principally at tubules in the renal cortex and medulla and is an important 
candidate for Ang II mediated matrix synthesis(162). TGF β1 upregulates cellular volume 
responsive kinase, hSGK1 (serum glucocorticoid inducible kinase 1), which stimulates 
epithelial sodium channels. An increase in cellular sodium inflow promotes enhanced cell 
swelling, proteolysis inhibition, increased protein synthesis and extracellular matrix 
expansion(162). Aldo stimulates TGFβ1 production in rat mesangial cells, an effect 
blocked by the addition of spironolactone(163). Aldo infusion in normal rats for 3 days 
increased urinary TGF-β excretion, with no effect on blood pressure or histology, an effect 
which was lost with the addition of spironolactone(164).  
Plasma levels of TGFβ 2 and 3 are undetectable, suggesting their effects are paracrine or 
autocrine(165). A study on human proximal tubular cells, whereby TGFβ1 was effectively 
silenced using small interference RNA methodology(166), demonstrated that silencing 
TGFβ1 was associated with a 3-fold increase in  TGFβ2 and 2-fold increase in TGFβ3 
measured by PCR, suggesting that TGFβ1 endogenously inhibits TGFβ2 and 3. TGFβ2 
and TGFβ3 have been shown to stimulate TGFβ1 production in rat mesangial cells. These 
different isoforms have not been closely studied in CKD.  
1.7.2  GM-CSF, IL6, IL8 
Granulocyte/macrophage colony-stimulating factor (GM-CSF) is a pro-inflammatory 
cytokine produced by stimulated cells in response to IL-1 or LPS. In vitro it acts as a 
mediator to stimulate cell proliferation and activation, commonly cells of macrophage 
lineage, increasing inflammation(167). GM-CSF deficient mice fail to develop crescentic 
glomerulonephritis(168), indicating that it has a role in the pathogenesis of renal disease. 
IL-6 is a pro-inflammatory cytokine produced by a variety of cells in response to IL-1(169) 
and which has been shown to increase the signalling response to TGF-beta(170). IL-8 is a 
proinflammatory cytokine secreted by a number of cells, typically monocytes and 
macrophages, which encourages cellular recruitment, amplifying the immune response 
(171). 
1.7.3  Collagen 
Collagens are the main component of connective tissue. They aggregate as fibrils made up 
of three alpha chains. Collagen 1 is the most abundant collagen and is the main component 
of fibrotic tissue. Collagen 2 forms hyaline cartilage, collagen 3 forms granulation tissue, 
before being replaced by collagen 1, and collagen 4 forms the glomerular basement 59 
membrane. Accumulation of collagen, predominantly 1, 3 and 4 (26), is seen in interstitial 
fibrosis, the dominant histological feature of CKD. 
1.7.4  Aldosterone mineralocorticoid receptor binding 
The intracellular signalling pathways downstream of Aldo binding to the MR have been 
characterised, but the exact mechanisms by which the pro-inflammatory and pro-fibrotic 
effects are exerted are not clear, and the way in which sodium status influences the 
response to activation of the MR is not understood. A new protein kinase family has 
become the subject of much study, the with-no-K[Lys] protein kinases (WNK)(172); their 
role in controlling sodium channels is of interest in relation to mineralocorticoid binding. 
1.7.5  Renal sodium reabsorption 
Renal tubular sodium reabsorption is a major determinant of renal oxygen 
consumption(173) and sodium overload might cause hypoxia, development of reactive 
oxygen species, production of NF-κB, local production of Ang II and a resultant pro-
inflammatory response(174).  
Normal Sprague-Dawley rats were exposed to a range of sodium loads, without 
haemodynamic changes, and a corresponding increase in TGF β1, RANTES, NF- κB and 
Ang II expression was seen on renal histology(162). Intracellular dehydration also 
promotes NF- κB production and may be contributing to the effects seen. Similarly, studies 
of rat aortic endothelial cells demonstrated that cellular salt intake exerts a dose-dependent 
increase in endothelial production of TGF-B1 via shear force and MAPK 
activation(68;175;176). 
Cultured cardiomyocytes treated with sodium (146 mmol/liter) shrink in size, an effect 
which was inhibited by Aldo, via activation of the NHE1 receptor. Treatment was 
accompanied by an increase in intracellular pH(177), cell hypertrophy, and BNP 
production.  
1.7.6  Intra-renal RAAS 
The kidney is known to be a site of local AgII production, which is thought to act in a 
paracrine or autocrine fashion. The AT1 receptor is the dominant AgII receptor, mediating 
the classic effects of AgII. It is widely expressed within the kidney vasculature, glomerulus 60 
and tubule. The AT2 receptor is also found within the kidney although it’s precise role is 
less clear and thought to be antagonistic to AT1(178).  AgII acting via the AT1 receptor 
directly inhibits renin release from juxtaglomerular apparatus. Renin mRNA has however 
also been located in the collecting duct and the intra-renal RAAS is activated early in the 
course of diabetes.  
Prorenin, the renin precursor, binds the prorenin receptor and becomes enzymatically 
active, possibly increasing local AgII production. In mesangial cells, prorenin receptor 
binding results in a profibrotic phenotype(179), but the overall pathological significance of 
prorenin remains to be elucidated. Detection of angiotensinogen in the urine is thought to 
be good evidence for the existence of an intrarenal RAAS because it is unlikely to be 
filtered because of its molecular weight. Levels have been found to be elevated in patients 
with chronic kidney disease and associated with an increased risk of renal 
progression(180). 
1.7.7  In vitro effects of aldosterone 
In cultured mesangial cells, Aldo promotes expression of CTGF, TGF-β, collagen IV and 
fibronectin(149) via activation of SGK-1. HKC cells (human kidney cortex cells) treated 
with Aldo were shown to increase gene and protein expression of collagen types III and 
IV, with no effect on collagen I and II, an effect inhibited by the addition of spironolactone 
or U0126, an ERK inhibitor(181). In rat renal fibroblasts, Aldo can stimulate gene 
expression and synthesis of collagen I, III and IV (182). Similarly, in inner medullary 
collecting duct cells, Aldo alone increased collagen expression two-fold whilst cortisol 
alone did not after 48h, an effect blocked by MR inhibition (152).  
Aldo also induces collagen synthesis in cultured cardiac fibroblasts(183), an effect 
inhibited by spironolactone(184). Additionally, Angiotensin II has been shown to induce 
collagen 1 gene expression in mice aorta and renal cortex in vivo(185) as well as 
stimulating cell proliferation and matrix synthesis in renal fibroblasts(186). 
Another mechanism by which Aldo promotes a pro-fibrotic phenotype is via epithelial-
mesenchymal transition (EMT). EMT is the process by which tubular cells lose their 
epithelial phenotype and migrate to the interstitium, adopting a myofibroblast phenotype, 
determined in vitro by the loss of E-cadherin (an epithelial marker) and the expression of 61 
ʱ-SMA (a myofibroblast characteristic).  Aldo has been shown to induce EMT in HKC 
cells(181) and HK-2 cells(187). 
Mesangial cell (188), cortical collecting duct cell(189), vascular smooth muscle cell(190) 
and cardiac fibroblast(191) proliferation has been induced by Aldo, via ERK signalling and 
variably via MCR binding. Conversely, Aldo has also been shown to promote apoptosis in 
HK-2 proximal tubular cells with up to 30% of cells having apoptosed at 24h when treated 
with Aldo (10
-6M), an effect occurring through oxidative stress and mediated by the MR 
(192). Of note, this is a high dose. A similar effect was reported in podocytes(193). 
1.8  Left ventricular mass in CKD 
Left ventricular hypertrophy (LVH) is a predictor of cardiovascular and all cause mortality 
in patients with hypertension and patients with CKD (194;195). Reduction of LV mass has 
been associated with reduced mortality in a variety of groups at high cardiovascular (CV) 
risk (196). Patients with CKD have increased CV risk, above that of the general 
population, which increases as renal function declines (5). However, the mechanisms 
responsible for this increased risk remain poorly elucidated, with the majority of interest 
focussing on patients with end stage renal disease (ESRD). 
1.8.1  Measurement 
1.8.1.1  Echocardiography 
Existing studies of LVH in renal disease have used echocardiography or ECG. The 
dependence of echocardiography on intravascular volume leads to an overestimation of 
LVMI in patients with advanced renal disease(197) and whilst ECG criteria can be applied, 
this is generally less reliable(198).  
1.8.1.2  Cardiac magnetic resonance imaging 
Magnetic resonance imaging (MRI) maps proton density (hydrogen nuclei) by utilising the 
proton spin in a high strength magnetic field, with the application of radiofrequency pulses.  
Normally, protons spin randomly, but the application of a magnetic field will result in 
protons aligning to the Z-axis, either in a parallel or anti-parallel direction, where they will 
continue to precess at their own frequency (Larmor frequency). A small excess of protons 
is always in the low energy state, resulting in a net magnetisation vector. The application 62 
of a radiofrequency pulse results in alignment of the phase of the spins and an increase in 
the number of protons in the high energy state, altering the net magnetisation vector 
(Figure 1-9).  
Cessation of the signal results in protons re-emitting energy and reverting to the lower 
energy state. This releases a signal in the form of radio waves, which induces a voltage 
across the coil. Reverting to the lower energy state occurs in two distinct processes – 
longitudinal relaxation (T1) and transverse relaxation (T2) (Figure 1-10). Differing T1/T2 
properties of different tissues results in different signal intensities at different times, 
allowing differentiation between tissues. Weighting of the image allows focus on different 
properties. In T1 weighted images fluid is black because fluid has a high T1, meaning that 
the application of a second radiofrequency pulse affects relatively few protons as they are 
still relaxing from the previous pulse, therefore there is little signal. In T2 weighted images 
fluid is white. 
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Figure 1-9: Graphical representation of the result of the application of a radiofrequency pulse to 
protons in a magnetic field, where protons precess together and a net magnetisation vector is 
produced. 
 
• T2 – transverse (fast) • T1 – longitudinal (slow)
 
Figure 1-10: Graphical representation of T1 (longitudinal) and T2 (transverse) relaxation. 
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Cardiac MRI (CMR) utilises the ECG trace to time RF pulses, ensuring that each image is 
acquired at the same stage of the cardiac cycle. Gadolinium acts as an extracellular contrast 
agent and all current CMR contrast agents contain gadolinium. The recent recognition of 
gadolinium contrast induced nephrogenic systemic fibrosis has limited the use of this 
contrast agent to patients with an eGFR of >30ml/min/1.73m
2 (199). Prior to this, 
gadolinium contrast agents were central to the redefinition of uraemic cardiomyopathy, 
whereby the marked increase in left ventricular mass in patients with renal disease was 
noted to be due not only to myocyte hypertrophy, but also due to diffuse fibrosis, as 
evidenced by late gadolinium enhancement(200).  
1.8.2  Determinants of left ventricular mass in CKD 
1.8.2.1  Gender 
After adjustment for body surface area, left ventricular mass remains higher in men 
compared with women. Definitions of LVH take into account sex specific variations. 
1.8.2.2  Systolic blood pressure 
In patients receiving maintenance haemodialysis, we have shown systolic blood pressure to 
be the main determinant of LVH (201). Systolic blood pressure is a measure of the 
afterload. Afterload is determined by inherent wall properties (arterial stiffness), 
neurohumoral factors such as sympathetic stimulation, vasoconstriction and drugs. 
Increasing afterload increases strain on the heart resulting, via Starling’s law, in an 
increase in myocardial stretch which over time leads to myocyte hypertrophy. Pulse wave 
velocity, a marker of arterial stiffness, which contributes to the afterload has been shown to 
correlate with SBP and left ventricular mass in patients with ESRD(202). 
1.8.2.3  Level of renal function 
Studies using echocardiography (198;203) have found a step-wise increase in the 
prevalence of left ventricular hypertrophy with declining renal function (CKD stages 1-4).  
1.8.2.4  Proteinuria 
The presence of microalbuminuria has also been shown to be predictive of LVH in patients 
with essential hypertension using echo(204;205) and ECG criteria(206) and also in patients 
with diabetes(207) without overt nephropathy. The relationship between proteinuria and 65 
left ventricular mass index in patients with chronic kidney disease is however unclear. The 
MONICA/KORA study demonstrated using echo that albuminuria, even at low levels, was 
a significant predictor of LVMI (208). Paoletti et al recruited 244 patients with non-
diabetic kidney disease stages 1-5 and calculated LV mass using echo and proteinuria with 
24h collection. In the regression model LVMI was associated only with pulse pressure, 
proteinuria and duration of hypertension. When only patients with CKD 3-5 were 
considered, LVMI was associated with pulse pressure and age only – the association with 
proteinuria was lost. Using ECG Cornell voltage criteria, Nobakhthagighi(209) et al found 
an association between urinary albumin excretion, LVM and mortality, which they 
postulated may be due to diffuse microvascular injury. 
1.8.2.5  Steroids 
The impact of steroids on left ventricular mass has not been directly examined in patients 
with CKD. In EH, LVMI, as determined by echo, was shown to correlate significantly with 
morning plasma Aldo levels in a small group of untreated hypertensives off medications. 
Plasma Aldo levels were within the normal range and the majority of patients had LVH. 
The relationship persisted after adjustment for blood pressure(210). LVH has been reported 
in Cushing’s disease as has dilated cardiomyopathy, often in the context of glucocorticoid 
driven hypertension(211). A small study of patients with hypertension without known 
glucocorticoid excess demonstrated a correlation between 24h urinary cortisol and LVMI. 
This was not seen in normotensive individuals. Of some concern, there was only a 
borderline correlation between 24h blood pressure and LVMI in that study(212). 
1.8.2.6  Sodium 
Cross-sectional analyses have reported an association between increased dietary sodium 
intake (as evidenced by increased urinary sodium excretion) and left ventricular mass(213). 
Others have demonstrated a reduction in LV mass with sodium restriction(214). In 
contrast, the Framingham Offspring study found no relationship between a spot urinary 
sodium:creatinine ratio and LV mass(215). 
It is clear that patients with CKD have increased left ventricular mass compared with the 
general population and that by the time of commencing RRT over 50% will have left 
ventricular hypertropthy. However, the determinants of left ventricular mass in CKD have 
not been closely studied and therefore approaches to limiting LVH in these patients are 
guided by approaches used to treat hypertension. It is not unreasonable to suppose that 66 
there may be factors specific to CKD which are not addressed by this approach and this 
will be studied further in this thesis. 
1.9  The vasculature in chronic kidney disease 
Large and small vessel function is altered in chronic kidney disease.  
 
1.9.1  Pulse wave velocity and augmentation index – physiological concept  
The arterial tree is as a visco-elastic tube which permits both forward and retrograde 
pressure waves. Cardiac contraction results in the forward wave, with the branch points 
and high resistance of the distal vessels generating retrograde waves. The compliance of 
the vessel is a product of the distensibility of the vessel wall and the blood volume 
contained within (216). The stiffer the artery, the faster the forward and retrograde wave 
speed. Arterial pressure can be increased by higher ventricular ejection, increased heart 
rate, higher vascular resistance and earlier wave reflection. 
Due to differences in the proportions of collagen and elastin(217), proximal arteries are 
more elastic and distal arteries stiffer. Pulse wave velocity, as a reflection of stiffness, is 
therefore higher in more distal arteries (Table 1-3).  
Therefore, as the pulse travels peripherally the amplitude increases and it has a narrower 
systolic peak. At a normal heart rate in a normal young individual, the brachial pulse 
pressure will be 20-50% greater than blood pressure in the aorta. Brachial pressure is 
therefore not a good surrogate of aortic pressure (218). 
As arterial stiffness increases or arteriolar constriction occurs (218), the speed of the 
reflected arterial wave increases. It arrives early in systole, augmenting the forward wave, 
boosting systolic pressure further and resulting in a proportionately lower diastolic blood 
pressure. This reflection of arterial stiffness – the degree to which the reflected wave 
boosts the forward wave - is termed the augmentation index (Figure 1-11).  67 
 
Site  PWV (m/s)(219;220) 
Ascending aorta  4-5 
Abdominal aorta  5-6 
Iliac / femoral  8-9 
Table 1-3: Pulse wave velocity according to site.  
From O’Rourke and Staessen 2002(221).  
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Figure 1-11: Graphical representation of the pulse wave and derived functions.  
The augmentation index (AIx) is the augmentation pressure (AP) divided by the pulse pressure (PP). The 
augmentation pressure is the pressure difference between the maximal systolic peak and the inflection 
point (the merging point between the incident and reflected wave). Adapted from Janner et al(222). 
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Pulse wave velocity is derived from the distance between two recording sites in the line of 
pulse travel, and the time delay between corresponding points of the pressure wave which 
are not influenced by wave reflection – usually the initial upstroke(221). Carotid-femoral 
PWV is accepted as the gold-standard measurement of arterial stiffness(218) – its 
assessment is simple, non-invasive and reproducible.  
1.9.2  Alterations in arterial structure in CKD 
Traditional contributors to increasing arterial stiffness such as increasing age, diabetes, 
dyslipidaemia, hypertension and atherosclerosis are associated with CKD. However a 
number of other abnormalities also lead to the increased arterial stiffness seen in these 
patients. Vascular calcification, predominantly affecting the media, with transformation of 
smooth muscle cells to chondrocytes(223) contributes significantly. In addition, disordered 
bone metabolism, malnutrition, inflammation, oxidative stress fluid overload, renin-
angiotensin system activation, insulin resistance and hyperhomocystinaemia are all thought 
to contribute to increased arterial stiffness(224).  
The role of arteries in delivering blood to the periphery, as well as their role in cushioning 
the waveforms which are a consequence of ventricular ejection, are both affected by the 
remodelling which occurs in a uraemic environment due to the factors described above. 
Failure of the conductive role of arteries to provide sufficient blood to the tissues results in 
ischaemia. Failure to damp down the propulsive waveform, due to loss of elasticity, results 
in pulsatile surges in blood pressure, which in the kidney can lead to ‘barotrauma’ and 
glomerular damage. Increased arterial stiffness also contributes to a widened pulse 
pressure, left ventricular hypertrophy, increased myocardial oxygen demand, and impaired 
diastolic relaxation(225). 
1.9.3  Determinants of AIx and PWV 
In younger age, the PWV and velocity of the reflected wave are slow, therefore the wave 
returns during diastole. This relative proximal elasticity reverses with increasing age, in 
particular the stiffness of the carotid artery increases disproportionately when compared 
with the common femoral or radial arteries, which stiffen little. The stiffness of the 
common carotid artery of a 70 year old is 6 fold higher than that of a 20 year old(226;227). 
The determinants of AIx are detailed in Table 1-4. AIx is higher in women than men, 
which is thought to reflect the smaller diameter of the vessels. Shorter height is associated 70 
with a higher AIx due to less distance for the reflected wave to travel(228). Higher DBP, 
higher AIx; increasing age is associated with a higher AIx until the age of 60, but after the 
age of 60 DBP falls(222). Increasing heart rate reduces AIx due to a shorter systolic 
ejection period resulting in less overlap between forward and reflected waves(229). When 
a gender specific approach is adopted, AIx has been shown to correlate with established 
cardiovascular risk factors and the degree of coronary artery disease(222). An increasing 
augmentation index causes increased left ventricular strain and reduced diastolic coronary 
perfusion. 71 
 
Factors associated with higher AIx  Factors associated with lower AIx 
Female gender  Increasing heart rate 
Shorter height   
Higher diastolic blood pressure   
Increasing age   
Table 1-4: Determinants of the augmentation index. 
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1.9.4  PWV and AIx – correlation with pathological outcome 
Aortic stiffness increases progressively as renal function declines(230;231), even when 
eGFR is within the normal range(232), and has been associated with the urinary 
albumin:creatinine ratio in diabetic patients. PWV has been shown to be predictive for 
cardiovascular events and mortality in the general population(233;234) and those with end 
stage renal disease(235-237). On cross-sectional analysis of carotid-femoral PWV, there 
was a linear relationship between aortic stiffness and the severity of angiographically 
defined coronary artery disease in patients with varying stages of CKD(238), and similarly 
between PWV and electron beam computerized tomography coronary calcification score in 
CKD patients(239). PWV has also been shown to be an independent predictor of loss of 
GFR in patients with CKD(240-242).  
The AIx has similarly been correlated with outcome. London et al demonstrated that each 
10% increase in AIx was associated with a 50% increase in the relative risk of mortality in 
patients with ESRD(243). Takenaka et al demonstrated that a higher AIx is associated with 
decline in renal function in patients with relatively well preserved renal function(244). 
Similarly, Taal et al found an AIx above the group median to be associated with a 17.5 fold 
increased risk of requiring RRT in patients with CKD 4-5(240). 
1.9.5  Endothelial function in CKD 
The vascular endothelium has multiple roles including mediating coagulation, platelet 
adhesion and the immune response. Importantly, the endothelium also mediates vascular 
tone via production of vasodilators, particularly nitric oxide (NO) and prostacyclin. When 
the endothelium becomes dysfunctional, production of these vasodilators is reduced 
resulting in impaired vasodilatation. In atherogenesis, endothelial dysfunction and 
inflammation are important early interrelated steps(245). CKD is associated with an excess 
risk of cardiovascular disease not adequately explained by conventional risk factors and 
may be contributed to by endothelial dysfunction.  
Whether endothelial dysfunction is a cause or consequence of renal disease is not clear. 
Endothelial dysfunction within the kidney may result in inflammation and oxidative stress 
which may be involved in the progression of CKD(246). However the endothelial 
dysfunction associated with CKD is not confined to the renal vascular bed, suggesting it 
may have a role in the systemic vascular disease associated with CKD. 73 
1.9.6  Endothelial dysfunction measures and adverse outcome in CKD 
Declining GFR has been shown to be associated with impaired endothelial function 
assessed using brachial flow mediated dilatation(247;248),  circulating markers of 
endothelial function(249) and markers of oxidative stress(250). Dysfunction of the 
endothelium is central in the pathogenesis of a number of disorders such as haemolytic 
uraemic syndrome. Endothelial dysfunction is also known to exist in ESRD where patients 
exhibit an altered response to ischaemia, acetylcholine and hyperthermia (251).   74 
1.10   Aims of this thesis 
The aims of this thesis are as follows: 
  To determine whether dietary sodium intake is associated with renal and overall 
patient outcomes. 
  To ascertain whether mineralocorticoid or glucocorticoid levels are elevated in 
patients with chronic kidney disease, compared with patients with normal renal 
function. 
  To assess the determinants of left ventricular mass and vascular function in patients 
with CKD. 
  To determine whether elevated mineralocorticoid levels are associated with left 
ventricular hypertrophy, proteinuria excretion, endothelial dysfunction, pulse wave 
velocity and whether there is a synergistic relationship between endogenous 
mineralocorticoids, dietary sodium intake and pathological features. 
  To ascertain whether human proximal tubules produce inflammatory or pro-fibrotic 
mediators when stimulated by steroids in a high sodium environment. 75 
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1-12: Summary of thesis – Interaction of sodium, DOC and aldosterone and effects on key organs and 
pertinent chapters. 
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1.11   Hypothesis 
The hypothesis of this thesis is that chronic kidney disease is associated with 
proportionately higher levels of endogenous steroids than would be expected, which in 
association with a high dietary sodium intake, is associated with poor prognostic features 
(elevated LV mass, proteinuria, endothelial dysfunction and poor vascular function). 
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2  Chapter Two - Methods  78 
2.1  Clinical Study 
2.1.1  Ethics committee approval 
The studies performed in this thesis were approved by the West Glasgow Research Ethics 
Committee. All subjects gave informed consent utilising forms approved by the committee 
(Appendix 1) after reading and digesting the patient information sheet (Appendix 2). The 
patient’s general practitioner was informed of their participation in the study (Appendix 3).  
2.1.2  Subjects and exclusion criteria 
Adult patients with chronic kidney disease stage 3 or 4 (eGFR 15-60ml/min) were 
recruited from renal clinics in the West of Scotland. Patients were included if they had 
diabetic nephropathy, IgA nephropathy or membranous nephropathy. The diagnosis of 
diabetic nephropathy was clinician defined in the majority of patients – i.e. patients with 
known diabetes mellitus (type 1 or 2), microvascular complications such as proliferative 
retinopathy, proteinuria and an absence of alternative explanation for their renal failure. A 
minority had undergone native renal biopsy. Diagnosis of IgA nephropathy and 
membranous nephropathy were made from native renal biopsy. Patients with hypertension 
requiring drug treatment, ECG evidence of LVH and normal kidney function were 
recruited as control subjects from hypertension clinics at the Western Infirmary Glasgow.  
Patients were excluded if they had a condition which would interfere with aldosterone 
metabolism or conditions which would make ability to complete follow-up unlikely. These 
were a known aldosterone secreting tumour or adrenal hyperplasia, treatment with an 
aldosterone antagonist (spironolactone or eplerenone) and patients who were pregnant or 
lactating. Known drug abusers and patients with an active psychiatric condition were 
excluded. Exclusion criteria for CMR scanning were implantable ferromagnetic devices 
(n=0), pacemaker (n=1), obesity (weight >130Kg or waist circumference greater than 
120cm) (n=2) or claustrophobia (n=10).  Membranous nephropathy patients receiving 
active immunosuppression other than low dose maintenance cyclosporin (<100mg/day) 
and prednisolone (≤ 5mg/day) were excluded. Cyclosporin does not interfere with 
aldosterone levels. There was no proteinuria cut off for renal patients.  79 
2.1.3  Study design 
Subjects visited the Glasgow Clinical Research Facility at 0900 on the day of assessment. 
For the preceding 24 hours patients performed a 24 hour urine collection. They were 
advised to collect all urine during the 24h period, after bladder emptying first thing in the 
morning, finishing the collection on the morning of assessment. From this, three aliquots of 
20ml urine were stored at -80°C for urinary steroid analysis. The remainder was sent for 
routine laboratory measurement of urinary protein and electrolytes. A history was taken to 
ascertain current health, medications, smoking history and history of cardiovascular 
disease. Simple anthropometric measurements of height, weight and waist circumference 
were made. The patients then underwent more detailed phenotyping during the same visit. 
2.1.4  Blood pressure measurement 
After 15 minutes of supine rest, blood pressure was measured three times using the Omron 
MX2. An average of the three readings was obtained and used in further analysis. A 
minority of patients completed 24h blood pressure monitoring with the Tracker 
NIBP2/90217 device. During the day readings were taken every 15 minutes and every 30 
minutes overnight. 
2.1.5  Blood sampling 
After 30 minutes of supine rest, 40ml of blood was taken for routine biochemistry (urea 
and electrolytes, bicarbonate, bone profile, liver function tests, C-reactive protein, urate, 
lipids and parathyroid hormone) and haematology (full blood count); plasma samples were 
obtained for aldosterone and renin measurement and stored at -80°C until analysis. An 
EDTA sample was obtained for genotyping.  
2.1.6  Electrocardiogram 
A standard 12-lead ECG was recorded at 25mm/s and 1mV/cm standardisation. The ECG 
was assessed as abnormal if the patient was not in sinus rhythm, had pathological Q waves, 
evidence of LVH (Sokolow-Lyon: S in V1 and R in V5 or V6 ≥35mm; R in aVL≥11mm), 
bundle branch block (QRS > 120ms), T inversion or ST depression >1mm. 80 
2.1.7  Vascular stiffness 
2.1.7.1  SphygmoCor Vx 
In this study vascular function was measured non-invasively using the aortic augmentation 
index (AIx) and gold-standard carotid-femoral pulse wave velocity (PWV). The 
SphygmoCor® Vx system (Atcor Medical, Sydney, Australia) was used which utilises a 
Millar tonometer and the method of applanation tonometry (Figure 2-1). This has been 
validated in patients with CKD(238).  81 
 
 
Figure 2-1: Demonstration of the principle of applanation tonometry.  
The artery is compressed against a rigid structure, e.g. bone, and the tonometer senses alterations in 
pressure as each wave is propagated. The tonometer records these waves which are fed back to the 
computer for analysis. 
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Measurements were performed after an ECG, to ensure sinus rhythm, and blood pressure 
measurement. Measurements were standardised as follows(216): 
  All usual drugs were continued prior to measurement.  
  Patients were requested to refrain from smoking for at least 3h before measurement 
as smoking increases sympathetic tone and arterial stiffness. 
  Room temperature was 21-23°C to standardise peripheral vasoconstriction 
  Patients were assessed fasted as eating decreases systemic vascular resistance  
  All patients were assessed at the same time of day as there is diurnal variation in 
arterial diameter with vessels being larger at night  
  Patients were semi-recumbent for at least 10 minutes 
2.1.7.2  Contraindications  
Under certain conditions PWA / PWV cannot be performed (non-sinus rhythm, aortic 
valve disease). In this study two patients in atrial fibrillation were excluded.  
2.1.7.3  Acquisition and analysis of augmentation index 
The augmentation index was measured at the right radial artery, with the wrist dorsiflexed. 
Once an acceptable waveform was obtained, recordings were taken for a 15 second period, 
then waveforms manually inspected. The operator index, which is a composite of 
individual quality indices (pulse height variation <5%, diastolic variation <5%, shape 
variation <5%, average pulse height >100units), was reviewed and deemed acceptable if 
above 80%. Three readings were obtained for each subject and an average taken. 
Augmentation index was recorded on three occasions and an average taken. The arterial 
pressure waveform is analysed from a derived central waveform – the radial waveform is 
converted mathematically to derive the central waveform using Fourier transformation. 
Analysis was performed using the calculated augmentation index (AIx@75bpm), which is 
corrected to a heart rate of 75bpm, allowing more standardised comparison (Figure 2-2).  83 
 
 
Figure 2-2: Example of measurement of the augmentation index.  
In the upper left hand panel green dots identify the systolic upstroke. The white trace is the radial 
waveform and the yellow trace the derived central (aortic) waveform. In the quality control section (top 
right panel) the values are white or green and therefore are all acceptable. The overall operator index is 
100%. The aortic AIx (augmentation pressure / pulse pressure) is 20% and once adjusted for a heart rate 
of 75bpm, 15%. 
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2.1.7.4  Acquisition and analysis of pulse wave velocity 
The principle of pulse wave velocity is graphically demonstrated in Figure 2-3. Three ECG 
leads were connected to the patient’s chest. The ECG recording was manually inspected to 
ensure the R wave was upright and that the patient was in sinus rhythm. The right carotid 
artery pulse was located and the distance from this to the suprasternal notch was measured 
in millimetres. The right femoral artery was then located and the distance from the 
suprasternal notch to femoral artery, via the umbilicus, was measured in millimetres. To 
calculate the overall length, the values were entered into the SphygmoCor Vx, which uses 
a subtraction method to calculate length. This is distal distance (sternum to femoral) minus 
proximal distance (sternum to carotid). Pulse wave analysis was performed at the right 
carotid and right femoral arteries with the patient supine. Three readings with a standard 
deviation of less than 10% of the mean were obtained for each subject. Measurements were 
performed by the researcher or one of three supervised trained research nurses. 
PWV = Distance (metres) / time (seconds). Figure 2-3 demonstrates the principles.  
The SphygmoCor Vx measures the time between the R wave of the ECG (ventricular 
systole) and foot of the pressure wave at each site. Time between the R wave and proximal 
upstroke (carotid) is subtracted from the time between the R wave and distal upstroke 
(femoral), to obtain the transit time. Transit time is time of travel of the foot of the wave 
over a known distance. Pulse wave velocity was recorded in m/s and an average of 3 
readings was used in analysis (Figure 2-4).85 
 
 
Figure 2-3: Ascertainment of the pulse wave velocity.  
ʔt is the difference in time between the upstroke in the common carotid artery and the upstroke in the 
common femoral artery, after the R wave. ʔL is the distance the pulse wave has to travel. 
 
 
Figure 2-4: Example of measurement recording for carotid-femoral pulse wave velocity.  
The green dots highlight the ECG R wave (ventricular systole) and the foot of the systolic wave at the 
carotid (upper panel) and femoral (lower panel) pulse. From these measurements, the times of 103.2ms 
and 165.3ms were determined. These readings were acceptable as the standard deviations (3.0, 3.6) were 
coloured green. The time difference of 62.1ms, together with the distance (430mm) results in a PWV of 
6.9m/s. The SD was 0.5, which is 7% and therefore acceptable. 
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2.1.7.5  EndoPAT 2000 Principles 
In this study, endothelial function was assessed using changes in Peripheral Artery Tone 
(PAT) volume by use of the Endo-PAT2000 system. This method is a quick, non-invasive, 
operator independent technique of assessing digital pulse amplitude during reactive 
hyperaemia, after a period of vascular occlusion. The subject acts as his own control, with 
endothelial function being tested in one arm, with the contralateral arm serving to monitor 
systemic vascular changes.  
The principle of flow mediated dilatation is that ischaemia is induced (e.g. arterial 
occlusion), followed by restoration of blood flow, causing reactive hyperaemia. The 
increased flow results in increased shear stress which causes endothelium dependent 
vasodilation. The gold standard uses assessment of this dilation by ultrasound at the 
brachial artery but is highly operator dependent and requires extensive training. Endo-PAT 
uses the PAT technique to measure changes in the finger. The method measures nitric-
oxide mediated vasodilation, in that the vasodilatory response was shown to be blocked by 
the administration of L-NAME (a nitric oxide inhibitor) (252). Studies have demonstrated 
close correlations between FMD and PAT methods(253;254).  
The PAT signal is measured from the fingertip by recording finger arterial pulsatile 
volume changes. The measurement apparatus utilises modified plethysmography sensors. 
The probes also impart a uniform subdiastolic pressure to the distal two thirds of the finger 
tips to prevent distal venous blood pooling, increasing the signal to noise ratio (Figure 2-5). 87 
 
 
 
Figure 2-5: PAT technology – probe on index finger. 
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The EndoPAT system has been extensively validated. EndoPAT has been correlated with 
coronary artery endothelial function assessed by intra-coronary acetylcholine 
infusion(255). An EndoPAT reactive hyperaemia index cut-off of 1.67 provided a 
sensitivity of 82% and specificity of 77% for diagnosing coronary endothelial function. 
EndoPAT was validated in the Framingham cohort(256), where nearly 2000 subjects were 
assessed, and the reactive hyperaemia index (RHI) was been shown to be inversely 
correlated with male sex, body mass index, cholesterol, diabetes, smoking and coronary 
artery disease(253;255;256), but not  blood pressure. The utility of EndoPAT has not been 
examined in patients with chronic kidney disease. 
2.1.7.6  EndoPAT 2000 contraindications 
Patients with Raynaud’s or arterio-venous fistulae would be excluded, however no such 
persons were identified in this study. 
2.1.7.7  EndoPAT 2000 acquisition and analysis 
The fasted subject lies semi-recumbent in a quiet room with a temperature of 21-23°C.  
The probes are fitted onto both index fingers and baseline readings are taken for 5 minutes. 
A blood pressure cuff is then inflated over the brachial artery for 5 minutes to 200mmHg, 
or 60mmHg above systolic pressure. Following the 5-minute supra-systolic occlusion 
period, readings in the reactive hyperaemia phase are recorded for another 5 minutes.   
Analysis is automated using software provided by Itamar medical. The RHI is calculated as 
a ratio of the average amplitude of PAT i.e. the ratio of the post-deflation pulse amplitude 
to baseline pulse amplitude in the intervention arm is normalised to the control arm (Figure 
2-6). Endothelial dysfunction results in a lower peripheral hyperaemic response. 89 
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Figure 2-6: Pictoral demonstration of PAT signal in both arms during the three phases of the test with 
demonstration of how the RHI is calculated.  
Probe 1 records the intervention arm and probe 2 the control arm. Sections B&D show the signal over the 
initial 5 minutes. The second 5 minutes (blue signal) demonstrates no flow through the finger of the 
intervention arm, whilst the cuff is inflated. The third 5 minutes shows an increase in flow through the 
intervention arm finger (A) compared with baseline (B) and control (C). The RHI result is calculated from 
(A/B) / (C/D). 
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2.1.8  Cardiac Magnetic Resonance Imaging 
2.1.8.1  Principles 
 
Magnetic resonance imaging (MRI) maps proton density (hydrogen nuclei) by utilising the 
proton spin in a high strength magnetic field with the application of radiofrequency pulses. 
The application of a radiofrequency pulse results in a proton net magnetization vector for 
the duration of the pulse. Once the RF pulse ceases, the protons will return to their natural 
state, emitting energy. This emitted energy generates a voltage and is measured using a 
coil. 
2.1.8.2  Features specific to cardiac imaging 
RF pulses of varying duration or strength and the application of magnetic-field gradients, 
that are adjusted to highlight desired tissue characteristics, form a pulse sequence. Basic 
pulse sequences used in CMR are spin-echo and gradient-echo sequences. Spin echo 
sequences are often used for assessment of cardiac morphology and flowing blood 
normally appears black. In gradient echo sequences, flowing blood is represented by high 
signal intensity and turbulences as areas of signal void – utilised for assessing valvular 
lesions, shunts and great vessels. In this study, the TrueFISP (fast imaging with steady-
state precession) sequence was used. This is the Siemens pulsed gradient-echo sequence.  
Cardiac gating uses the ECG tracing to trigger the radiofrequency signal, meaning that 
each image is always acquired at the same phase of the cardiac cycle so that phase mis-
mapping from cardiac motion is reduced. Respiratory motion artefact is minimised by 
breath holding.  
2.1.8.3  Utility 
Cardiovascular magnetic resonance imaging (CMR) is a non-invasive method used to 
accurately define ventricular dimensions and is accepted as the ‘gold standard’ for 
assessing left ventricular mass and function. Echocardiography derives LV mass and 
dimensions from one- or two-dimensional data, using assumptions of cardiac geometry, 
unlike CMR where actual myocardial mass and volumes are obtained. CMR does not 
utilise ionising radiation and therefore has advantages over techniques such as computed 
tomography. In comparison to echo scanning, assessment of the LV dimensions is ‘volume 91 
independent’, which is extremely attractive in patients with chronic kidney disease who are 
prone alterations in intravascular volume status.  
2.1.8.4  Contraindications 
Patients are unable to enter the scanner if they have implanted ferromagnetic objects. 
Intraocular shards of metal e.g. former welders and intracerebral clips are 
contraindications. A cardiac pacemaker or implantable defibrillator remains an absolute 
contraindication to CMR scanning. One patient was excluded on this basis. Patients with 
claustrophobia may not tolerate study with CMR – ten patients were excluded on this 
basis. Lastly, extreme central adiposity or weight >130Kg is a contraindication as patients 
are physically unable to enter the scanner (n=2). Prior to entering the scanner patients are 
assessed using a standard MRI safety screening questionnaire. 
 
2.1.8.5  Image acquisition  
Non-contrast CMR was performed using a 1.5 Tesla Siemens (Erlangan) cardiac MRI 
scanner. All scanning was performed by the investigator, with supervision by a cardiac 
radiographer (Ms. Tracey Steedman, Glasgow CMR Unit, Western Infirmary).  
2.1.8.6  Patient positioning 
The patient lies supine and enters the scanner head first. Patients are connected to ECG 
leads and the cardiac chest coil. Headphones are used to relay breath holding instructions. 
2.1.8.7  Left ventricular mass and function 
Each set of images are acquired using repeat breath-holds (duration approximately 8 
seconds each) and retrogated to the electrocardiogram. Each scan takes approximately 30 
minutes. No contrast agents/drugs are required for the scan.  
Initial localizers are performed using long-axis pilot scans followed by a fast imaging with 
steady-state precession (FISP) sequence, which was used to acquire cine images in long-
axis planes (vertical long axis, horizontal long axis, LV outflow tract) followed by 
sequential short-axis LV cine loops (8-mm slice thickness, 2-mm gap between slices), from 
the atrioventicular ring to the apex. Slices were contiguous.  
The complete protocol is as follows: 92 
1. Initial multi-slice localiser in end expiration.  
2. Using an axial image of the left ventricle, the vertical long axis localiser (VLA) is 
obtained through the apex of the left ventricle, aligning it with the centre of the mitral 
valve (Figure 2-7). 
3. From this image, the four chamber horizontal long axis localiser (HLA) is planned 
through the mid-point of the mitral valve and apex of the left ventricle.  
4. The HLA localiser is used to produce three short axis (SA) localiser slices with 
orientation parallel to the mitral valve plane through the atrioventricular groove. 
5. The SA images are then utilised to plan three long axis cine views – the 4-chamber, 2-
chamber and left ventricular outflow tract (LVOT) views.  
6. From the cine 4-chamber study serial 8-mm-thick short-axis images were obtained. The 
first image was positioned in orientation across the mitral valve plane using the 
atrioventricular groove to orientate (Figure 2-8). 
Imaging parameters, which were standardized for all patients, included repetition 
time/echo time/flip angle/voxel size/field of view of 3.14 ms/1.6 ms/60°/2.2 _ 1.3 _ 8.0 
mm/340 mm.  93 
 
 
Figure 2-7: Left panel – vertical long axis view. Right panel – horizontal long axis view. 
 
 
Figure 2-8: Axial slices through the horizontal long axis cine in maximal diastole producing a short 
axis cine stack, with measurements performed for Argus analysis. 
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2.1.8.8  Image analysis – Left ventricular mass and function 
Left ventricular mass and function was analysed from the left ventricular short axis cine 
loops using manual tracing of epicardial and endocardial end-systolic and end-diastolic 
contours. End-systolic volume (ESV), end-diastolic volume (EDV) and LVM were 
calculated using analysis software (Argus; Siemens). Values were adjusted for body 
surface area using the Mosteller formula: 
Body surface area (m
2) = √((weight (Kg) x height (cm))/3600))  
Left ventricular ejection fraction was calculated as: 
LVEF = ((EDV-ESV)/EDV) x 100 
Left ventricular abnormalites were defined as follows (Table 2-1) using published mean 
normal LV dimensions for healthy volunteers plus two standard deviations(257). Analysis 
of left ventricular mass and function required 10 minutes per patient. 
Left ventricular 
abnormality 
Measure  Male  Female 
LVSD  LVEF  <55%  <55% 
LVH  LVMI (LVM/BSA)  >84.1g/m
2  >66.3g/m
2 
LV dilatation  EDV/BSA  >111.7ml/m
2  >99.3ml/m
2 
LV dilatation  ESV/BSA  92.8ml/ m
2  70.3ml/ m
2 
Table 2-1: Definitions of left ventricular abnormality, subdivided by gender. 
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2.1.9  Plasma analysis  
2.1.9.1  Routine biochemistry and haematology 
Samples were sent to biochemistry for analysis of urea and electrolytes, bicarbonate, bone 
profile, liver function tests, C-reactive protein, urate, lipids and parathyroid hormone 
(Diasorin Liason). Full blood count was measured routinely by haematology.  
2.1.9.2  Aldosterone 
After 15-20 minutes of supine rest, 5ml of blood was withdrawn into a ZZ tube and then 
spun at 2500RPM for 10 minutes, with the plasma frozen at -80°C. Aldosterone was 
measured in batches by the biochemistry department utilising a radioimmunoassay 
(Siemens, TKAL2, Coat-A-Count). Normal range for a supine adult: 100-400pmol/l. 
2.1.9.3  Renin 
After 15-20 minutes of supine rest, 4ml of blood was withdrawn into a potassium EDTA 
tube (1mg/ml) and then spun at 2500RPM for 10 minutes, with the plasma frozen at -80°C. 
Plasma renin concentration was measured in the routine biochemistry laboratory using the 
DIASORIN analyser. Normal range for a supine adult: undetectable-40mIU/l.   
2.1.10   Urine analysis  
2.1.10.1 Sodium and creatinine 
24 hour urine collection was collected in a bottle without preservative. Urine was analysed 
in the routine laboratory for electrolytes using flame photometry.  
2.1.10.2 Urinary steroid analysis 
After completion of the 24h urine collection, urine volume was noted and three 20ml 
aliquots of urine were collected in plain universal containers and stored at -80°C. 24-hour 
excretion rates of each steroid were determined by gas chromatography-mass spectrometry 
using the Shackleton method(258) (performed by Ms. Mary Ingram, MRC Blood Pressure 
Group, British Heart Foundation Cardiovascular Research Centre). Urinary free cortisol 
and cortisone were measured by Dr. Stephen Miller (MRC Blood Pressure Group, British 
Heart Foundation Cardiovascular Research Centre) utilising a high performance liquid 
chromatography assay(259). Table 2-2 describes measured metabolites. 96 
 
Abbreviation  Metabolite name  Full name  Urinary 
excretion 
reference 
range 
(g/24h) 
Urinary 
excretion 
reference 
range 
(mol/24h) 
THALDO  Tetrahydroaldosterone  3ʱ,11β,21-
trihydroxy-18-al-
5β-pregnane-20-
one 
10-120 
μg/24h 
27-330 
nmol/24h 
THDOC  Tetrahydrodeoxycorticosterone  3ʱ,21-
dihydroxy-5β-
pregnane-20-one 
2-28 μg/24h  6-84 
nmol/24h 
THF  Tetrahydrocortisol  3ʱ,11β, 17ʱ,21-
tetrahydroxy-5β-
pregnane-20-one 
310-3680 
μg/24h  
1-10 
μmol/24h 
ALLO THF  Allo-tetrahydrocortisol  3ʱ,11β, 17ʱ,21-
tetrahydroxy-5 
ʱ-pregnane-20-
one 
490-3480 
μg/24h 
1-10 
μmol/24h 
THE  Tetrahydrocortisone  3ʱ,17ʱ,21-
trihydroxy-5 β-
pregnane-11,20-
dione 
1100-5100 
μg/24h 
3-14 
μmol/24h 
THS  Tetrahydro-11-deoxycortisol  3β,17 ʱ,21-
trihydroxy-5 β-
pregnane-20-one 
3-130 μg/24h   9-370 
nmol/24h 
F  Cortisol    3.5-45 
μg/24h 
9.7-124.2 
nmol/24h 
E  Cortisone    17-129 
μg/24h 
47.3-358.6 
nmol/24h 
Table 2-2: Table of urinary metabolites analysed, including abbreviation, full name and urinary 
excretion reference range in ug/24h and nmol/24h. 
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2.1.11  Genetic analysis 
2.1.11.1 DNA extraction 
DNA was extracted from whole venous blood (EDTA) samples, after refrigeration, using 
the Autopure LS (Large Sample Nucleic Acid Purification Instrument) by Gentra Systems. 
After DNA extraction the samples were quantified using a Nanodrop 1000 to give a 
260/280 ratio (>1.6 acceptable) and a DNA value in ng/ml. This was performed by Mr. Jim 
McCulloch (Chief Technician). 
2.1.11.2 SNP analysis 
Aldosterone synthase gene -344C/T polymorphism genotyping was performed by Dr. 
Samantha Alvarez-Madrazo (Research Assistant). The region of DNA containing the –344 
C/T polymorphism was amplified by polymerase chain reaction (PCR) using primers 
(Oswel DNA Service, Southampton, UK) (F 5′GTG TCA GGG CAG GGG GTA3′. R 
5′AGG CGT GGG GTC TGG ACT3′). The 228 base pair product was digested by Hae III 
(Promega, Southampton, UK) and subject to electrophoresis in 3% MetaPhor agarose gel. 
2.2  Laboratory project 
2.2.1  Materials 
2.2.1.1  Biochemicals 
Unless otherwise stated all chemicals were obtained from Sigma, Poole, UK. Chemicals 
were stored at -20°C until usage and were diluted with media to the required concentration 
prior to use. Repeated freeze-thaw was avoided. Table 2-3 lists chemicals used. 98 
 
Chemical   Company  Catalogue 
number 
Molecular 
weight 
Initial dissolving 
protocol 
Aldosterone  Sigma-
Aldrich 
A9477  360.44  5mg diluted in 5ml 
ethanol and 9ml media to 
concentration 10
-3 M 
Cortisol  Sigma-
Aldrich 
C2505  346.46  0.034g was dissolved in 
10ml ethanol to 
concentration of 0.01M. 
Angiotensin II  Sigma-
Aldrich 
A9525  1046.2  0.001g was dissolved in 
9.558ml of sterile water 
to concentration of 10
-4 
M 
 
Canrenoic acid  Sigma-
Aldrich 
C7287  397.57  0.3975g were dissolved 
in 10ml of DMSO to a 
concentration of 100mM 
Lipopolysaccharides  Sigma-
Aldrich 
L4005    1mg was diluted in 10ml 
PBS 
Table 2-3: Chemicals used during laboratory project including source, molecular weight and initial 
dissolving protocol. 
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2.2.1.2  Immunochemicals 
The antibodies used in this study are detailed in Table 2.4. 
Protein target  Manufacturer  Species  Concentration 
Collagen 1A  AbCam  Mouse  1/2000 
Collagen 1A  Santa-Cruz  Mouse  1/200 
pERK p44/42 MAP kinase  NEB  Rabbit  1/1000 
Total ERK  NEB  Rabbit  1/1000 
GAPDH  Abcam  Rabbit  1/1000 
Anti-mouse HRP  Amersham  Sheep  1/2000 
Anti-rabbit HRP  Amersham  Donkey  1/2000 
Table 2-4: Immunochemicals used, manufacturer, species and concentration antibody utilised at. 
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2.2.1.3  Cell biology 
Human kidney 2 (HK-2) cells are a proximal tubular epithelial cell line derived from 
normal adult human kidney (CRL-2190; American Type Culture Collection, Rockville, 
MD)(260) immortalized with the human papilloma virus 16 (HPV-16) E6/E7 (Figure 2-9). 
Cells were utilised between passages 3 and 25. Cells were incubated at 37°C in
 5% CO2 
with keratinocyte
 serum-free medium (K-SFM; Life Technologies, Grand Island, NY)
 
containing 1 mM glutamine, 5 ng/ml epidermal growth factor,
 40 µg/ml bovine pituitary 
extract, 25 U/ml penicillin,
 and 25 µg/ml streptomycin. At near confluence, the cells
 were 
trypsinized and transferred to either additional flasks for passage or to plates at a minimum 
density of 2 x 10
5 cells for experimentation. Experiments were conducted
 24 hours after 
passage, with the cells in a subconfluent state. 101 
 
 
Figure 2-9: HK-2 cells under light microscopy. 
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2.2.2  Molecular biology 
2.2.2.1  RNA extraction and complementary DNA synthesis 
Cytoplasmic RNA was extracted from trypsinised cells using the Qiagen RNeasy Mini Kit 
(Qiagen). RNA concentration was determined by measuring absorbance at 260nm and 
purity estimated by checking the 260nm:280nm absorbance ratio using the Thermo 
Scientific Nanodrop 1000 spectrophotometer (Ratio >1.6). RNA was stored at -80°C. 
Complementary DNA was synthesised using the Invitrogen M-MLV reverse transcriptase 
kit. 1ug of RNA, 1ul hexamers (0.5ug/ul), 1ul 10 mM dNTP mix and sterile water to a 
volume of 12ul were heated to 65°C for 5 minutes and chilled on ice. Thereafter 4ul of 5x 
First-Strand buffer, 2ul 0.1M DTT and 1ul RNaseOUT (recombinant ribonuclease 
inhibitor) were added. Samples were incubated at 37°C for 2 minutes before adding 1ul of 
reverse transcriptase and incubating at 37°C for 50 minutes followed by 70°C for 15 
minutes. Each sample was also amplified without reverse transcriptase to ensure there was 
no DNA contamination. Samples were subsequently diluted 1/5 to a final volume of 100ul 
with distilled water and stored at -20°C. 
2.2.2.2  Polymerase chain reaction - Primer design 
Intron spanning primers were designed using the Roche universal probe library 
(https://www.roche-applied-science.com/sis/rtpcr/upl/index.jsp?id=UP030000). Primers 
were ordered from Integrated DNA Technologies (Belgium). Table 2-5 lists primers and 
characteristics. 103 
 
Target 
gene 
Accessio
n no. 
Forward 
primer 
Reverse primer  Ann. 
Temp    
Probe 
no. 
Amp. 
size  
TGFβ1  NM_000
660.3 
gcagcacgtggagct
gta 
cagccggttgctgaggta  59  72  64 
TGFβ2  NM_003
238.1 
ccaaagggtacaatg
ccaac 
cagatgcttctggatttatg
gtatt 
60  67  114 
TGFβ3  NM_003
239.2 
aagaagcgggctttg
gac 
gcgcacacagcagttctc  60  38  63 
Collagen I  NM_000
088.3 
gggattccctggacc
taaag 
ggaacacctcgctctcca  59  67  63 
Collagen 
IV 
NM_001
845.4 
cgggtacccaggact
catag 
ggacctgcttcacccttttc  59  81  60 
Beta-actin  NM_001
101.3 
ccaaccgcgagaag
atga 
ccagaggcgtacaggga
tag 
59  64  97 
11BHSD2  NM_000
196.3 
gtcaaggtcagcatc
atcca 
cactgacccacgtttctca
c 
59  71  65 
MCR  M16801
.1 
aacaggtagacggc
gagaga 
Tcagggagactgtggta
gcc 
60  58  73 
Table 2-5: Oligonucleotide gene targets, NCBI NM accession number, oligonucleotide sequences 
(forward and reverse primers), optimal annealing temperature (Ann temp), paired Universal Probe 
number (Probe no.) and amplicon size (Amp. Size). 
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2.2.2.3  Polymerase chain reaction 
Polymerase chain reaction (PCR) was performed using a PTC-100 programmable thermal 
controller. A 25ul reaction volume consisted: 1ul of template (0.2ng), 0.25ul 100nM 
forward and reverse primers, 0.5ml 10mM dNTPs, 0.25ul Taq polymerase, 5ul 5x buffer 
and PCR-grade water. The following thermal cycling profile was used for 35 cycles: 
Samples were denatured at 94°C for 30 seconds then primers annealed at 55°C for 45 
seconds and DNA extension at 68°C for 1 minute. 
2.2.2.4  Real time polymerase chain reaction  
Real time PCR was used to determine relative quantification of mRNA transcripts 
following reverse transcription. The Roche Universal Probe Library (Roche) was used in a 
probe-based detection scheme. This method utilises a time sensitive quantification of PCR 
template (i.e. real time), as opposed to endpoint detection, with the fluorescent reporter 
signal being detected and quantified at the end of each cycle, with the signal increasing 
proportionally to the amount of PCR product in the reaction. A fixed fluorescence 
threshold is set above baseline (the threshold cycle (Ct)) which is the cycle number at 
which fluorescence emission exceeds threshold and is exponential.  
The Taqman probe is an oligonucleotide which is shorter than primers. There is a 
fluorescent dye at the 5’ base and a quenching dye on the 3’ base. When the probe is intact, 
there is no emission of fluorescence. The probes are designed to anneal to a region of the 
PCR product. When polymerase replicates a template on which a Taqman probe is bound, 
the 5’exonuclease activity cleaves the 5’ end of probe which contains the reporter dye 
(FAM) and the reporter emits fluorescence – increasing with each cycle proportional to the 
rate of cleavage. Accumulation of product is detected by monitoring increase in 
fluorescence compared with passive reference dye e.g. Rox. 
An internal control gene, which is more abundant and remains constant in proportion to 
total RNA, is also amplified e.g. B actin. This allows normalisation of the mRNA target to 
take account of differences in total RNA added to each reaction. Relative quantification of 
gene expression is then undertaken using the comparative CT method, where the difference 
between the CT values of two PCRs for the same initial template amount varies. This is 
then normalised to a baseline reference sample for comparison to be made (ʔʔCT 
method).  105 
A 10ul well volume was composed of: 0.2ng of template (2ul), 0.1ul 100nM probe, 0.4ul 
of 100nM forward and reverse primers, 2.1ul PCR-grade water, 5ul QPCR mix with 120 
nM ROX (reference dye). 384 well plates were plated and beta-actin was used as the 
housekeeping gene. Controls of non-reverse transcribed template and mastermix without 
template were also run to ensure there was no contamination.  Using the TaqMan cycler, 
the block was heated to 50°C for 2 minutes then samples heated to 95°C for 10 minutes 
(‘hot start’) followed by 40 cycles of denaturing at 95°C for 15 seconds and 1 minute 
annealing / extension at 60°C. In order to assess specificity of amplified product and to 
avoid spurious results from primer-dimer formation and amplification, dissociation curves 
showing product melting points were assessed (Figure 2-10) and samples of product were 
run and visualised on agarose gels.       106 
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Figure 2-10: Amplification plot of normalised fluorescence intensity versus cycle number. 
 The threshold cycle (CT) is defined as the point when a statistically significant rise in the amount of DNA 
product is detected. 
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2.2.2.5  Agarose gel electrophoresis of DNA  
DNA samples were mixed with 6x blue loading buffer (Promega) and run on agarose gels 
with tris-acetate (TAE) electrophoresis buffer (0.04M Tris-acetate, 0.001M EDTA). 2% 
agarose gels were made (0.8g agarose for molecular biology (Sigma), 40ml TAE buffer, 
4ul ethidium bromide) and 15ul of sample loaded and run at 100V for 1hour. Bands were 
visualised on an ultraviolet transilluminator and images recorded on the BioRad ChemiDoc 
XRS digital imaging system. 
2.2.3  Biochemical assays and methods 
2.2.3.1  Preparation of cell lysates 
Cells were lysed after trypsinisation using RIPA buffer supplemented with protease 
inhibitors (benzamidine and soya bean), orthovanadate and PMSF. Bio-Rad Protein assay 
was undertaken to quantify cell lysate protein concentration by measuring absorbance of 
Coomassie Brilliant Blue G-250 at 595nm. Bovine serum albumin standards were used to 
construct a standard curve. Protein concentrations of all samples were routinely measured 
in duplicate. Lysates were stored at -80°C until use. 
2.2.3.2  Polyacrylamide gel electrophoresis and immunoblotting 
Proteins were resolved using the NuPAGE 4-12% Bis-Tris precast gel system (Invitrogen). 
Minimum sample protein content was 10ug per well. Protein samples were denatured in 
NuPAGE LDS (lithium dodecyl sulphate) sample buffer by heating to 70°C for 10 
minutes. In order to reduce proteins, 50mM dithiothreitol was added immediately prior to 
sample denaturing. 
Proteins resolved by polyacrylamide gel electrophoresis were transferred to Protran 
nitrocellulose membranes using the NuPAGE XCell II blotting apparatus and 
manufacturer’s transfer buffer which was supplemented with 20% methanol. Transfer was 
performed at 40V for 60mins. Transfer efficiency was assessed by staining membranes 
with Ponceau S solution followed by washing with TBS (20mM Tris-HCl pH 7.6, 135mM 
sodium chloride) containing 0.1% Tween 20 (TBST). 
The nitrocellulose membranes were then blocked in 4% non-fat powdered milk (Marvel) 
for 1hour at room temperature. Blots were incubated with primary antibodies at the optimal 
concentration in milk overnight at 4°C. Three washes of 5 minutes with TBST were then 108 
carried out prior to incubation with the appropriate horseradish peroxidise conjugated 
secondary antibody for 2 hours in milk at room temperature. Blots were then washed with 
TBST for 5 minutes 5 times. Proteins were visualised by enhanced chemiluminescence 
(Amersham) and autoradiography. 
2.2.3.3  Enzyme linked immunosorbent assay (ELISA) 
 
ELISA kits were purchased from BD Biosciences (San Jose, CA, USA) and ELISA 
conducted on cell culture supernatant. Human TGF-β1 (559119), human IL-6 (555220), 
human GM-CSF (555126) and human IL-8 (555244) were analysed. Recommended study 
procedure was followed using 96 well plates, with results read on the Wallac Victor2 1420 
multilabel counter. Samples for GM-CSF analysis were diluted 1/5 at 24h and 1/10 at 48h. 
IL-6 and IL-8 were diluted 1/40 or1/80 at 24h and 48h respectively. One hour samples 
were run undiluted. Sample concentrations were calculated from standard curves and 
sample results normalised to the control well. 109 
3  Chapter Three - A study of urinary sodium excretion 
and outcomes in patients with chronic kidney disease  110 
3.1 Introduction 
Sodium is the main extracellular cation and plasma sodium concentration is maintained 
within a narrow range by the kidney. Despite its vital physiological role and the numerous 
mechanisms maintaining sodium homeostasis, elevated dietary sodium intake has been 
shown to have negative effects. In large population based studies(54) sodium intake has 
been shown to influence blood pressure, with sodium restriction being associated with a 
fall in both systolic and diastolic blood pressure(56) (64). Similarly, sodium intake is 
widely believed to influence progression of CKD, independent of effects on blood 
pressure(63). There is experimental evidence to suggest a direct pathogenic role for sodium 
in renal failure(64), however hard endpoint data in humans are lacking (see introduction 
section 1.3).  
Urinary sodium (UNa) excretion (mmol/24h) is the most reliable easily available method 
of assessing oral sodium intake, independent of dietary assessment. UNa mirrors dietary 
sodium intake in patients with CKD and reduced glomerular filtration rate (44), but 
difficulties might be anticipated with the interpretation of urinary sodium values in 
advancing kidney disease. As GFR declines appetite can be reduced, which might impact 
upon dietary sodium intake. Similarly, UNa is closely related to weight, and the impact of 
declining GFR on weight and muscle mass, and how best to adjust for these factors is not 
clear. 
As such, the aims of this study were to assess: 
  Levels of UNa in patients with impaired renal function.  
  The impact of declining renal function on the fractional excretion of sodium 
(FENa), a reflection of the percentage of sodium filtered versus the percentage 
sodium reabsorbed. 
  How best to report UNa excretion in patients with CKD - total urinary sodium 
excretion (mmol/24h) (UNa/24h) or UNa adjusted for urinary creatinine (UNa:Cr 
ratio).  111 
  Whether urinary sodium excretion correlates with renal outcome or patient survival 
in patients with CKD, and whether higher levels of dietary potassium intake are 
protective in this population. 
3.2  Methods   
3.2.1  Patients 
Adult patients attending the renal unit at Glasgow Royal Infirmary between 1992 and 2007 
who had at least one UNa/24h measurement were identified using the electronic patient 
record. Urinary electrolytes were measured using flame photometry in a standard 
laboratory. Baseline drug therapy, renal function, proteinuria, weight, blood pressure and 
Charlson index of comorbidity were recorded. Advice regarding oral sodium intake was 
physician determined and patients were not routinely assessed by a dietician. Patients who 
were receiving RRT at the time of measurement, patients without a weight recording, 
patients without a 4v-MDRD eGFR recording at time of measurement and at least one 
further reading, and patients with a decline in eGFR >10ml/min/yr were excluded.  
Fractional excretion of sodium = (Serum Cr * Urine Na) / (Serum Na * Urine Cr)% 
 
3.2.2  Adequacy of collection 
 
Oral sodium intake in the West of Scotland is high and patients with a UNa/24h less than 
70mmol were presumed to have incomplete collections and excluded on this basis (n=278). 
Following this, measured creatinine clearance was compared with estimated creatinine 
clearance using the Cockroft and Gault formula ((Expected – Observed) / Expected )) x 
100. A previous comparison showed that 94% of values estimated by this formula will fall 
within ± 35% of observed creatinine clearance(261).  Using this analysis, 17% of 
collections fell out with the ± 35% range, with the majority (69%) underestimating, 
suggesting incomplete collections, which will underestimate the total urinary sodium for 
24h. (Figure 3-1). Calculation of the UNa:Cr ratio and FENa is not dependent on the 
accuracy of collection. 
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Figure 3-1: Urine collection adequacy.  
Percentage derived from the expected creatinine clearance (measured using the Cockcroft and Gault 
formula) divided by the observed urinary creatinine clearance, multiplied by the expected %. ((E/O) X 
E)%. 113 
3.2.3  Outcomes and analysis 
Dates of starting renal replacement therapy (RRT) or death were recorded. Annual decline 
in eGFR was also calculated. Baseline demographics were compared using Student’s T 
test, Mann Whitney U test, Chi Square test or one-way ANOVA as appropriate. 
Correlations between urinary sodium measures and other factors were ascertained using 
Spearman’s or Pearson’s correlation coefficients, depending on normality of the data.  
Kaplan Meier survival analysis was performed based on time to RRT or death for tertiles 
of UNa and UNa:Cr. Binary logistic regression was performed to determine independent 
predictors of the requirement for RRT and multiple factors were then entered into a Cox 
survival model. Different measures of urinary sodium excretion were entered separately 
due to collinearity. 
3.3  Results 
3.3.1  Baseline demographics 
Table 3-1 summarises baseline demographics for the whole cohort. Four hundred and 
eighty eight patients were included. The primary renal disease was recorded as 
renovascular disease (n=76), diabetic nephropathy (n=34), tubulointerstitial disease / 
polycystic kidney disease (n=57), glomerulonephritis (n=55) and others (n=16). The 
remainder were classified as CRF. One hundred and three patients (21.1%) required RRT 
for CRF at a median of 2.2 (0.8-4.9) years. 113 patients died (23.2%) during follow-up at a 
median of 3.8 (IQR 2.0-6.7) years. Censoring for death or RRT, median follow-up for the 
whole cohort was 8.6 (IQR 4.2-11.4) years. Overall mean slope decline in eGFR was -2.8 
(4.0) ml/min/yr. 114 
 
Variable  Result 
 
(n=488)  Gender (% male)  50.4 
Age (years)  51.8 ±16.7 
Weight (Kg)  75.6±18.0 
eGFR at baseline (ml/min/1.73m
2)  48.4 ± 25.6 
SBP (mmHg)  139 ± 24 
DBP (mmHg)  79 ± 13 
ACR (mg/mmol)  10.0 (2.0-85.8) 
USod (mmol/24h)  159.3 ± 63.7 
UNa:Cr  16.6 ± 6.3 
FENa (%)  1.44 (1.0-2.5) 
UPot (mmol/24h)  55.5 ± 20.8 
Diuretic therapy (%)  23.3 
ACEi / ARB (%)  25.4 
Deaths (n,%)     113 (23.2%) 
RRT (n,%)  103 (21.1%) 
Time to death (years)  3.8 (2.0-6.7) 
Time to RRT (years)  2.2 (0.8-4.9) 
eGFR loss (ml/min/1.73m2/yr)  -2.8 (4.0) 
Table 3-1: Baseline demographics of cohort. 
Mean ± SD or median (IQR).  115 
3.3.2  Urinary sodium excretion in patients with CKD 
Urinary sodium excretion is lower in patients with more advanced renal failure. As can be 
seen in Figure 3-2, the predominant reduction is in CKD stage 5, although there is a 
significant difference across all 5 groups (p=0.002). 
Fractional excretion of sodium is higher in patients with reduced renal function. Figure 3-3 
shows the scatterplot of log FENa versus log MDRD4 eGFR (R
2 = 0.79) i.e. renal function 
is the predominant determinant of fractional excretion of sodium. Figure 3-4 demonstrates 
a 3D boxplot of eGFR by tertile of UNa and tertile of FENa. It can be seen that those with 
a high FENa and low UNa have the lowest eGFR.  
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Figure 3-2: Bar chart of median urinary sodium excretion (mmol/24h) by CKD stage.  
P=0.002 by Kruskall Wallis test. 
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Figure 3-3: Log-log plot of FENa and eGFR. 
Fitted linear regression line and R-square value derived from linear regression. 
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Figure 3-4: 3D boxplot of mean eGFR by tertile of UNa and tertile of FENa.  
Error bars = 1SD. 1= Lowest tertile, 3=Highest tertile.  119 
3.3.3  Correlations 
To ascertain which factors correlated significantly with UNa, the following factors were 
entered into a correlation matrix: age, gender, weight, eGFR, diuretic usage, ACEi usage, 
blood pressure, proteinuria, RRT, death and eGFR loss over time. 
3.3.3.1  UNa correlations 
UNa correlated significantly with higher weight, higher eGFR, male gender and 
requirement for RRT. There was no significant correlation seen with blood pressure, age, 
death, diuretic therapy, inhibitors of the renin-angiotensin system or eGFR loss over time 
(Table 3-2).  
Due to the close correlations between UNa and weight (r=0.379), weight and urinary 
creatinine (r=0.466) and UNa and urinary creatinine (r=0.543), the correlation matrix was 
repeated after adjusting UNa for weight in Kg and adjusting for urinary creatinine 
excretion. Adjusting for weight in Kg failed to remove the correlation between UNa and 
weight but adjusting for urinary creatinine did, therefore this measure was adopted for 
further analysis. There was no correlation between eGFR and weight. 
3.3.3.2  UNa:Cr correlations 
UNa:Cr correlated significantly with older age, male gender, higher SBP, lower eGFR, 
higher log ACR, diuretic usage, requirement for RRT and death. There was no significant 
correlation seen with DBP, weight, ACE usage or eGFR loss over time (Table 3-2). 
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  UNa/24h    UNa/Kg/24h    UNa:Cr   
Variable  r  P  r  p  r  p 
DBP  0.11  0.017  -0.293  <0.001  0.062  0.176 
SBP  0.1  0.031  -0.06  0.196  0.191  <0.001 
eGFR   0.151  0.001  0.183  <0.001  -0.226  <0.001 
Male gender   0.296  <0.001  -0.248  <0.001  0.183  <0.001 
Age  -0.032  0.48  -0.044  0.342  0.23  <0.001 
Weight   0.379  <0.001  0.267  <0.001  -0.071  0.116 
LogACR  -0.105  0.033  -0.14  0.004  0.18  <0.001 
RRT   -0.115  0.01  -0.118  0.01  0.194  <0.001 
Death   -0.109  0.016  -0.68  0.138  0.243  <0.001 
eGFR loss/yr  0.066  0.146  0.102  0.026  -0.059  0.192 
Diuretic usage  -0.033  0.467  -0.003  0.944  0.201  <0.001 
ACEi usage  0.072  0.113  0.046  0.321  0.115  0.011 
Table 3-2: Correlation matrix between demographic variables and measures of urinary sodium 
excretion. 
Correlations – Pearson’s or Spearman’s as appropriate. P<0.01 = significant (highlighted 
in bold and cell coloured yellow).  
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3.3.4  Urinary sodium and risk of requirement for RRT or death 
 
To ascertain whether urinary sodium excretion was associated with an increased risk of 
death or requiring RRT, patients were separated into tertiles of UNa and UNa:Cr and 
Kaplan Meier analysis was performed.  
Table 3-3 and 3-4 demonstrates the demographics of patients in each tertile. Those in the 
highest tertile of UNa had the highest eGFR and highest weight. Those in the highest tertile 
of UNa:Cr had the highest urinary sodium and lowest eGFR, likely reflecting reduced 
urinary creatinine excretion.  122 
 
  All 
patients 
N=488 
T1 
UNa 
N=163 
T2 
UNa 
N=162 
T3 
UNa 
N=163 
P 
eGFR (ml/min/1.73m2)  48.5 (25.6)  43.1 
(25.5) 
51.7 
(27.1) 
51.0 
(23.7) 
0.004 
Age (y) 
 
51.6 (16.7)  53.4 
(16.9) 
49.0 
(16.9) 
52.2 
(16.1) 
NS 
% male  50.4  33.3  50.0  67.7  <0.001 
SBP (mmHg)  139.0 
(23.0) 
136.5 
(24.7) 
139.0 
(22.2) 
141.3 
(21.8) 
NS 
LogACR  1.1 (0.9)  1.2 (0.9)  1.1 (0.9)  1.1 (0.9)  NS 
Weight (Kg)  75.6 (18.0)  68.8 
(15.2) 
74.2 
(16.3) 
83.7 
(19.0) 
<0.001 
Charlson co-morbidity 
score 
2.3 (1.6)  2.4 (1.5)  2.2 (1.6)  2.2 (1.7)  NS 
UNa (mmol/24h)  159.4 
(63.8) 
100.3 
(15.7) 
147.9 
(15.2) 
228.8 
(56.7) 
<0.001 
UNa:Cr  16.6 (6.3)  14.4 (5.3)  15.5 (4.8)  19.9 (7.1)  <0.001 
UCr (mmol/24h)  10.2 (3.7)  7.8 (2.8)  10.3 (2.9)  12.5 (3.8)  <0.001 
U Potassium (mmol/24h)  55.4 (20.8)  42.1 
(16.0) 
55.8 
(18.0) 
66.8 
(20.0) 
<0.001 
eGFR loss (ml/min/yr)   -2.8 (2.8)  -2.8 (3.3)  -2.7 (4.2)  -2.8 (4.0)  NS 
RRT (n, %)  102, 20.9  40 (24.7)  32 (19.8)  31 (18.9)  NS 
Deaths (n, %)  113, 23.2  49 (30.2)  28 (17.3)  36 (22.0)  0.02 
Table 3-3: Demographics of patients in each tertile of UNa. 
 
T1 = Tertile 1; T2 = Tertile 2; T3 = Tertile 3. Comparisons by one-way ANOVA, Chi-square or Kruskall-
Wallis test as appropriate. 
 123 
  
Variable  All 
patients 
N=488 
T1 
UNa:Cr 
N=163 
T2 
UNa:Cr 
N=162 
T3 
UNa:Cr 
N=163 
 
eGFR (ml/min/1.73m
2)  48.5 (25.6)  55.4 (23.9)  48.3 (26.0)  41.9 (25.1)  <0.001 
Age (y)  51.6 (16.7)  46.5 (14.8)  51.7 (17.2)  56.7 (16.6)  <0.001 
% male  50.4  60.9  56.3  34.2  <0.001 
SBP (mmHg)  139.0 
(23.0) 
134.2 
(21.8) 
139.4 
(22.5) 
143.6 
(23.8) 
0.001 
LogACR  1.13 (0.89)  0.93 (0.85)  1.15 (0.84)  1.32 (1.0)  0.001 
Weight (Kg)  75.6 (18.0)  77.1 (17.5)  76.4 (19.1)  73.3 (75.6)  NS 
Charlson co-morbidity 
score 
2.3 (1.6)  1.9 (1.3)  2.3 (1.7)  2.5 (1.7)  0.008 
UNa (mmol/24h)  159.4 
(63.8) 
128.6 
(37.7) 
160.0 
(55.5) 
189.7 
(76.8) 
<0.001 
U Cr (mmol/24h)  10.2 (3.7)  12.1 (3.5)  10.3 (3.5)  8.2 (3.2)  <0.001 
U Pot (mmol/24h)  55.4 (20.8)  55.2 (19.7)  56.7 (19.3)  54.4 (22.9)  NS 
eGFR loss (ml/min/yr)  -2.8 (2.8)  -2.5 (2.7)  -2.5 (2.8)  -2.9 (2.8)  NS 
Dead (n, %)  113, 23.2  20, 12.3  33, 20.4  60, 36.8  <0.001 
RRT (n, %)  102, 20.9  22, 13.5  37, 22.8  43, 26.4  0.004 
Table 3-4: Demographics of patients in each tertile of UNa:Cr. 
T1 = Tertile 1; T2 = Tertile 2; T3 = Tertile 3. Comparison via One-way ANOVA or Chi square as 
appropriate. 124 
3.3.5  Kaplan Meier survival analysis of time to RRT or death 
3.3.5.1  UNa 
Kaplan Meier analysis of time to RRT by tertile of UNa was performed and revealed no 
significant difference in risk between tertiles. With regards to risk of dying, those in T1 
(lowest tertile) were significantly more likely to die than those in the T2 (p=0.006) and 
there was a trend to an increased risk in T2 compared with those in the T3 (0.093). 
3.3.5.2  UNa:Cr 
Those in the T3 (the highest tertile) of UNa:Cr were significantly more likely to require 
RRT (p=0.01) (Figure 3-5) or die (p<0.001) (Figure 3-6) compared with those in T1 (the 
lowest tertile). The relationships were unaltered when looking at gender.  
Therefore, those with a high UNa:Cr had a worse outcome with regards to risk of death or 
requiring RRT than those with a low UNa:Cr. Conversely, tertile of UNa had no effect on 
risk of requiring RRT but those in the lowest tertile of UNa were more likely to die.  125 
 
 
Figure 3-5: 1-survival plot of time to RRT by tertile of UNa:Cr.  
Comparison by log-rank test with estimate of significance. 
 
 
 
Figure 3-6: 1-survival plot of time to death by tertile of UNa:Cr.  
Comparison by log rank test and estimate of significance. 126 
3.3.6  Binary logistic regression model of factors predictive of death 
On univariate analysis UNa:Cr (ExpB 1.09 (1.05-1.13) p<0.001), UNa (0.995 (0.992-
0.999, p=0.02), age (ExpB 1.08 (1.06-1.10) p<0.001), SBP (ExpB 1.03 (1.02-1.04) 
p<0.001), eGFR (ExpB 0.95 (0.93-0.96) p<0.001) and logACR (ExpB 2.87 (2.1-3.9) 
p<0.001) were significant predictors of risk of death.  
3.3.7  Cox survival analysis of risk of dying 
When all significant univariate predictors of death were entered into a Cox survival model, 
UNa:Cr remained a significant independent predictor of death – the higher the Na:Cr, the 
higher the risk (Table 3-5, Figure 3-6) along with eGFR, age and logACR. UNa was not a 
significant independent predictor of death. 
Variable  Exp(B)  95% CI  P 
eGFR (ml/min)  0.971  0.96-0.98  <0.001 
Age (years)  1.054  1.03-1.08  <0.001 
Log ACR  1.596  1.171-2.174  0.003 
UNa:Cr  1.035  1.0-1.07  0.042 
SBP (mmHg)  1.005  1.0-1.01  0.35 
Table 3-5: Cox survival model for risk of dying.  
Chi square value for model = 131.0. 
3.3.8  Binary logistic regression model of factors predictive of requirement 
for RRT  
To clarify whether urinary sodium excretion was an independent predictor of outcome, 
binary logistic regression and Cox survival modelling was undertaken. 
On univariate analysis, UNa (ExpB = 0.995 (0.991-0.999) p=0.01), UNa:Cr (Exp B 1.071 
(1.036-1.108) p<0.001), baseline eGFR (ExpB 0.903 (0.89-0.92) p<0.001), log ACR 
(ExpB 5.017 (3.4-7.4) p<0.001), age (ExpB 1.024 (1.01-1.04) p=0.001) and SBP (ExpB 
1.021 (1.011-1.031) p<0.001) were all significant predictors of requirement for RRT. 
Gender was not a significant independent predictor. 
3.3.9  Cox survival analysis of risk of requiring RRT 
Significant univariate predictors of requirement for RRT were entered together into a Cox 
survival model to ascertain which factors were significant independent predictors. UNa and 
UNa:Cr were entered separately due to high collinearity. Neither UNa:Cr nor UNa were 127 
significant independent predictors of time to RRT when entered separately into a Cox 
survival model with age, SBP, logACR and eGFR. eGFR and logACR were significant 
independent predictors of risk of requiring RRT. 
Variable  Exp(B)  95% CI  P 
eGFR 
(ml/min/1.73m
2) 
0.91  0.892-0.928  <0.001 
Log ACR  2.392  1.609-3.557  <0.001 
Na:Cr  1.002  0.965-1.041  0.911 
UNa (mmol/24h)  0.999  0.995-1.003  0.703 
Age (years)  0.989  0.974-1.005  0.181 
SBP (mmHg)  1.004  0.994-1.013  0.452 
Table 3-6: Cox survival model for risk of requiring RRT.  
Chi square for model =246.4. 
3.3.10   Urinary sodium, blood pressure and proteinuria 
On linear regression analysis, UNa:Cr was a significant independent predictor of mean 
arterial pressure (p=0.001). The relationship persisted when patients prescribed diuretics 
were excluded. Similarly, UNa was a significant independent predictor of MAP p=0.005). 
Both measures of urinary sodium were also significant independent predictors of logACR 
on linear regression (UNa p=0.03, UNa:Cr p=0.001) after adjusting for blood pressure and 
renal function.  
3.3.11  Urinary potassium as a predictor of outcome 
UK/24h correlated significantly with baseline renal function (r=0.235, p<0.001), risk of 
death (r= -0.156, p=0.003) or RRT (r= -0.16, p=0.011). UK/24h was a significant 
univariate predictor of death on binary logistic regression (ExpB 0.981 (0.97-0.99) 
p=0.004) and RRT (Exp B 0.98 (0.97-0.99) p=0.012), but not independent of renal 
function. UK:Cr did not correlate with risk of RRT or death. There was no correlation 
between UK:Cr or UK/24h and SBP or logACR. 
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3.4  Discussion 
This study has demonstrated the following key findings: 
  Urinary sodium excretion is lower in patients with lower eGFR 
  Fractional excretion of sodium is higher in patients with a lower eGFR 
  A high urinary sodium, adjusted for urinary creatinine excretion, is independently 
associated with an increased risk of death in patients with CKD 
  Urinary sodium excretion is associated with requirement for RRT, but not 
independently of eGFR or proteinuria excretion 
  No measure of urinary sodium is associated with rate of decline in renal function 
3.4.1  Sodium excretion and eGFR 
The kidney adapts to reduction in nephron mass by altering its handling of sodium and 
increasing the fractional excretion of sodium. As the overall glomerular filtration rate 
declines with falling nephron mass, there is an increase in single nephron GFR, decreased 
proximal tubular sodium reabsorption and altered capacity of the distal tubule to reabsorb 
sodium(262), increasing the fractional excretion of sodium. Through this mechanism, the 
kidneys maintain the ability to adjust to changes in sodium, thus maintaining equilibrium 
between sodium intake and excretion.  
Despite this, in this study it was shown that urinary sodium excretion is lower in patients 
with a lower eGFR, most markedly in CKD 5. This may be due to a reduced dietary intake, 
perhaps due to loss of appetite. Alternatively, despite the increase in the fractional 
excretion of sodium, perhaps the failing kidneys are unable to fully excrete sodium 
appropriately. However, even if sodium was stored in the recently proposed non-
osmotically active form(263) the accumulation of vast sodium stores over a number of 
years would likely lead to storage sites being overwhelmed, water retention and 
catastrophic consequences. 129 
3.4.2  Reporting of urinary sodium excretion rates 
24h urinary sodium excretion is a good marker of dietary sodium intake, even in patients 
with reduced eGFR, where 90% of ingested sodium is excreted in the urine under 
thermoconstant conditions (55). In this study, urinary sodium was adjusted for urinary 
creatinine excretion, which likely had two purposes. It will adjust for muscle mass, but 
may also take into account reduced GFR or reduced tubular secretion of creatinine, as a 
reflection of renal failure. It also removes uncertainty about the completeness of a 24h 
urine collection, although using a 24h sample to measure the ratio ensures it will accurately 
represent daily intake.   
3.4.3  Urinary sodium and risk of requirement for RRT or death 
Assessing whether urinary sodium excretion, the marker of dietary sodium intake, is 
associated with risk of renal progression and requirement for RRT will be confounded by 
baseline eGFR. To control for this, if one assumes that progression of renal disease is 
predominantly linear and unaffected by GFR, the absence of any association of urinary 
sodium measures with annual slope decline in eGFR suggests that sodium is not primarily 
involved in determining rate of renal decline. This is supported by the finding that urinary 
sodium excretion was not an independent predictor of requirement for renal replacement 
therapy, after adjusting for eGFR and urinary ACR, whichever measure was used.  
After adjusting urinary sodium for urinary creatinine excretion, those in the highest tertile 
of UNa:Cr had the highest urinary sodium excretion and the highest risk of death, even 
after adjusting for age, renal function, blood pressure and proteinuria. Those in the highest 
tertile of UNa:Cr also had the lowest urinary creatinine suggesting that a high dietary 
sodium intake should be viewed in proportion to muscle mass and body weight. This is a 
novel finding in patients with CKD.  
Dietary sodium intake was high in this cohort, however similar to a male cohort from 
Italy(264). Current recommendations are for a daily salt intake of not more than 6g/day 
(approximately 100mmol of sodium)(55), which our patients clearly exceed by around 
60%. This is despite a likelihood of 15% of patients providing an incomplete urinary 
collection. 130 
3.4.4  Potential pathogenic mechanisms of high sodium intake 
The potential pathogenic mechanisms explaining sodium mediated damage are multiple. 
Haemodynamic effects mediated via volume retention, resulting in increased shear stress, 
endothelial dysfunction, elevated preload, vascular stiffness and elevated afterload and left 
ventricular hypertrophy are plausible. Non-haemodynamic factors such as oxidative stress 
via superoxide production(67) and inflammatory mediators have been widely studied in rat 
models (68) (265;266). Normotensive and hypertensive rats fed a high salt diet developed 
vascular, glomerular and interstitial fibrosis(73), suggesting a directly nephrotoxic effect of 
dietary sodium.  
3.4.5  Population evidence of negative effects of high dietary sodium intake 
Damaging effects of dietary sodium on end-organs have been shown in a variety of 
populations. In observational studies, a study of normotensive and never treated 
hypertensives (59) demonstrated  that patients with a high dietary sodium intake exhibited 
increased left ventricular mass and albuminuria compared with those in the lowest quintile, 
which they hypothesised to be due to an amplification of the effect of hypertension. The 
Framingham Offspring Study, using a spot urinary sodium sample normalised to 
creatinine, demonstrated that each standard deviation increment in log urine sodium index 
to be associated with a 22% increase in urinary ACR, similar to my findings and also 
replicated by others(60;61). The Scottish Heart Health Study, looking at 11629 healthy 
middle aged individuals, with median urinary sodium excretion of 228 mmol/d, showed 
that urinary sodium excretion did not predict coronary heart disease in men but did in 
women, whilst urinary potassium excretion was protective(267).  
Tempering the findings of sodium reduction being associated with a reduction in 
cardiovascular events are data from hypertensive patients demonstrating an inverse 
relationship between urinary sodium values and risk of cardiovascular morbidity and 
mortality(268). It was postulated by these authors that low sodium intake results in 
increased renin-angiotensin system activation and resultant detrimental effects. A recent 
Cochrane review failed to conclude that reducing dietary sodium intake was convincingly 
associated with a reduction in cardiovascular events(269). Furthermore, a recent large 
prospective study in a Flemish population without cardiovascular disease found low 
urinary sodium excretion to be associated with an increased cardiovascular risk(270). 
Alderman has proposed a J-shaped effect, that when patients dietary sodium intake is 
particularly low or particularly high they are at increased cardiovascular risk(271).  131 
Similar findings were seen in the NHANES I cohort, where estimates of dietary sodium 
intake showed an inverse relationship with mortality(272). There were however limitations 
in the study designs of these trials(273). It is difficult to directly compare these cohorts 
with the patients in this study as my data relate to patients with impaired renal function and 
alternative physiological explanations may exist for urinary sodium excretion.  
The role of dietary potassium has largely been neglected despite good evidence that 
potassium intake is of great significance to vascular and endothelial health(64), and in 
INTERSALT the urinary potassium:sodium ratio had a significant inverse relationship 
with blood pressure, stronger than that of sodium or potassium excretion alone(54). In this 
study no evidence was found to support an independent protective effect of urinary 
potassium excretion in patients with CKD. 
3.4.6  Evidence for a negative effect of dietary sodium in patients with CKD 
In patients with renal disease, no studies have shown a high dietary sodium intake to be 
associated with the risk of requiring renal replacement therapy or death. A small cohort 
study from Italy(65) addressed the impact of sodium intake on progression of renal disease. 
They subdivided their group into those with a urinary sodium excretion of <100meq/day or 
>200meq/day and found the low sodium group to have a lower creatinine clearance at 
baseline, similar to our cohort, but a slower loss in renal function, which differs from our 
cohort, where no difference in rate of renal decline was noted in different groups. 
Dietary sodium intake has been shown to reduce proteinuria excretion, independent of a 
reduction in blood pressure, over 6 weeks (66). In patients with end stage renal failure 
treated with peritoneal dialysis, a low dietary sodium intake independently predicted 
increased risk for overall and cardiovascular death and was not explained by adjusting for 
deficient protein and energy intake(274).  
It should be emphasised that the anti-proteinuric response to inhibitors of the renin-
angiotensin system, the mainstay of drug therapy for renal protection, is augmented by a 
low sodium diet(275), presumably due to effects on volume status, providing a powerful 
argument for salt restriction in patients with CKD. 132 
3.4.7  Limitations 
This was a retrospective cohort analysis, although data were prospectively recorded, using 
real world patients prescribed a number of different medications; however by necessity 
most such studies are observational. An interventional approach is required to be certain of 
risks and benefits. Variations in diet during follow-up are not accounted for. An 
assessment of nutritional status would have been useful in this cohort. 
3.5  Conclusions 
 
As renal function declines, the kidneys compensate by increasing fractional excretion of 
sodium, but total urinary sodium excretion is lower in CKD5. Urinary sodium is closely 
related to weight and adjustment for urinary creatinine addresses this issue.  
A high urinary sodium:creatinine ratio, reflective of a proportionally high dietary sodium 
intake, in patients with chronic kidney disease, is associated with a significantly and 
independently increased risk of death. This is a novel finding and the first to confirm 
relationship between sodium intake and mortality in CKD. No measure of urinary sodium 
excretion was independently associated with decline in renal function or requirement for 
RRT. 133 
4  Chapter 4 - Mineralocorticoids and the renin-
angiotensin system in chronic kidney disease and 
essential hypertension; Determinants, impact of 
therapy, effects on end-organs and interaction with 
sodium. 
4.1  Introduction 
Patients with primary hyperaldosteronism, or hypertension in the context of an elevated 
aldosterone to renin ratio, suffer more adverse cardiovascular events than patients with 
essential hypertension(276). Animal models have shown that high aldosterone or 
deoxycorticosterone levels, together with a high sodium intake, affect the heart and kidney. 
Biventricular cardiac hypertrophy and fibrosis, renal glomerulosclerosis and tubular 
atrophy are seen (141). A number of clinical trials have demonstrated the cardiovascular 
benefits of mineralocorticoid receptor antagonists in patients with heart failure(125) or 
post-myocardial infarction(126) and anti-proteinuric effects in patients with CKD(119). 
These findings are discussed in detail in section 1.5.5. 
Despite significant laboratory and interventional trial evidence of the benefits of MR 
blockade, there remains a paucity of data regarding the physiological control and actions of 
mineralocorticoids in CKD. Older studies assessing plasma aldosterone levels in patients 
with CKD suggest that aldosterone levels rise as renal function falls(277). However, the 
value of single measurements of plasma aldosterone levels is limited by the impact of 
posture, episodic secretion of the hormone and diurnal variation, although less so than for 
cortisol.  
Measurement of urinary steroid metabolites over 24h is more representative of aldosterone 
status as it eliminates these variations, but it has not been widely adopted in studies of 
renal disease (See section 1.4.9).  
The aims of this study were therefore as follows: 
1.  To compare levels of aldosterone, deoxycorticosterone and cortisol in patients with 
CKD with those in patients with EH, as a control group. Are levels higher in 
patients with CKD for the same level of blood pressure?  134 
2.  Do patients with diabetes mellitus have higher steroid levels than other patient 
groups?  
3.  Are determinants of mineralocorticoid excretion rates (reflecting regulation of 
synthesis), similar in patients with CKD and patients with EH?  
4.  Are steroid levels associated with end-organ damage as exemplified by left 
ventricular mass, proteinuria, pulse wave velocity and endothelial function?  
5.  Does the level of sodium intake modulate the damaging effects of steroids? 
4.2  Methods 
Patients were recruited and assessed according to the protocol described in chapter 2. 
Statistical analysis was performed using SPSS (Illinois) version 15.0. 
4.3  Results 
4.3.1  Patient Demographics 
Table 4-1 describes the baseline demographics of the cohort, stratified by group.  
Patients with EH and CKD were well matched with no significant differences in gender, 
age, weight or LV mass. EH patients had a significantly higher DBP and significantly 
lower PWV. Within the CKD cohort, patients with IgAN were significantly younger and 
had significantly lower SBP. Diabetic patients had a significantly higher PWV and LVMI.  
Fifteen patients agreed to undergo 24h blood pressure monitoring. There was close 
correlation between the clinic blood pressure reading average and the daytime average 
(SBP p<0.001, DBP p<0.001) and the 24h blood pressure average (SBP p<0.001, DBP 
p<0.001). 
Biochemical differences between the EH and CKD cohorts are as would be expected 
(Tables 4-2 & 4-3). Renal patients had significantly lower eGFR levels, had higher 
concentrations of serum urate, CRP, potassium, serum phosphate and PTH and lower 
concentrations of vitamin D, serum albumin and haemoglobin. Serum sodium was not 
significantly different between groups, but serum potassium was significantly lower in the 135 
EH group. Renal patients had higher levels of proteinuria and significantly lower levels of 
urinary potassium excretion rates. Within the renal cohort, patients with membranous 
nephropathy had better preserved renal function, lower levels of PRC and higher levels of 
serum cholesterol. Patients with diabetic nephropathy had poorer renal function and lower 
haemoglobin levels.  136 
 
Variable  EH 
controls 
 
N=30 
CKD 
patients 
 
N=70 
p  DMN 
 
 
N=34 
IgAN 
 
 
N=27 
MGN 
 
 
N=9 
p 
Age (y)  55.4 (9.2)  58.2 (12.8)  NS ∞  61.8 (13.0)  52.9 
(12.1) 
60.5 (9.2)  0.019 ʔ 
% Male  83.3  75.7  NS δ  76.5  77.8  66.7  NS δ 
Smoker (%) 
-Current 
-Ex 
-Never 
 
10 
26.7 
63.3 
 
20.0 
32.9 
47.1 
 
 
 
NS δ 
 
14.7 
41.2 
41.2 
 
18.5 
22.2 
59.3 
 
33.3 
33.3 
33.3 
 
 
 
NS δ 
Weight (Kg)  88.4 (15.2)  85.6 (19.7)  NS ∞  88.0 (16.6)  85.7 
(25.1) 
76.2 (6.6)  NS ʔ 
BMI (Kg/m2)  29.3 (4.8)  29.3 (5.8)  NS ∞  30.7 (5.7)  28.4 (6.1)  26.8 (4.9)  NS ʔ 
Waist circumference 
(cm) 
100.5 (12.1)  99.9 (13.5)  NS ∞  104.5 
(12.0) 
96.7 
(15.3) 
92.7 (7.3)  0.021 ʔ 
SBP (mmHg)  151.5 (19.7)  147.2 (23.0)  NS ∞  156.8 
(21.3) 
135.6 
(17.9) 
145.4 
(28.4) 
0.001 ʔ 
DBP (mmHg)  93.4 (11.4)  82.1 (12.3)  <0.001 
∞ 
80.0 (13.4)  85.6 
(10.0) 
83.0 (13.7)  NS ʔ 
MAP (mmHg)  112.8 (13.3)  103.8 (14.0)  NS ∞  105.6 
(14.9) 
101.6 
(11.7) 
103.8 
(17.6) 
NS ʔ 
PP (mmHg)  58.1 (13.4)  65.0 (19.0)  0.004 ∞  76.8 (14.9)  51.0 
(13.1) 
62.4 (19.5)  <0.001 
ʔ 
HR (bpm)  70.2 (12.5)  72.3 (13.4)  NS ∞  74.7 (14.4)  70.9 
(12.6) 
67.4 (10.9)  NS ʔ 
ECG abnormality (%)  16.7  35.3  0.049 ∞  45.5  35.3  0  NS ʔ 
AIx  26.4 (11.6)  23.7 (10.3)  NS ∞  24.6 (10.7)  21.1 (9.7)  27.9 (10.1)   NS ʔ 
AIx@75bpm  24.9 (10.8)  22.1 (10.1)  NS ∞  23.7 (10.0)  19.1 
(10.4) 
24.7 (8.8)  NS ʔ 
PWV (m/s)  7.9 (6.7-
9.1) 
9.4 (7.3-
13.5) 
0.006 ∞  11.8 (9.3-
15.3) 
7.0 (5.8-
9.4) 
7.7 (6.3-
10.3) 
<0.001 
ʔ 
RHI  1.9 (1.7-
2.4) 
1.8 (1.5-2.4)  NS ∞  1.6 (1.4-
2.2) 
2.0 (1.6-
2.5) 
1.8 (1.5-
2.7) 
NS ʔ 
EF (%)  68.1 (10.5)  68.9 (10.9)  NS ∞  71.0 (7.7)  67.1 
(12.6) 
67.9 (13.6)  NS ʔ 
cEDV (ml/m
2)  67.1 (15.6)  60.3 (16.1)  NS ∞  57.8 (12.0)  62.4 
(11.8) 
61.7 (31.6)  NS ʔ 
cESV (ml/m
2)  21.8 (19.9)  19.9 (10.3)  NS ∞  16.9 (6.2)  21.3 (9.4)  24.5 (19.1)  NS ʔ 
MC mass ED (g)  175.9 (53.5)  170.3 (49.8)  NS ∞  193.1 
(50.0) 
151.6 
(41.7) 
160.4 
(50.5) 
0.01 ʔ 
LVMI (g/m
2)  87.1 (22.2)  84.7 (20.4)  NS ∞  94.1 (19.9)  75.4 
(15.0) 
84.3 (25.1)  0.004 ʔ 
Table 4-1: Baseline demographics stratified by group. 
Data presented as mean (SD) or median (IQR). Comparisons made using t-test (∞) or one-way ANOVA 
(ʔ) for normally distributed data and Mann Whitney U-test (ε) or Kruskall-Wallis test (γ) for non-
parametric analysis. Categorical variables were compared using the Chi Square test (δ). P<0.01 = 
significant (highlighted in bold). 
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Variable  EH controls 
 
N=30 
CKD 
patients 
N=70 
p  DMN 
 
N=34 
IgAN 
 
N=27 
MGN 
 
N=9 
p 
MDRD4 
(ml/min/1.73m
2) 
92.1 (18.5)  40.3 (24.2)  <0.001 
∞ 
32.4 (17.1)  41.1 (23.5)  64.3 (33.8)  0.001  
ʔ 
MDRD6 
(ml/min/1.73m
2) 
90.4 (18.2)  38.6 (24.1)  <0.001 
∞ 
30.8 (17.9)  41.3 (24.1)  60.1 (32.0)  0.003 
ʔ 
C&G 
(ml/min/1.73m
2) 
113.8 (89.2-
143.8) 
45.3 (30.4-
65.0) 
<0.001 
ε  
38.8 (27.7-
53.2) 
49.9 (29.3-
88.1) 
59.9 (44.9-
100.5) 
NS γ 
Cr (umol/l)  76 (66-88)  176 (129-
258) 
<0.001 
ε 
222 (155-
268) 
175 (113-
261) 
107 (71-
153) 
0.007 γ 
UCrCl   129.9 (102.0-
166.1) 
43.3 (29.5-
66.4) 
<0.001 
ε 
35.5 (28.2-
53.9) 
46.7 (27.6-
97.9) 
62.7 (56.9-
99.7) 
0.01 γ 
Total Chol (mmol/l)  4.8 (0.9)  4.5 (1.2)  NS ∞  4.0 (0.9)  4.6 (1.2)  5.8 (1.5)  <0.001 
ʔ 
HDL (mmol/l)  1.3 (0.4)  1.2 (0.5)  NS∞  1.13 (0.4)  1.3 (0.5)  1.4 (0.5)  NS ʔ 
LDL (mmol/l)  2.9 (0.8)  2.4 (0.9)  NS∞  2.0 (0.6)  2.7 (1.0)  3.2 (0.4)  NS ʔ 
Chol:HDL  3.9 (1.0)  4.0 (1.3)  NS∞  3.8 (1.3)  3.9 (1.1)  4.6 (1.7)  NS ʔ 
TG (mmol/l)  1.5 (1.2-2.2)  1.5 (1.1-2.2)  NS∞  1.4 (1.0-2.5)  1.6 (1.2-
2.0) 
1.1 (1.0-
3.0) 
NS γ 
Urate (mmol/l)  0.34 (0.09)  0.45 (0.13)  <0.001 
∞ 
0.47 (0.13)  0.45 (0.13)  0.41 (0.1)  NS ʔ 
Sodium (mmol/l)  139 (2)  139 (3)  NS ∞  139 (3)  139 (3)  140 (2)  NS ʔ 
Potassium (mmol/l)  3.8 (0.3)  4.6 (0.6)  <0.001 
∞ 
4.7 (0.5)  4.5 (0.5)  4.5 (0.8)  NS ʔ 
CRP (mg/l)  1.5 (0.9-3.6)  2.9 (1.5-6.2)  0.01 ε  3.3 (1.7-6.5)  2.4 (1.1-
4.3) 
4.6 (1.3-
9.1) 
NS γ 
Albumin (g/l)  39.7 (3.3)  36.9 (3.9)  <0.001 
∞  
35.9 (4.4)  38.6 (2.9)  35.5 (2.4)  NS ʔ 
PO4 (mmol/l)  1.0 (0.23)  1.20 (0.23)  <0.001 
∞ 
1.21 (0.19)  1.18 (0.28)  1.18 (0.20)  NS ʔ 
AdCal (mmol/l)  2.40 (0.07)  2.38 (0.10)  NS ∞  2.38 (0.08)  2.37 (0.12)  2.41 (0.10)  NS ʔ 
CaPO4  2.39 (0.60)  2.80 (0.63)  0.003 ∞  2.79 (0.68)  2.79 (0.61)  2.85 (0.54)  NS ʔ 
PTH (pmol/l)  5.8 (4.8-6.7)  11.5 (6.0-
20.9) 
<0.001 
ε 
14.6 (7.4-
23.6) 
9.0 (6.4-
18.1) 
6.5 (4.9-
11.2) 
NS γ 
Vit D (ng/ml)  19.5 (13.8-
26.3) 
13.0 (5.0-
19.3) 
0.005 ε  12.0 (2.5-
17.3) 
11.0 (7-19)  18 (13-28)  NS γ 
Hb (g/dl)  14.6 (1.3)  12.3 (1.8)  <0.001  
∞ 
11.5 (1.6)  13.2 (1.6)  12.6 (1.4)  0.001 
ʔ 
PAC (pmol/l)  236.5 (163.2-
331.3) 
254.5 
(162.3-
442.5) 
NS ε  263.0 
(140.5-
421.3) 
256.0 
(185-542) 
160 (131-
420) 
NS γ 
PRC (uIU/ml)  32.4 (17.7-
91.2) 
62.4 (17.0-
213.9) 
NS ε  59.3 (19.1-
226.9) 
81.6 (28.2-
371.8) 
9.7 (1.0-
61.6) 
0.01 γ 
ARR  7.0 (1.9-
11.0) 
3.9 (1.2-
17.9) 
NS ε  3.4 (1.2-
13.2) 
3.6 (1.0-
17.1) 
21.1 (4.3-
190.0) 
NS γ 
Table 4-2: Plasma and serum measurements by group. 
Data presented as mean (SD) or median (IQR). Comparisons made using t-test (∞) or one-way ANOVA 
(ʔ) for normally distributed data and Mann Whitney U-test (ε) or Kruskall-Wallis test (γ) for non-
parametric analysis. Categorical variables were compared using the Chi Square test (δ). P<0.01 = 
significant (highlighted in bold). 138 
 
Variable  EH 
controls 
N=30 
CKD 
patients 
N=70 
P  DMN 
 
N=34 
IgAN 
 
N=27 
MGN 
 
N=9 
p 
U Sod  
(mmol/l) 
80.0 (45.1)  79.3 (33.2)  NS ∞  75.4 (24.2)  79.9 (36.2)  92.1 (51.0)  NS 
ʔ 
U Sod 
(mmol/24h) 
155.7 (79.7)  162.9 (70.4)  NS ∞  169.8 (69.4)  149.9 (59.7)  173.5 
(100.6) 
NS 
ʔ 
U Pot  
(mmol/l) 
41.6 (19.1)  29.6 (12.3)  0.003 ∞  27.6 (8.3)  34.0 (15.6)  24.1 (10.5)  NS 
ʔ 
U Pot (mmol/24h)  86.4 (31.1)  61.0 (24.1)  <0.001 
∞ 
60.7 (20.2)  64.0 (27.6)  53.3 (27.5)  NS 
ʔ 
QP 
(g/l) 
0.0 (0.0-0.0)  0.5 (0.2-1.1)  <0.001 ε  0.7 (0.2-1.7)  0.3 (0.2-
0.7) 
0.5 (0.4-1.2)  NS γ 
QP 
(g/24h) 
0.1 (0.1-0.1)  1.0 (0.3-2.8)  <0.001 ε  1.5 (0.4-3.6)  0.6 (0.3-
1.4) 
1.0 (0.4-3.2)  NS γ 
uPCR  
(mg/mmol) 
0.0 (0.0-2.0)  75 (21-220)  <0.001 ε  132 (19-
270) 
48 (19-153)  75 (35-285)  NS γ 
Table 4-3: Urine measurements by group. 
Data presented as mean (SD) or median (IQR). Comparisons made using t-test (∞) or one-way ANOVA 
(ʔ) for normally distributed data and Mann Whitney U-test (ε) or Kruskall-Wallis test (γ) for non-
parametric analysis.  139 
4.3.2  Urine collection adequacy 
In this study, 84% of measured creatinine clearance rates were within 35% of the expected 
creatinine clearance rates. In the majority of patients out with this range (12 patients), the 
24h measured creatinine clearance was greater than the expected creatinine clearance, 
suggesting error relating to the estimation calculation (Cockcroft and Gault) rather than 
incomplete collections (Figure 4-1) and therefore the collections are valid. 
Measured CrCl = ((UCr (mmol/l)*1000) * UVol (ml)) / (Scr (mmol/l) * 1440) 
Estimated CrCl (C&G) = ((140-age)*weight (Kg) *1.23 male, 1.04 female) / sCr 
A previous study found that in 94% of normal individuals, the measured creatinine 
clearance will be within ± 35% of the estimated creatinine clearance(261). 
4.3.3  Measured levels of urinary steroids, plasma aldosterone and plasma 
renin concentration in study cohort.   
Excretion rates of THALDO, THDOC and cortisol metabolites did not differ between 
patients with essential hypertension and patients with CKD (Table 4-4). Similarly, there 
were no significant differences in excretion rates between primary renal diseases (DMN, 
IGAN or MGN) (Figure 4-1).  
PAC and PRC did not differ significantly between patient groups. PRC was significantly 
lower in patients with membranous nephropathy compared with DMN or IgAN (p=0.01). 
Three of these patients were prescribed cyclosporine, which ordinarily would increase 
PRC, but in fact these patients had a PRC of less than 10uIU/ml. If these patients are 
excluded the median PRC in the membranous group remained significantly lower at 17.5 
(7.5-112.9) uIU/ml (p=0.02).  
THE levels were higher in essential hypertensives. The ratio of (THF + aTHF) : THE 
(reflecting hepatic 11βHSD1 activity – see section 1.4.8) was higher in CKD patients. 
Table 4-5 shows that urinary free cortisone and cortisol measurements, which were 
available for 78 patients, did not differ significantly between groups, nor did the urinary 
F:E ratio (predominantly reflecting 11βHSD2 activity). 140 
THS, the derivative of deoxycortisol, and total cortisol metabolite excretion rates did not 
differ between patients with hypertension and patients with CKD, nor did the ratio of S 
(deoxycortisol) to F (cortisol).  141 
 
Variable  Normal 
range 
  
EH 
controls 
N=30 
CKD 
patients 
N=70 
P  DMN 
 
N=34 
IgAN 
 
N=27 
MGN 
 
N=9 
p 
THALDO 
(mcg/24h) 
10-120  62.3 (24.0)  56.7 (22.8)  NS ∞  59.1 (25.5)  53.5 
(21.6) 
56.2 
(14.5) 
NS 
ʔ 
THDOC 
(mcg/24h) 
2-28  75.2 (32.5)  66.1 (23.0)  NS ∞  68.9 (22.5)  62.3 
(24.5) 
65.8 
(21.3) 
NS 
ʔ 
THS (mcg/24h)  3-130  50.1 (20.7)  43.3 (20.8)  NS ∞  45.7 (21.8)  38.6 
(19.2) 
46.5 
(21.3) 
NS 
ʔ 
CORT 
METAB 
(mcg/24h) 
  100049 
(4985) 
8507 (5050)  NS ∞  7425 
(3831) 
10506 
(6442) 
7268 
(3444) 
NS 
ʔ 
Ratio (THF + 
aTHF: THE) 
  1.7 (1.5-
2.1) 
2.3 (1.8-
4.0) 
0.001 ε  2.5 (1.8-
4.2) 
2.1 (1.7-
3.9) 
2.0 (1.5-
3.2) 
NS 
γ 
Ratio (THS : 
THF + aTHF) 
  0.025 
(0.025) 
0.021 
(0.011) 
NS ∞  0.022 
(0.007) 
0.018 
(0.01) 
0.029 
(0.02) 
NS 
ʔ 
THE (mcg/24h)  1100-5100  3297 (2175-
4644) 
2030 (1293-
2905) 
<0.001 
ε 
1648 
(1229-
2515) 
2388 
(1304-
3890) 
2103 
(1385-
3271) 
NS 
γ 
THF (mcg/24h)  310-3680  2969 (1758-
3932) 
2235 (1442-
3131) 
NS ε  2187 
(1336-
2869) 
2574 
(1702-
3658) 
1740 
(1169-
3066) 
NS 
γ 
ATHF 
(mcg/24h) 
490-3480  3112 (1628-
4518) 
3074 (1671-
4694) 
NS ε  2541 
(1257-
4396) 
4035 
(1970-
7062) 
3366 
(1929-
3739) 
NS 
γ 
PAC 
(pmol/l) 
100-400 
(supine) 
236.5 
(163.2-
331.3) 
254.5 
(162.3-
442.5) 
NS ε  263.0 
(140.5-
421.3) 
256.0 
(185-542) 
160 (131-
420) 
NS 
γ 
PRC 
(uIU/ml) 
0-40 
(supine) 
32.4 (17.7-
91.2) 
62.4 (17.0-
213.9) 
NS ε  59.3 (19.1-
226.9) 
81.6 
(28.2-
371.8) 
9.7 (1.0-
61.6) 
0.01 
γ 
ARR  <35  7.0 (1.9-
11.0) 
3.9 (1.2-
17.9) 
NS ε  3.4 (1.2-
13.2) 
3.6 (1.0-
17.1) 
21.1 (4.3-
190.0) 
0.05 
γ 
Table 4-4: Urinary steroid metabolites and plasma RAAS measurements in the whole cohort and 
stratified by group.  
Data presented as mean (SD) or median (IQR). Comparisons made using t-test (∞) or one-way ANOVA 
(ʔ) for normally distributed data and Mann Whitney U-test (ε) or Kruskall-Wallis test (γ) for non-
parametric analysis. Categorical variables were compared using the Chi Square test (δ). P<0.01 = 
significant. Reference range for PRC(278). 
Variable  Whole 
cohort 
N=78 
EH 
controls 
N=25 
CKD 
patients 
N=53 
p  DMN 
 
N=27 
IgAN 
 
N=17 
MGN 
 
N=9 
P 
F  8.2 (4.4-
12.6) 
7.0 (4.0-
15.7) 
8.8 (4.4-12)  NS 
ε 
7.6 (4.2-
13.3) 
8.8 (6.6-
11.0) 
10.3 (3.7-
12.3) 
NS 
γ 
E  31.6 (13.8)  34.6 (13.9)  30.3 (13.6)  NS 
∞ 
34.4 
(15.0) 
28.3 (9.1)  21.6 (12.7)  NS 
ʔ 
F:E  0.3 (0.2-
0.4) 
0.2 (0.1-
0.4) 
0.3 (0.2-
0.5) 
NS 
ε 
0.3 (0.2-
0.4) 
0.3 (0.2-
0.6) 
0.5 (0.2-
0.9) 
NS 
γ 
Table 4-5: Urinary free steroid measurements (mcg/24h) by group.  
Data presented as mean (SD) or median (IQR). Comparisons made using t-test (∞) or one-way ANOVA 
(ʔ) for normally distributed data and Mann Whitney U-test (ε) or Kruskall-Wallis test (γ) for non-
parametric analysis. Categorical variables were compared using the Chi Square test (δ). P<0.01 = 
significant.  
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Figure 4-1: Bar chart of mean (SD) levels of steroid and renin by disease group. 
THAldo (A), THDOC (B), log PAC (C) and square root PRC (D) concentrations according to patient 
group. Comparisons made using one-way ANOVA. 143 
4.3.4  Urinary cortisol and cortisone measurements 
Seventy-eight patients had measurements of 24h urinary free cortisol (F) excretion rate, of 
whom 25 had EH and 53 had CKD. Seventy-five had 24h urinary free cortisone (E) 
excretion rates, of whom 24 had EH and 51 had CKD (Table 4-5). There were no 
significant differences in measurements of F, E or F:E ratio between patients with CKD or 
EH. There was no correlation between measurements of F, E or F:E and eGFR, LVMI, 24h 
UProt, 24h USod, THDOC or THALDO excretion. There was therefore no evidence to 
support the hypothesis that there is reduced 11BHSD2 activity in CKD. 
4.3.5  Association between renal function measurements and THALDO, 
THDOC, plasma aldosterone and plasma renin concentration.  
No significant association was seen between level of renal function, estimated using the 
MDRD6 formula, and steroid measurements (THALDO, THDOC), PRC or PAC levels, in 
the cohort as a whole (Figure 4-2). There was a trend towards higher PRC levels with 
poorer renal function but this did not reach statistical significance (p=0.053). When 
patients prescribed β-blockers were excluded, this relationship was significant (r=-0.289, 
p=0.02).  
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Figure 4-2: Scatterplot of THAldo excretion (A), THDOC excretion (B), PAC (C) and PRC (D) and 
eGFR with fitted linear regression line and estimate of significance. 
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4.3.6  Association between prescribed medications and steroid 
measurements 
Drug therapies are described in Table 4-6. CKD patients were prescribed a higher number 
of anti-hypertensives compared with the hypertensive cohort (2.6 vs. 2.1 p=0.045), and 
were significantly more likely to be prescribed a loop diuretic, an HMG CoA reductase 
inhibitor, a β-blocker and an ACE inhibitor. Hypertensive patients were more likely to be 
prescribed a thiazide diuretic. Within the CKD cohort, patients with IgA nephropathy were 
less likely to be prescribed an alpha blocker. 
4.3.6.1  Urinary steroid excretion and drug prescription 
To assess whether different drug classes affected urinary steroid metabolite excretion or 
plasma measures, levels were compared in patients prescribed these medications versus 
those not (Table 4-7). 
ARB treatment of patients with CKD resulted in significantly higher excretion of 
THALDO (61.6 vs. 50.4, p=0.018) and THDOC (72.7 vs. 50.4 p=0.042), which was not 
seen in the EH group. No effect was seen with ACEi in either group. Patients with EH 
demonstrated a marked increase in THALDO (78.9 vs. 47.3 mcg/24h, p<0.001) and 
THDOC (97.4 vs. 54.5 mcg/24h, p<0.001) excretion with aspirin treatment but this was 
not seen in patients with CKD.  
4.3.6.2  PAC and drug prescription 
PAC was significantly lower in CKD patients prescribed an ACEi (p=0.01; median 217 vs. 
415 pmol/l). Prescription of an ACEi did not significantly affect PAC levels in EH 
patients.  
4.3.6.3  PRC and drug prescription 
Patients with EH prescribed thiazide diuretics had a higher median PRC (83.8 vs. 
24.1uIU/ml, p=0.018), which was not seen in CKD patients, perhaps due to the low 
thiazide usage in this group. Patients with EH prescribed a statin had a significantly lower 
median PRC (20.9 vs. 78.7 uIU/ml, p=0.004), reflected in a significantly higher ARR 
(p=0.002), than patients who were not prescribed a statin. 146 
Clearly, the possibility of interpreting these values is limited because patients were not 
prescribed individual drugs in isolation and the impact of different drugs on the RAAS 
varies e.g. loop diuretics increase PRC and plasma Aldo levels whilst ACEi reduce plasma 
Aldo and increase PRC (see intro section 1.4.10). 
4.3.6.4  Independent drug effects on steroid measurements  
Looking at all patients together, a multivariate linear regression model was constructed 
entering all the hypertensive drug classes together for the predicted variable of √PRC. β-
blocker treatment resulted in a significantly lower level of PRC (B= -0.21, p=0.04). 
Undertaking the same analysis for log PAC, ACEi (B= -0.204, p=0.002) and loop diuretics 
(B= 0.169, p=0.016) were significant independent predictors. No drug significantly 
predicted THALDO excretion using the same analysis. 147 
 
DRUG 
% prescribed 
EH 
N=30 
CKD 
N=70 
P  DMN 
N=34 
IGAN 
N=27 
MGN 
N=9 
P 
ACE  36.7  64.3  0.01  67.6  63.0  55.6  NS 
ARB  43.3  42.9  NS  35.3  48.1  55.6  NS 
ACE & ARB  0  25.7  0.001  29.4  18.5  33.3  NS 
β blocker  13.3  32.9  0.035  41.2  33.3  0.0  NS 
CCB  56.7  44.3  NS  52.9  44.4  11.1  NS 
Central  0.0  4.3  NS  2.9  3.7  11.1  NS 
α blocker  12  17.1  NS  26.5  0.0  33.3  0.009 
Loop  4  50  <0.001  55.9  40.7  55.6  NS 
Thiazide  56  5.7  <0.001  8.8  3.7  0.0  NS 
Aspirin  48  47  NS  55.9  37.0  44.4  NS 
Statin  43  68.6  0.016  79.4  63.0  44.4  NS 
Total number anti-
BP meds 
2.1  2.6  0.045  2.9  2.4  2.2  NS 
Table 4-6: Drug prescriptions by group – expressed as percentage of patients prescribed.  
Comparisons made using Chi Square test. 
Patient group  Drug  THALDO  THDOC  PAC  PRC  ARR 
CKD patients  ACEi      0.01    0.03 
  ARB   0.02  0.04       
EH patients  Thiazide        0.02   
  Aspirin  <0.001  <0.001       
  Statin        0.004  0.002 
Table 4-7: Significant differences, expressed as a p value, in measures of urinary steroid metabolites 
and plasma measures in patients prescribed certain drugs versus those not, stratified by patient group. 
Comparisons made by t-test or Mann Whitney U test as appropriate.  148 
4.3.7  Correlations between steroid and RAAS measurements and clinical 
measurements 
Levels of THALDO and THDOC excretion, cortisol metabolites, PAldo, PRC and ARR 
were entered into a correlation matrix with the following demographic and laboratory 
markers: age, sex, weight, waist circumference, SBP, DBP, AIx, AIx@75bpm, ECG 
abnormalities, PWV, RHI, EF, EDV/BSA, ESV/BSA, LVMI, eGFR (MDRD6), CRP, 
urate, total cholesterol, TG, HDL, LDL, C/HDL ratio, AdCal, phosphate, PTH, vitamin D, 
Hb, 24h QP, PCR, USod (mmol/24h) and UPot (mmol/24h). Spearman’s or Pearson’s 
correlation coefficients are reported as appropriate with p<0.01 deemed as significant. 
There were significant differences between groups in terms of significant correlates 
(Tables 4-8 and 4-9).  
THALDO and THDOC excretion rates correlated significantly positively with 24h USod 
excretion and 24h UPot excretion in CKD patients, but not in EH. There was also a strong 
correlation between THALDO and THDOC excretion and urinary protein excretion and 
LVMI in patients with CKD. In EH patients the strongest correlate with THALDO and 
THDOC excretion was serum parathyroid hormone. 
Plasma aldosterone concentration correlated significantly with LVMI and female gender in 
EH but not CKD. 
In EH patients PRC correlated significantly with thiazide diuretic and statin usage. In 
CKD, PRC was inversely correlated with SBP, DBP, serum sodium and AIx@75bpm. 
ARR correlated more closely with PRC than PAC in both groups, suggesting PRC is a 
stronger determinant. Correlations with the ARR reflected those seen with PRC. 
Excretion of cortisol metabolites correlated significantly with weight in both groups and 
waist circumference in EH. There was also a positive correlation with 24h USod in CKD 
patients and cortisol metabolite excretion correlated with EDV/BSA and AIx@75bpm in 
CKD patients.  
 149 
 
EH patients 
N=30 
THAldo  THDOC  Cort 
Metab 
PAC  PRC  ARR 
THAldo  1  0.963 
<0.001 
       
THDOC  0.963 
<0.001 
1         
PAC            0.517 
0.004 
PRC            -0.839 
<0.001 
Age             
Male sex        -0.537 
0.002 
   
Weight      0.623 
<0.001 
     
Waist 
circumf. 
    0.572 
0.001 
     
SBP             
DBP             
Serum Na             
PTH  -0.673 
<0.001 
-0.625 
0.001 
       
C/HDL             
UNa 
(mmol/24h) 
           
UPot 
(mmol/24h) 
           
uPCR             
24h QP             
EDV/BSA             
LVMI        0.57 
0.001 
   
AIx@75bpm             
Thiazide 
diuretic 
      0.523 
0.009 
   
Statin 
therapy 
      -0.512 
0.005 
   
Table 4-8: Correlation matrix including EH patients. 
Only significant correlations reported. Data expressed as r (correlation coefficient) and p (significance).  150 
 
CKD 
patients 
N=70 
THAldo  THDOC  Cort 
Metab 
PAC  PRC  ARR 
THAldo  1  0.917 
<0.001 
       
THDOC  0.917 
<0.001 
1         
PAC            0.424 
<0.001 
PRC            -0.907 
<0.001 
Age             
Male sex             
Weight      0.404 
0.001 
     
Waist 
circumf. 
           
SBP          -0.485 
<0.001 
0.395 
0.001 
DBP          -0.31 
0.009 
 
Serum Na          -0.338 
0.004 
0.326 
0.006 
PTH             
C/HDL             
UNa 
(mmol/24h) 
0.614 
<0.001 
0.526 
<0.001 
0.331 
0.007 
     
UPot 
(mmol/24h) 
0.538 
<0.001 
0.481 
<0.001 
       
uPCR  0.354 
0.004 
0.32 
0.009 
       
24h QP  0.426 
<0.001 
0.371 
0.002 
       
EDV/BSA      0.383 
0.004 
     
LVMI  0.43 
0.001 
0.447 
0.001 
       
AIx@75bpm      -0.388 
0.002 
  -0.359 
0.001 
 
Thiazide 
diuretic 
           
Statin 
therapy 
           
Table 4-9: Correlation matrix including CKD patients.  
Only significant correlations reported. Data expressed as r (correlation coefficient) and p (significance).  151 
4.3.8  Relationship between urinary steroid excretion and urinary 
electrolytes 
4.3.8.1  Urinary sodium excretion and steroid excretion rates 
Aldosterone promotes sodium reabsorption and a high plasma sodium should suppress 
aldosterone release. In patients with CKD, THALDO and THDOC each strongly positively 
associated with urinary sodium excretion (THALDO R
2 = 0.38, THDOC R
2=0.28) (Figure 
4-3). In patients with EH no relationship was seen between THALDO excretion and 
urinary sodium. 152 
 
 
Figure 4-3: Scatterplot of urinary sodium excretion (mmol/24h) versus THAldo or THDOC excretion, 
with fitted linear regression line and estimate of significance.  
A and B = CKD patients, C and D = EH patients. 153 
4.3.8.2  Urinary potassium and urinary steroid excretion rates 
In both groups, a higher 24h UPot excretion was associated with a higher 24h THAldo 
excretion rate (CKD patients R
2=0.36, p<0.001 and EH patients R
2=0.15, p=0.04) (Figure 
4-4).  154 
 
 
Figure 4-4: Scatterplot of THAldo excretion versus urinary potassium excretion (mmol/24h) with fitted 
linear regression line and an estimate of significance. A = EH patients; B = CKD patients. 
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4.3.8.3  THE, THF and THS and urinary electrolyte excretion 
If excretion rates of THAldo and THDOC were simply a reflection of solute drag in 
patients with CKD, then THE, THF and THS would similarly exhibit correlations with 
urinary electrolytes. In fact, there was no correlation between these measures with urinary 
potassium and only a weak correlation with urinary chloride (r=0.28 p=0.02) and urinary 
sodium (r=0.356, p=0.03) in patients with CKD. In patients with EH, no correlation was 
seen between urinary electrolytes and urinary cortisol metabolites. 
4.3.9  The relationships between steroid levels and traditional trophins. 
To determine whether PRC, serum potassium, serum sodium and ACTH are associated 
with Aldo levels, linear regression models were constructed for patients with EH and 
patients with CKD. 
4.3.9.1  PRC  
No significant relationship was seen in CKD patients between PRC and PAC, THALDO or 
THDOC excretion (Figure 4-5). There was a non-significant trend towards a higher level in 
the three variables with higher PRC in patients with EH (p=0.2). 156 
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Figure 4-5: Scatterplot of PRC and THAldo, THDOC and PAC.  
A,C and E = EH patients. B,D and F = CKD patients. Fitted linear regression line and estimates of 
significance.  
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4.3.9.2  Serum potassium 
In patients with CKD, a higher serum potassium was associated with a lower PAC, 
contrary to what would be expected. When patients prescribed an ACEi  were excluded, no 
relationship was seen. In patients with EH there was no relationship (Figure 4-6). Serum 
potassium was not associated with THALDO excretion in either group. 158 
 
 
Figure 4-6: Scatterplot of serum potassium versus PAC and THAldo excretion with fitted linear 
regression line and estimate of significance.  
A & B = EH .C & D = CKD. 
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4.3.9.3  ACTH 
In EH patients, there was a trend towards a negative correlation between THAldo excretion 
and cortisol metabolite excretion (a surrogate for ACTH stimulation) (p=0.06). In patients 
with CKD the contrary was seen, with a positive correlation between cortisol metabolites 
and THAldo (p=0.05). (Figure 4-7). 
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Figure 4-7: Scatterplot of THAldo and cortisol metabolite excretion with fitted linear regression line.  
A=EH patients. B=CKD. 160 
4.3.9.4  Relationship between PRC and plasma sodium concentration  
In patients with EH and CKD, PRC was significantly lower in patients with a high plasma 
sodium (Figure 4-8).  
4.3.9.5  Relationship between PAC and plasma sodium concentration 
There was no relationship between PAC and plasma sodium concentration in patients with 
EH or patients with CKD. 
 
 
Figure 4-8: Scatterplot of plasma sodium concentration and √ plasma renin concentration, with fitted 
linear regression line and estimate of significance.  
A = EH patients, B = CKD patients. 161 
 
4.3.10   Determinants of THALDO and THDOC excretion in patients with 
CKD 
Significant correlates with THALDO and THDOC were entered separately into a linear 
regression model to assess determinants of excretion. Due to high collinearity between 
THALDO and THDOC they were not entered together into subsequent multivariate 
models. The measure of proteinuria which correlated most closely with THALDO and 
THDOC excretion (24h QP) was entered into the model. 
Significant univariate predictors of THALDO excretion were THDOC excretion, 24h 
urinary sodium and potassium, 24h QP and LVMI. Significant independent predictors of 
THALDO excretion on multivariate analysis were 24h urinary sodium and potassium 
excretion (Table 4-10).  
Similarly, significant univariate predictors of THDOC excretion were THALDO excretion, 
24h urinary sodium and potassium, 24h QP and LVMI. Significant independent predictors 
of THDOC excretion on multivariate analysis were 24h urinary sodium and potassium 
excretion and logLVMI (Table 4-11). 162 
 
 
 
Variable 
UNI 
B 
 
95% CI 
 
β 
 
P 
MULTI 
B 
 
95% CI 
 
β 
 
p 
USod  
(mmol/24h) 
0.17  0.11-0.22  0.61  <0.001  0.10  0.03-0.17  0.38  0.004 
U Pot (mmol/24h)  0.43  0.26-0.60  0.54  <0.001  0.24  0.04-0.43  0.30  0.02 
THDOC  0.77  0.68-0.85  0.92  <0.001  -  -  -  - 
Log 24h QP  13.03  5.3-20.7  0.39  0.001  -  -  -  - 
Log LVMI  66.10  17.3-115.0  0.35  0.009  -  -  -  - 
Table 4-10: Univariate (UNI) and multivariate (MULTI) linear regression model for predicted 
variable THAldo excretion.  
Significant correlates entered as univariate predictors. R-square for multivariate model 0.492, p<0.001 
 
Variable 
UNI 
B 
 
95% CI 
 
β 
 
P 
MULTI 
B 
 
95% CI 
 
β 
 
p 
THALDO  1.10  0.98-1.22  0.92  <0.001  -  -  -  - 
USod  
(mmol/24h) 
0.17  0.10-0.24  0.53  <0.001  0.091  0.003-0.18  0.28  0.04 
U Pot (mmol/24h)  0.46  0.25-0.67  0.48  <0.001  0.285  0.04-0.54  0.30  0.03 
Log LVMI  90.8  33.57-148.07  0.40  0.002  63.2  4.34-122.1  0.28  0.04 
Log 24h QP  13.92  4.52-23.31  0.35  0.004  -  -  -  - 
Table 4-11: Univariate (UNI) and multivariate (MULTI) linear regression model for predicted 
variable THDOC excretion.  
Significant correlates entered as univariate predictors. R-square for multivariate model 0.417, p<0.001.  163 
4.3.11  Aldosterone synthase C-344T genotype frequency and association 
with demographics 
63 patients had suitable blood samples for genotyping and were genotyped for the C-344T 
aldosterone synthase polymorphism. It can be seen that there was no difference in 
genotype frequency between the patients with CKD and the patients with EH (Table 4-12). 
There was no significant difference in PAC or THALDO excretion rates between genotype 
groups. Similarly there was no difference in LVMI, QP, cAIx, RHI, PWV or urinary 
sodium between genotypes.  
Genotype  All 
N=63 
CKD 
N=40 
EH 
N=23 
CT  33 (52.4%)  21 (52.5%)  12 (52.2%) 
CC  14 (22.2%)  9 (22.5%)  5 (21.7%) 
TT  16 (25.4%)  10 (25%)  6 (26.1%) 
Table 4-12: Genotype frequency for the C-344T polymorphism by patient group. 
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4.3.12  Predictors of proteinuria in patients with CKD 
Significant correlates (Spearman’s (r,p)) with 24h QP in patients with CKD were: weight 
(0.254, p=0.04), SBP (0.407, p=0.001), pulse pressure (0.318, p=0.008), eGFR (-0.271, 
p=0.03), phosphate (0.289, p=0.02), 24h USod (0.317, p=0.009), THDOC (0.371, 
p=0.002) and THAldo (0.426, p<0.001) (Figure 4-9). 
The significant correlates were entered separately into univariate linear regression models 
for prediction of log 24hQP and all were significantly predictive (Table 4-13). Two 
multivariate models were then constructed, entering THAldo and THDOC excretion 
separately with the other significant predictors. This showed that THAldo and SBP were 
the only significant independent predictors of proteinuria excretion. THDOC was not a 
significant independent predictor (Table 4-13).  
In patients with hypertension, proteinuria levels were very low and in the absence of 
microalbuminuria measurements, difficult to interpret. The only significant independent 
predictor of proteinuria in these patients was eGFR. 165 
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Figure 4-9: Scatterplot of THAldo (A), THDOC (B) and U Sod (C) versus log of 24h quantified 
proteinuria with fitted linear regression line and estimate of significance.  166 
 
 
Variable 
UNI 
B 
 
95% CI 
 
β 
 
P 
MULTI 
B 
 
95% CI 
 
β 
 
p 
THALDO  0.01  0.005-0.02  0.39  0.001  0.008  0.0-0.02  0.28  0.04 
SBP  0.01  0.003-0.02  0.36  0.003  0.009  0.004-0.015  0.365  0.001 
THDOC  0.01  0.003-0.02  0.35  0.004  -  -  -  - 
24h USod  0.003  0.001-0.005  0.32  0.009  -  -  -  - 
eGFR  -0.006  -0.01 – 0.001  -0.27  0.03  -  -  -  - 
Weight  0.01  0.001-0.01  0.26  0.03  -  -  -  - 
Phosphate  0.69  0.10-1.29  0.28  0.02  -  -  -  - 
Table 4-13: Univariate (UNI) and multivariate (MULTI) linear regression models for prediction of log 
24h QP.  
Due to multicollinearity, THAldo and THDOC were entered separately. R
2 value for THALDO 
multivariate model 0.375. 167 
4.3.13  Proteinuria in patients with CKD : Interaction between steroids and 
sodium 
Previous studies have suggested that aldosterone and sodium may interact synergistically 
to increase proteinuria excretion. Figure 4-10 demonstrates graphically that patients in the 
highest tertile of THAldo excretion and highest tertile of USod excretion had the highest 
median 24h QP. A 2-way ANOVA was carried out which revealed that there was no 
statistically significant interaction between tertiles of USod and THAldo excetion and level 
of proteinuria. 168 
 
 
Figure 4-10: 3D bar chart of median 24h QP by tertile of urinary sodium and tertile of THALDO in 
CKD patients. 
Tertile 1 = low, tertile 3 = high. 
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4.3.14   Relationship between mineralocorticoids, renin and blood pressure 
No correlation was seen between urinary mineralocorticoid excretion (THALDO, 
THDOC), PAC and blood pressure (SBP, DBP) in CKD or EH patients. Similarly, there 
was no relationship between PRC and blood pressure in EH (Figure 4-11). In CKD, PRC 
was inversely related to SBP (r= -0.485, p<0.001) and DBP (r= -0.31, p=0.009). This 
relationship was strengthened when patients prescribed β-blockers were excluded. 170 
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Figure 4-11: Scatterplot of the square root of plasma renin concentration versus systolic blood 
pressure. 
Patients with CKD (A) and EH (B) with fitted linear regression line and estimate of significance. 
 171 
4.4  Discussion 
This study demonstrates a number of novel findings in relation to steroid levels, 
metabolism and effects in chronic kidney disease. The addition of a well-matched essential 
hypertensive group allows for the effects of hypertension to be controlled for. There were 
differences in drug prescriptions between the two groups which should be borne in mind 
when interpreting the data.  
The key findings were: 
1.  Excretion rates of steroid metabolites and plasma concentrations of aldosterone and 
renin do not differ between patients with CKD and patients with EH. Levels also do 
not differ between patients with primary (IgAN and MGN) and secondary (DMN) 
renal disease. 
2.  The F:E ratio is not altered in patients with CKD suggesting that 11βHSD2 activity 
is not reduced. 
3.  Urinary sodium excretion is a strong independent predictor of THALDO and 
THDOC excretion in patients with CKD. This relationship is novel and not seen in 
patients with EH. 
4.  Urinary potassium excretion is directly proportional to THALDO excretion in 
patients with CKD and patients with EH. 
5.  Traditional adrenal cortical trophins do not exhibit predicted effects in CKD. PRC 
does not influence measures of aldosterone (PAC, THALDO excretion) in patients 
with CKD but in patients with EH there is a trend towards a directly proportional 
relationship. Serum potassium concentration is inversely related to PAC in patients 
with CKD but not EH. 
6.  Plasma renin concentration was inversely proportional to plasma sodium in patients 
with CKD and patients with EH.  
7.  Plasma renin concentration was inversely proportional to systolic and diastolic 
blood pressure in patients with CKD but not EH. This relationship persisted when 
patients prescribed beta-blockers were excluded. 172 
8.  THALDO excretion, with SBP, is an independent predictor of proteinuria excretion 
in patients with CKD. An interaction between urinary THALDO excretion, urinary 
sodium excretion and urinary protein excretion was demonstrated in that patients in 
the highest tertile of THALDO excretion and highest tertile of urinary sodium 
excretion had the highest amount of proteinuria excretion. 
9.  Cortisol metabolite excretion was not associated with urinary electrolyte excretion 
in patients with CKD or patients with EH. Cortisol metabolites had no association 
with left ventricular mass or proteinuria excretion in patients with CKD or EH.  
4.4.1  Steroid measurement methods and levels in CKD 
Previous evidence suggests that 24h excretion of steroid metabolites is more reflective of 
steroid hormone status than random plasma measurements (101). This study was not 
designed to test this, but did show that urinary excretion rate of aldosterone and 
deoxycorticosterone  is of more prognostic significance than plasma concentrations, in that 
THALDO and THDOC excretion rates correlate significantly with pathological features 
(proteinuria excretion and left ventricular mass index) in patients with CKD whereas 
plasma aldosterone and plasma renin concentrations did not.  
There is no evidence from this study that levels of urinary steroid excretion, plasma 
aldosterone or plasma renin concentrations relate to eGFR in patients with CKD stages 2-4 
in the context of current antihypertensive treatments. This study also demonstrates that 
there were no differences in steroid measurements between patients with CKD and patients 
with EH, or patients with diabetic renal disease and patients with primary glomerular 
disease. This is contrary to what one would expect in CKD where an intravascular 
overload is presumed, and hypertension and elevated serum potassium which should 
suppress trophic factors.  
Our findings differ from previously published data showing that PAC levels were higher 
with poorer renal function. Hene et al(120) showed that PAC increased with declining 
renal function in patients on no medications and with primary renal disease. The increase 
was most marked when CrCl was between 3-10ml/min. Our study did not include patients 
with such significantly impaired kidney function as this and this may explain why this 
association was not found. 173 
A more recent study by Hammer et al(279) is the only comparable study which reports 
urinary steroid excretion in patients with CKD. There are differences between the Hammer 
cohort and this study cohort - Hammer assessed 112 patients with non-diabetic, minimally 
proteinuric renal disease with well preserved renal function (CKD 3). My patients had 
CKD 3 or 4, a median of 1g proteinuria per day and half had diabetic nephropathy. 
Hammer et al reported THALDO excretion was not associated with eGFR, SBP or DBP 
but did find that PAC correlated weakly with THALDO excretion, which was not seen in 
this cohort. In terms of drug effects, in their cohort ACEi/ARB treatment had no effect on 
PAC, PRA or THALDO excretion, unlike my cohort where PAC was lower in patients 
prescribed an ACEi and THALDO excretion was higher in patients prescribed an ARB. 
They did not assess determinants of steroid excretion or report pathological correlates. The 
frequency of aldosterone synthase genotype (C-344T) did not differ between patients with 
CKD and those without and had no impact upon steroid levels in this cohort. 
In patients with type 1 diabetes and normal renal function, levels of aldosterone and renin 
were found to be significantly higher than in normal patients on a high salt diet(280). The 
failure of this study to demonstrate higher levels of these measures in patients with diabetic 
nephropathy may reflect the presence of renal disease, the inclusion of patients with type 2 
diabetes, or that the control group were not ‘normal’ or alternatively the modulating effects 
of medications. 
4.4.2  Regulation of mineralocorticoid synthesis and the RAAS in CKD 
In this study, the regulation of aldosterone synthesis appears to differ from expected 
physiological principles in patients with CKD and patients with EH. In patients with CKD, 
the strongest independent determinant of THALDO and THDOC excretion was 24h 
urinary sodium excretion rate. This is a novel and unanticipated finding and was not seen 
in patients with EH alone, which is in agreement with other groups’ findings (281). 
The observed relationship between urinary electrolyte excretion and urinary steroid 
excretion in CKD patients could simply reflect an increase in non-selective glomerular 
permeability. THALDO and THDOC excretion is closely correlated with USod and UPot, 
and to a lesser extent U Chloride and U Creatinine. However, if the test simply measures 
molecules (THALDO, THDOC) which are ‘dragged along’ with electrolytes, then one 
would expect the same picture with THE, THF and THS, which is not seen.  174 
Similarly, the relationship is not seen in patients with EH and therefore it is particular to 
CKD.  Further validation of the use of THALDO / THDOC is provided by their expected 
close correlation in both cohorts. Furthermore, THS correlates with its metabolites THE 
and THF. Finally, could the relationship be an artefactual finding based on urine volume? 
This would not appear to make sense as both measures (urinary steroid and urinary 
electrolytes) are reported over 24h and derived from the same urine volume, so correlating 
the two measures will obviate this relationship. Therefore, in chronic kidney disease, 
excretion of THALDO and THDOC is closely associated with urinary electrolyte 
excretion, particularly sodium. This relationship is not seen with total cortisol metabolites. 
Explanation of these novel findings is potentially multi-fold. It may be that adrenal Aldo 
production in CKD is more closely regulated by other factors such as catecholamines, 
endothelin and arginine vasopressin(282) than traditional trophins such as AgII, volume 
and potassium, which seems unlikely. Alternatively the lower plasma pH in patients with 
CKD may modulate Aldo production or adrenal response to stimuli. The TASK (TWIK-
related acid-sensitive K) channel is found in the zona glomerulosa and activity is 
significantly reduced at lower pH(283). TASK knockout mice demonstrate zona 
glomerulosa depolarization and increased Aldo production in response to stimuli(284).  
Local Aldo production is also known to occur in the kidney and vasculature but production 
rates are very small and it is unlikely to be detected by serum or urine analysis. It may be 
that these systems are responsible for the pathological effects mediated via the MR and are 
regulated differently to traditional adrenal cortical production.  
No other studies report determinants of THDOC excretion in patients with CKD and no 
studies have analysed the relationship between urinary electrolytes and mineralocorticoids 
in patients with CKD(281).  
Utilising UFF:UFE is a more accurate assessment of the 11βHSD2 enzyme than 
THF:THE, which mainly reflects 11βHSD1(97). We found no association between level of 
renal function and F:E ratio, which was similar to findings of a small study of patients with 
nephrotic syndrome(98). Quinkler et al(99) however found that the F:E ratio (measured 
using GCMS) increased as eGFR declined in patients with CKD, supporting a loss of 
11βHSD2 function. These results are contrary to our findings. 175 
There was no relationship between THALDO excretion and PAC, perhaps reflecting the 
snapshot view PAC provides, rather than an integrated 24h measure. THALDO did not 
correlate with PRC (a surrogate for angiotensin II) in patients with EH or CKD, suggesting 
the adrenal cortex may be less sensitive to AgII in the context of hypertension, renal failure 
or drug therapy.  
PRC was inversely correlated with a higher plasma sodium in both EH and CKD, 
suggesting that the juxtaglomerular apparatus still senses intravascular volume status as 
one would expect as renal function declines. This supports older research where salt 
loading in patients with CKD or patients on HD was associated with suppression of plasma 
renin activity(285). 
Contrary to what might be expected, PAC was inversely related to serum potassium in 
CKD and there was no significant relationship in EH patients. There was a trend towards 
an inverse relationship between THALDO excretion and cortisol metabolites (a surrogate 
for ACTH) in patients with CKD and no significant relationship in patients with EH.  
Data with which to compare our findings are sparse. Most existing literature regarding 
determination of aldosterone levels in CKD relates to patients with more advanced renal 
disease and describes aldosterone responses to administered stimuli.  
Berl and Katz in 1978 (121) showed that eight patients with advanced renal failure 
responded to marked sodium restriction or the assumption of an upright posture with a rise 
in PAC, i.e. they responded appropriately to stimuli despite advanced renal failure.  
More recently, Bomback(286) assessed haemodialysis patients and healthy volunteers and 
found that in haemodialysis patients serum potassium did not influence serum aldosterone 
levels, unlike in my CKD cohort. They also established that, in healthy volunteers, sodium 
loading led to increased extracellular volume (as assessed by bioimpedence) and lower 
PAC. In HD patients intradialytic weight gain resulted in increased ECV and suppressed 
PAC, but to a much lesser degree than in normal controls, i.e. the response was blunted.  
Kohagura found that the determinants of PAC in HD patients were serum potassium and 
renin(122). They also reported that 50% of patients had elevated PAC but this was not 
associated with a worse mortality risk.  176 
The majority of patients included in this study were overweight, with a mean BMI of 
29.3Kg/m
2. Adipocytes are known to release potent mineralocorticoid releasing factors and 
insulin resistance and hyperinsulinaemia stimulate aldosterone synthesis in vitro. 
Therefore, obesity may be modulating some of the findings in these patients, although 
there was no significant difference in BMI between the two groups. 
4.4.3  Steroid excretion levels, blood pressure and proteinuria 
No relationship was seen between urinary steroids or PAC and blood pressure in either 
patients with CKD or patients with EH. This may be due to the modulating effects of 
antihypertensive medications and was also found by Hammer et al(287). In patients with 
EH, there was no relationship between blood pressure and PRC but in CKD PRC was 
inversely proportional to SBP and DBP. This finding again suggests that the renin-
angiotensin functions differently in CKD compared with patients with EH. Urinary steroid 
excretion correlated with LVMI, which is the focus of chapter 5.  
The degree of proteinuria excretion is an independent predictor of both progression of 
renal disease and mortality in patients with CKD. THALDO, THDOC and 24h USod 
excretion were shown to be significant univariate predictors of proteinuria excretion in this 
cohort, with THALDO excretion and SBP being the only significant multivariate 
predictors. This has not been demonstrated in patients with CKD before and lends weight 
to MR blockade as treatment for proteinuria reduction.  
There was a suggestion of a relationship between USod, THALDO and proteinuria 
excretion, although this was not significant on 2-way ANOVA. Using linear regression 
THALDO / THDOC and 24h urinary sodium are independent predictors of proteinuria, 
although the steroid is a stronger predictor. It may be that a larger sample size is needed to 
assess the effect. 
4.4.4  Limitations 
The study findings are limited by the fact that this was a heterogenous cohort and patients 
were prescribed multiple different medications, a number of which are known to impact 
upon aldosterone or renin production. It would however be unethical to perform a study of 
this nature in CKD in a drug free environment. This may explain why there was no 
association seen between renal function, renin and aldosterone and why THALDO and 
THDOC excretion is perhaps higher than one would expect for the level of hypertension 177 
and renal failure. It is difficult to comment on the role of intravascular volume in 
determining steroid excretion as this is difficult to measure. Similarly, measurement of 
total body sodium would be of value. Lastly, it would have been useful to include a normal 
control group receiving no medication. 
4.5  Conclusion 
This study is the first to compare urinary steroid production in patients with CKD and 
patients with EH. This novel comparison allows for the effects of hypertension and 
medication to be controlled for and clearly demonstrates that regulation of steroid 
production differs in CKD. The usual regulatory mechanisms of serum potassium and 
angiotensin II appear to be uncoupled in patients with CKD and the strong association 
between urinary sodium excretion and THALDO and THDOC excretion suggests that 
alternative regulatory mechanisms are involved. USod is directly proportional to urinary 
steroid excretion. This is counter-intuitive when the usual physiological role of 
mineralocorticoids is considered. Conventionally, mineralocorticoids increase expression 
of the epithelial sodium channel and encourage reabsorption of sodium. Therefore, a 
negative relationship between urinary sodium levels and urinary steroids, or no relationship 
(as is seen in the hypertensive control cohort) would be expected. Furthermore, this is the 
first study to demonstrate that levels of steroid excretion correlate with adverse end organ 
effects in CKD and that levels interact with sodium status, which supports the concept that 
blockade of the MR and reduction in dietary sodium intake should be considered in CKD. 178 
5  Chapter Five - A study of the determinants of left 
ventricular abnormalities in patients with CKD  179 
5.1  Introduction 
Renal disease is associated with a variety of cardiovascular abnormalities leading to a 
graded increased cardiovascular risk, such that patients with CKD stage 5 are thirty times 
more likely to die a cardiovascular death than age matched controls(5). Left ventricular 
hypertrophy (LVH) is present in at least 50% of patients with CKD by the time they 
require renal replacement therapy (198) and LVH is an independent risk factor for 
mortality, both in patients with ESRD(288) and in the general population(289). Other LV 
abnormalities are also seen in patients close to or requiring RRT and are termed uraemic 
cardiomyopathy. This includes left ventricular hypertrophy (LVH), dilatation, systolic 
dysfunction (LVSD) and myocardial fibrosis(200).  
However, left ventricular abnormalities are less well studied in patients with earlier stages 
of renal disease. Previous studies have utilised echocardiography(290) which is limited by 
its reliance on intravascular volume status or electrocardiography(291) which can be 
unreliable. In this study, the gold standard measurement of left ventricular mass, cardiac 
magnetic resonance imaging (CMR), was used to measure left ventricular mass and 
function in patients with CKD and patients with EH. By comparing the two groups, it was 
aimed to control for the effects of hypertension.  
The aims of this study were: 
1.  To describe left ventricular abnormalities in patients with CKD and compare these 
with a group of patients with EH. 
2.  To assess the factors associated with LV abnormalities in CKD, particularly level 
of renal function, steroid status and sodium status; and to assess whether an 
interaction existed between these factors. 
5.2  Methods 
 
Patients were recruited and assessed according to the patient protocol in chapter 2. CMR 
scanning was performed as previously described and was undertaken at the same time as 
blood and urinary assessments. Cut-offs for left ventricular abnormalities were as 
described in Table 5-1. Statistics were performed using SPSS (Illinois) version 15. 180 
Left ventricular 
abnormality 
Measure  Male  Female 
LVSD  LVEF  <55%  <55% 
LVH  LVMI (LVM/BSA)  >84.1g/m
2  >76.4g/m
2 
LV dilatation  EDV/BSA  >111.7ml/m
2  >99.3ml/m
2 
LV dilatation  ESV/BSA  92.8ml/ m
2  70.3ml/ m
2 
Table 5-1: Gender specific cut-offs for left ventricular abnormalities. 
 
5.3  Results 
5.3.1  Demographics 
87 out of a potential 100 patients were included in the study. One patient was excluded due 
to having a permanent pacemaker. Nine patients were unable to complete the scan due to 
claustrophobia and three patients were unable to enter the scanner due to extreme obesity. 
Of included patients, 29 patients had essential hypertension (EH) and 58 had CKD (25 
patients had diabetic nephropathy (DMN), 25 had IgA nephropathy (IGAN) and 8 had 
membranous nephropathy (MGN)). Baseline demographics are described in table 5-2. 
Mean eGFR and haemoglobin were significantly lower in the CKD group than the EH 
group and median proteinuria and PWV significantly higher. Diastolic blood pressure was 
significantly higher in the EH group. No CKD patients had nephrotic syndrome, 1 patient 
was taking a phosphate binder, 1 patient was taking a vitamin D analogue and 5 were 
prescribed an erythropoiesis stimulating agent.  
Within the CKD group, there were some differences in demographics between primary 
renal diseases. Patients with DMN had significantly lower eGFR and haemoglobin and 
significantly higher waist circumference, pulse wave velocity, SBP, pulse pressure and 
LVMI. Patients with IgAN had significantly less proteinuria excretion. 181 
 
  EH 
 
(n=29) 
CKD 
 
(n=58) 
EH vs. 
CKD 
DMN  
 
(n=25) 
IgAN  
 
(n=25) 
MGN 
 
(n=8) 
All groups 
(p value) 
PRD 
Age (y)  55.7 
(9.2) 
57.9 
(13.2) 
NS  61.3 
(14.1) 
53.2 
(12.3) 
61.8 (9.0)  NS  NS 
% Male  82.8%  72.4%  NS  72%  76%  38%  NS  NS 
Waist circ (cm)  100.7 
(12.3) 
99.6 
(12.5) 
NS  106.1 
(11.5) 
95.2 
(12.3) 
93.8 (7.0)  0.009  0.003 
BMI (Kg/m
2)  29.3 
(4.9) 
29.1 
(5.2) 
NS  30.9 (5.2)  28.0 (4.8)  27.0 (5.2)  NS  NS 
% History of 
vascular disease  
6.9  22.4  NS  36  12  12.5  NS  NS 
% Current smokers  10.3  15.8  NS  8.3  16  37.5  NS  NS 
SBP (mmHg)  151 (20)  147 (23)  NS  159 (18)  134 (18)  146 (30)  <0.001  <0.001 
DBP (mmHg)  93 (11)  82 (11)  <0.001  80 (12)  83 (9)  82 (14)  <0.001  NS 
PP (mmHg)  58 (14)  65 (20)  NS  79 (14)  51 (13)  64 (20)  <0.001  <0.001 
No. Anti-BP   2.1 (1.0)  2.6 (1.4)  NS  2.8 (1.5)  2.4 (1.3)  2.4 (1.3)  NS  NS 
% Prescribed 
ACE/ARB  
75.9  84.5  NS  76.0  92  87.5  NS  NS 
Hb (g/dl)  14.6 
(1.4) 
12.4 
(1.6) 
<0.001  11.6 (1.3)  13.2 (1.6)  12.5 (1.4)  <0.001  0.001 
eGFR 
(ml/min/1.73m
2) 
89.8 
(18.2) 
38.5 
(22.5) 
<0.001  29.5 
(13.4) 
42.5 
(24.3) 
54.5 
(29.0) 
<0.001  0.01 
uPCR (mg/mmol)  0.0 (0.0-
4.0) 
62 
(22.5-
199) 
0.003  120.5 
(81.2-
107.7) 
33.2 
(19.0-
99.5) 
90.5 (48-
313) 
<0.001  NS 
QP (g/24h)  0.1 (0.1-
0.1) 
0.8 (0.3-
2.6) 
<0.001  1.5 (0.5-
3.7) 
0.5 (0.3-
1.2) 
1.2 (0.6-
4.0) 
<0.001  NS 
USod (mmol/24h)  156.2 
(81.1) 
166.8 
(72.5) 
NS  180.5 
(68.5) 
147.9 
(61.8) 
179.9 
(105.6) 
NS  NS 
PRC (uIU/ml)  35.4 
(17.7-
99.3) 
69 (17-
214) 
NS  65.8 
(18.5-
221.5) 
112.4 
(36.3-
395.2) 
10.6 (2.5-
80.7) 
NS  NS 
PAC (pmol/l)  238 
(160-
333) 
249 
(162-
443) 
NS  264 (152-
416) 
253 (182-
521) 
155 
(125.8-
460) 
NS  NS 
THALDO 
(mcg/24h) 
62.5 
(24.4) 
55.0 
(20.1) 
NS  57.1 
(20.1) 
52.1 
(21.9) 
56.5 
(15.4) 
NS  NS 
THDOC (mcg/24h)  75.7 
(33.0) 
65.4 
(23.9) 
NS  70.2 
(24.4) 
60.0 
(23.5) 
66.2 
(22.7) 
NS  NS 
Cortisol metabolites 
(mcg/24h) 
10005 
(5068) 
8620 
(4641) 
NS  7538 
(3690) 
10065 
(5795) 
8029 
(2756) 
NS  NS 
PWV (m/s)  7.7 (6.7-
9.2) 
9.4 (7.0-
13.1) 
0.005  11.8 (9.6-
15.1) 
7.0 (5.6-
9.5) 
8.2 (6.2-
10.7) 
<0.001  <0.001 
Table 5-2: Baseline demographics of the different cohort groups. 
Data are mean (SD) or median (IQR). Comparisons of All groups (EH, DMN, IGAN, MGN) or by 
primary renal disease in patients with CKD (DMN, IGAN or MGN) undertaken by one-way ANOVA, 
Kruskall Wallis or Chi Square test as appropriate. EH vs. CKD compared by t-test, Mann Whitney U 
test or Chi-Square test. p<0.01 deemed as significant (highlighted in yellow). 182 
5.3.2  Left ventricular abnormalities 
Twenty eight patients with CKD had LVH (48.3%). Five patients out of 58 had LVSD 
(7.1%) and 2 patients (3.4%) had left ventricular dilatation (one of whom had LVSD).  
Sixteen patients with EH had LVH (55.2%), including 2 patients with other cardiac 
abnormalities. Two out of 29 patients had LVSD (6.9%), and the same 2 patients had left 
ventricular dilatation.  
There were no significant differences in frequency of LV abnormalities between patients 
with CKD and patients with EH, but within the CKD group, LVH was more common in 
patients with DMN (Table 5-3). 183 
 
  EH 
 
(n=29) 
CKD 
 
(n=58) 
EH vs. 
CKD 
DMN  
 
(n=25) 
IgAN  
 
(n=25) 
MGN 
 
(n=8) 
All groups 
(p value) 
PRD 
LVMI (g/m
2)  86.1 
(71.3-
98.4) 
81.2 
(70.1-
89.4) 
NS  92.6 (81.2-
107.7) 
72.3 
(63.4-
83.2) 
77.3 
(66.4-
101.8) 
0.009  0.004 
LVEF (%)  68.1 
(10.5) 
68.9 
(10.9) 
NS  70.9 (7.7)  67.1 
(12.6) 
68.6 
(10.7) 
NS  NS 
EDV/BSA 
(ml/ m
2) 
67.1 
(15.6) 
60.3 
(16.1) 
NS  57.8 (12.0)  62.4 
(11.8) 
61.8 
(31.6) 
NS  NS 
ESV/BSA 
(ml/ m
2) 
21.8 (8.6)  19.9 
(10.3) 
NS  16.9 (6.3)  21.3 (9.4)  24.5 
(19.1) 
NS  NS 
LVH (n,%)  16, 55%  28, 48%  NS  19, 76%  6, 24%  3, 38%  0.002  0.001 
LVSD (n,%)  2, 7%  5, 7%  NS  1, 4%  3, 12%  1, 13%  NS  NS 
LV dilatation 
(n,%) 
2, 7%  2, 3%  NS  0, 0%  1, 4%  1, 13%  NS  NS 
Table 5-3: Left ventricular measurements and frequency of abnormality by patient group.  
Data expressed as mean (SD), n (absolute number) or % (percentage of group). Comparisons by Student’s 
t-test, one-way ANOVA, chi-square or Kruskall Wallis test as appropriate. Significant differences (p<0.01) 
highlighted in yellow. 184 
5.3.3  Correlations between measures of cardiac structure and function and 
demographics  
Due to the small number of patients with LVSD or LV dilatation, these abnormalities were 
not considered further. This study will focus on left ventricular mass. 
5.3.3.1  Correlations with left ventricular mass index  
The following demographics were entered into a correlation matrix with LVMI: Age, sex, 
smoking status, drug treatment (ACE, ARB, BBl, CCB, Alpha block, diuretic, aspirin, 
statin), waist circumference, BMI, SBP, DBP, PP, MAP, HR, eGFR, albumin, CRP, urate, 
total cholesterol, phosphate, PTH, vitamin D, Hb, 24h QP, uPCR, 24h USod, logPAC, 
√PRC, THALDO, cortisol metabolites, THDOC, urinary free cortisone (E), urinary free 
cortisol (F) excretion, E:F ratio, RHI, PWV and AIx@75bpm. 
In patients with CKD, there was a significant correlation between LVMI and male gender, 
blood pressure (SBP, PP and MAP), urinary protein excretion (24h QP or uPCR), 
THALDO excretion, THDOC excretion and usage of alpha blockers (Table 5-4). 
In patients with EH there was also a significant correlation between male gender and 
LVMI, as well as AIx@75bpm and PAC. There was no significant correlation with SBP or 
DBP.  185 
 
Demographic  All patients  EH  CKD 
Male gender  0.491, <0.001  0.491, 0.007  0.479, <0.001 
Ablocker  0.357, 0.001    0.437, 0.001 
SBP  0.462, <0.001    0.55, <0.001 
PP  0.433, <0.001    0.491, <0.001 
MAP  0.353, 0.001    0.459, <0.001 
24h QP  0.323, 0.003    0.538, <0.001 
PCR  0.293, 0.006    0.513, <0.001 
AIx@75bpm    -0.486, 0.007   
Log PAC    0.57, 0.001   
THAldo      0.43, 0.001 
THDOC       0.447, 0.001 
Table 5-4: Significant correlations with LVMI in all patients, patients with EH and patients with CKD.  
Values are r,p. p<0.01 = significant. 186 
5.3.4  Specific associations with LVMI 
5.3.4.1  Impact of the level of renal function on LV mass and function 
Assessing all patients together, estimated glomerular filtration rate (eGFR), measured 
using the 6v-MDRD formula, was not associated with LVMI, EF, EDV adjusted for BSA 
(cEDV) or ESV adjusted for BSA (cESV)(Figure 5-1). 
Comparing the proportion of patients with LVH by stage of CKD (2, 3 or 4), it can be seen 
that more patients were classified as having LVH in the stage 4 group (63%) compared 
with the stage 3 group (35%) or stage 2 (20%), although this failed to reach significance 
(one-way ANOVA p=0.08) (Figure 5-2). 187 
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Figure 5-1: Scatterplot of estimated GFR (6v-MDRD formula) versus left ventricular measures.  
A: Left ventricular mass index; B: End diastolic volume/BSA; C: End systolic volume/BSA; D: Ejection 
fraction. Fitted linear regression line and an estimate of significance (p). All patients (CKD and EH) were 
included in analysis. 
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Figure 5-2: Bar chart of percentage of patients with LVH by stage of CKD 
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5.3.4.2  Association between plasma renin concentration, plasma aldosterone 
concentration and LVMI 
Analysing EH patients, a higher PAC was associated with a significantly higher LVMI 
(Figure 5-3). However, there was no significant association between PRC and LVMI. 
Assessing CKD patients and different CKD groups, no significant relationship was seen 
between PAC, PRC and LVMI (Figure 5-3).  189 
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Figure 5-3: Scatterplot, with fitted linear regression line, of logPAC and LVMI in patients with CKD 
(A) and EH (B).  
 190 
5.3.4.3  Association between proteinuria and LVMI 
In patients with CKD, there was a significant correlation between the level of proteinuria 
and LVMI. This relationship persisted whether looking at the 24h urinary quantified 
protein or spot protein:creatinine ratio and persisted when looking at individual primary 
renal diseases (IGAN, DMN, MGN) (Figure 5-4). 191 
 
 
Figure 5-4: Scatterplots of logPCR (A) and log24h QP (B) versus LVMI in patients with CKD and 
subdivided by primary renal disease (C).  
Fitted linear regression line and estimate of significance. 192 
5.3.4.4  Association between urinary sodium excretion and LVMI 
In CKD patients, urinary sodium excretion was a significant predictor of LVMI (p=0.03) 
but not in patients with EH. (Figure 5-5).  
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Figure 5-5: Scatterplot of urinary sodium excretion versus LVMI with fitted linear regression line.  
A = CKD, B = EH. 193 
5.3.4.5  Association between urinary steroid excretion and LVMI; interaction with 
urinary sodium 
THAldo and THDOC excretion both correlated significantly with LVMI in patients with 
CKD (Figure 5-6). On linear regression analysis, both were also significant univariate 
predictors of LVMI (THAldo R
2 = 0.12 p= 0.009, THDOC R
2=0.16 p=0.002) in patients 
with CKD. This relationship was not seen in patients with EH (Figure 5-6).  
In patients with CKD, to ascertain whether there was a synergistic relationship between 
THDOC excretion, urinary sodium (both significant univariate predictors) and LVMI, a 3D 
bar chart of tertiles was constructed (Figure 5-7). In the high THDOC group, increasing 
tertiles of USod were associated with in an incremental increase in LVMI. It can be seen 
that in the low THDOC group, higher USod is not associated with a higher LVMI. To 
ascertain whether there was a significant interaction between the effects of THDOC and 
USod on LVMI, two-way ANOVA was carried out based on group means, which revealed 
no significant interaction.  194 
 
 
Figure 5-6: Scatterplots of THALDO (A&C) and THDOC (B&D) excretion versus LVMI with fitted 
linear regression line and estimates of significance.  
A&B = CKD patients, C&D = EH patients.   195 
 
 
Figure 5-7: 3D bar chart of mean LVMI (g/m2) by tertile of THDOC excretion and tertile of 24h USod 
(1=low, 3=high).  
Graph displays CKD patients only. 
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5.3.5  Determinants of LVMI in patients with CKD versus patients with EH 
To determine whether significant predictors of LVMI in patients with CKD were different 
from patients with EH, significant correlates (Table 5-4) were entered individually into a 
univariate linear regression model, with the predicted variable of LVMI. Significant 
univariate predictors were then entered together into a multivariate model.  
THAldo and THDOC excretion were entered separately into the models due to 
multicollinearity. Similarly, only the most closely correlated measure of proteinuria and 
blood pressure were entered into the model.  
5.3.5.1  Patients with CKD 
Significant univariate predictors of LVMI in patients with CKD were male gender, SBP, 
THAldo, THDOC excretion, 24h USod, usage of alpha blockers and 24h QP. Table 5-5 
demonstrates the multivariate model when THAldo was included, demonstrating that 
THAldo was not a significant independent predictor of LVMI in patients with CKD but 
SBP, male gender and alpha blocker usage were. Table 5-6 shows the multivariate model 
when THDOC is included and it can be seen that THDOC excretion, SBP, male gender 
and usage of alpha blockers were significant independent predictors of LVMI in patients 
with CKD on multivariate analysis. Quantified proteinuria was no longer a significant 
independent predictor of LVMI when THDOC or THAldo excretions were included in the 
model. The addition of eGFR to the model did not alter the findings. 197 
 
 
 
Variable 
Univariate 
 
B 
 
 
95% CI 
 
 
β 
 
 
P 
Multivariate 
Model 1 
B 
 
 
95% CI 
 
 
ʒ 
 
 
p 
THALDO 
(mcg/24h) 
0.002  0.0-0.03  0.352  0.009  -  -  -  - 
SBP (mmHg)  0.002  0.001-
0.003 
0.546  <0.001  0.002  0.001-
0.003 
0.381  <0.001 
24h USod 
(mmol/24h) 
0.00  0.00-
0.001 
0.271  0.045  -  -  -  - 
Male gender  0.113  0.06-
0.165 
0.497  <0.001  0.075  0.0.32-
0.117 
0.315  0.001 
Log 24h QP  0.028  0.014-
0.041 
0.491  <0.001  -  -  -  - 
Alpha blockade  0.123  0.059-
0.187 
0.458  <0.001  0.083  0.036-
0.13 
0.31  0.001 
Table 5-5: Univariate and multivariate model of predictors of LVMI in patients with CKD when 
THAldo excretion analysed in model.  
Predicted variable logLVMI. R
2=0.662. 
 
 
Variable 
Univariate 
 
B 
 
 
95% CI 
 
 
ʒ 
 
 
P 
Multivariate 
Model 2 
B 
 
 
95% CI 
 
 
β 
 
 
P 
THDOC 
(mcg/24h) 
0.002  0.001-
0.003 
0.404  0.002  0.001  0.0-0.002  0.218  0.02 
SBP (mmHg)  0.002  0.001-
0.003 
0.546  <0.001  0.002  0.001-
0.003 
0.384  <0.001 
24h USod 
(mmol/24h) 
0.00  0.00-
0.001 
0.271  0.045  -  -  -  - 
Male gender  0.113  0.06-
0.165 
0.497  <0.001  0.074  0.033-
0.114 
0.312  0.001 
Log 24h QP  0.028  0.014-
0.041 
0.491  <0.001  -  -  -  - 
Alpha blockade  0.123  0.059-
0.187 
0.458  <0.001  0.08  0.034-
0.125 
0.297  0.001 
Table 5-6: Univariate and multivariate model of predictors of LVMI in patients with CKD when 
THDOC excretion analysed in model.  
Predicted variable log LVMI. R
2=0.683. 
 
 
Variable 
Univariate 
 
B 
 
 
95% CI 
 
 
ʒ 
 
 
P 
Multivariate 
Model 2 
B 
 
 
95% CI 
 
 
β 
 
 
P 
Log PAC  0.189  0.081-0.297  0.57  0.001  0.147  0.026-0.268  0.442  0.02 
AIx@75bpm  -0.005  -0.001- -0.008  -0.448  0.015  -  -  -  - 
Male gender  0.138  0.045-0.232  0.506  0.005  -  -  -  - 
Table 5-7: Univariate and multivariate model of predictors of LVMI in patients with EH.  
Predicted variable log LVMI. R
2=0.444 for multivariate model.  198 
Patients with EH 
Table 5-7 demonstrates the multivariate model for predictors of LVMI in patients with EH. 
It can be seen that PAC is the only significant independent predictor of LVMI in these 
patients. 
5.3.5.2  Differences between CKD and EH group predictors of LVMI 
It can therefore be seen that the predictors of LVMI differ between patients with EH and 
patients with CKD. Male gender is a significant univariate predictor in both groups but not 
a multivariate predictor in EH. In CKD, SBP, THDOC excretion and alpha blockade are 
significant multivariate predictors, which differs from EH patients where only PAC is a 
significant multivariate predictor of LVMI. 
5.4  Discussion 
This study of LV abnormalities in patients with CKD and patients with EH utilises 
volume-independent cardiac MR imaging. The groups were well matched in terms of 
baseline demographics, although patients with EH had a significantly higher DBP. The 
CKD group had lower levels of renal function and higher levels of proteinuria.  
The key findings were: 
1.  Around 50% of patients had evidence of left ventricular hypertrophy in both the EH 
and CKD groups.  
2.  Level of renal function is not directly associated with left ventricular mass. 
3.  Excretion of THDOC, in addition to gender, SBP and alpha blocker usage, is a 
significant independent predictor of LVMI in patients with CKD but not patients 
with EH. 
4.  An  inter-relationship between higher levels of urinary sodium excretion, higher 
levels of THDOC excretion and higher LVMI was seen in patients with CKD. 
5.  In patients with EH, plasma aldosterone concentration is a significant independent 
predictor of LVMI.  199 
Identification of the differing predictors of LVMI is of importance if we are to unravel 
the processes leading to the excess cardiovascular risk associated with LVH in both 
patients with CKD and patients with EH. 
5.4.1  Frequency of cardiac abnormalities in patients with CKD  
The predominant cardiac abnormality seen in patients with CKD was LVH, present in 48% 
of patients in this cohort. LVSD and LV dilatation were relatively infrequent. A 
comparable study of patients with ESRD assessed using CMR demonstrated that 71.6% of 
patients had LVH, 11.2% had LV dilatation and 8.2% had LVSD(200).  
Edwards et al(131) also utilised CMR to assess patients with non-diabetic minimally 
proteinuric CKD 2 or 3 (mean eGFR 53ml/min/m2) and reported a mean LVMI of 
59.2g/m
2 and a prevalence of LVH of only 8%. This is significantly lower than seen in our 
cohort. However, this is likely due to differences in the study populations, including better 
blood pressure control, better preserved renal function and the lack of diabetic patients in 
that study.  
The higher LVMI seen in patients with DMN than in patients with primary glomerular 
disease is similar to findings by Nardi et al(292), where the higher LVMI in diabetic 
patients was reported to be independent of other factors including blood pressure. It would 
have been useful to have a comparator group with diabetes without nephropathy in this 
study. 
Levin et al(293) found LVH by echocardiography to be present in 39% of patients with 
CKD, with the incidence increasing with declining eGFR. Nardi et al found a prevalence of 
LVH of 55.9% by echocardiography in patients with CKD, and found the ejection fraction 
to be well preserved. In a substudy of the CREATE study, prevalence of LVH (by echo) 
was 47% and significantly associated with cardiovascular risk(294). 
The lack of a significant difference in the prevalence of LVH reported using echo and 
CMR suggests that the inaccuracies associated with assessing chamber size using echo are 
perhaps less important in CKD than in ESRD, where volume overload is more of an issue. 
Using ECG Cornell criteria for LVH, Agarwal et al(291) found a prevalence of LVH of 
only 11% in patients with CKD. This is in keeping with findings in ESRD whereby the 
frequency of LVH reported by ECG is lower than other measures (295), suggesting that 200 
this method grossly underestimates the prevalence of LVH, making it of limited value for 
this purpose(197). 
 
5.4.2  Factors associated with left ventricular mass index in CKD 
 
5.4.2.1  LVMI and blood pressure 
The association of LV mass with systolic blood pressure seen in the CKD cohort is as 
would be expected in terms of increased preload and afterload. Volume overload results in 
myocardial stretch and proliferation, with eccentric remodelling. An increased systemic 
pressure requires increased strength of ventricular contraction to maintain stroke volume, 
enabled by concentric remodelling.  
Of interest, the lack of association of LVMI with carotid-femoral pulse wave velocity 
raises uncertainty about the role of increased arterial stiffness as a cause of increased 
afterload in CKD; this contrasts with the clear association in ESRD (202). The association 
of LVMI with pulse pressure suggests that perhaps fluid overload is of more importance. 
The use of alpha blockade was associated with a higher LVMI. This agent is most often 
resorted to in patients with difficult to control blood pressure, as a third or fourth line agent 
and therefore blood pressure may be the real determinant here. Patients prescribed an alpha 
blocker had a significantly higher pulse pressure (p=0.007). 
5.4.2.2  LVMI and level of renal function 
LVH was present in half of our patients with moderately impaired renal function, and LVH 
increased with stage of CKD, albeit non-significantly. Estimated glomerular filtration rate 
was not significantly associated with myocardial mass. Studies using echocardiography 
(198;203) have found a step-wise increase in the prevalence of left ventricular hypertrophy 
with declining renal function (CKD stages 1-4). The MESA study (296) looked at the 
association of LVMI, using CMR, and renal function in patients with primary 
atherosclerotic disease with concomitant reduced eGFR and found a non-linear association 
with renal function, whereby LVH was associated with a GFR between 60 and 75 ml/min, 
but this was lost above 75ml/min and below 60ml/min, once adjustment was made for 
blood pressure. It is clear that LV mass has increased significantly by the time a patient 
starts dialysis(200) and it may be that changes in the left ventricle occur early in the course 201 
of renal disease, in association with the development of hypertension and mild fluid 
overload. Further significant changes occur as renal function further deteriorates, in the 
pre-dialysis phase, in association with disturbances in bone metabolism and other uraemic 
factors(201).  
5.4.2.3  LVMI and proteinuria 
The association between proteinuria excretion and LVMI on univariate analysis in CKD is 
intriguing, but when included in multivariate analysis with measures of urinary steroid 
excretion, this finding was no longer significant. The role of proteinuria in determining LV 
mass has been explored by other investigators, but not with access to measures of steroid 
metabolism. 
5.4.2.4  LVMI and sodium 
 
In this study a higher urinary sodium was associated with a higher LVMI in patients with 
CKD. Urinary sodium excretion was not, however, a significant multivariate predictor of 
LVMI. The mechanism of the association of sodium status and LVMI is likely to include 
volume overload resulting in myocardial stretch. Also, increasing plasma sodium levels 
can impair the release of vasodilatory nitric oxide in the circulation(297), increasing 
systemic pressure. Additionally, salt sensitive hypertensive patients on a high sodium 
intake demonstrate increased sympathetic tone (increased urinary catecholamines) and 
enhanced pressure response to AgII, potentially favouring the onset of LVH(281). 
In patients with EH, no association was found between urinary sodium excretion and 
LVMI. The Framingham Heart Study(215) examined the relationship between urinary 
sodium excretion (normalised to creatinine from a spot sample) and LVMI (measured 
using echocardiography) in Framingham offspring and found no association between the 
two measures in normotensive or hypertensive individuals. Utilising a spot sample is 
however flawed as it assumes that urinary sodium excretion is constant throughout the day. 
 
5.4.2.5  LVMI and deoxycorticosterone (DOC)  
DOC is a largely overlooked mineralocorticoid. It is produced in the zona fasciculata of the 
adrenal cortex, as well as extra-adrenally by 21-hydroxylation of plasma-borne 
progesterone. Its levels do not depend upon aspects of electrolyte status but upon ACTH 202 
levels. It has an affinity similar to aldosterone for binding the mineralocorticoid receptor 
but is a weaker mineralocorticoid with a lower sodium retaining ability. There is, however, 
experimental and clinical evidence that DOC can have marked potency.  
Administration of DOCA to uninephrectomized rats receiving a high sodium diet resulted 
in left ventricular hypertrophy and increased perivascular collagen(139). Rats treated with 
ALDO similarly developed LVH but the distribution of collagen differed. These results 
were replicated by others who also demonstrated that these effects could be prevented or 
reversed  by  the  addition  of  eplerenone(143;298).  In  humans,  deficiency  of  11β-
hydroxylase  (in  a  rare  form  of  congenital  adrenal  hyperplasia)  results  in  elevated 
circulating DOC concentrations leading to hypertension in the majority of patients. In vivo 
work therefore suggests that DOC is a potential factor in the increase of cardiac mass in the 
context of a high sodium environment via collagen deposition and myocyte hypertrophy. 
However, its role in LVH in humans has not been examined prior to this study.  
 
Ligand specificity of the mineralocorticoid receptor in the distal tubule is maintained by 
11beta- hydroxysteroid dehydrogenase type 2 (11BHSD2), converting active cortisol (F) to 
inactive cortisone (E), leaving the MR free to bind with aldosterone. Recently, a similar 
enzyme has been identified which protects the MR from DOC binding(91). The aldo-keto 
reductase enzyme AKR1C3 converts DOC to inactive 20ʱ-hydroxy-DOC in renal cortical 
and  medullary  collecting  ducts,  impairing  activation  of  the  MR.  The  effective 
concentration  required  to  induce  a  50%  effect  (Ec50)  of  DOC  increased  1000-fold  in 
presence of AKR1C3. These findings remain to be confirmed in vitro, particularly as the 
Km of the enzyme is high (uM) in relation to circulating concentrations of DOC (pM). 
 
If, like 11BHSD2, the AKR1C3 enzyme is not expressed in the heart, it may leave DOC 
free to bind the MR, explaining the independent effect of DOC on left ventricular mass.   
 
This novel finding of an association between DOC and LVMI merits further study.  
 
5.4.2.6  LVMI and aldosterone 
 
LVH is more frequent and severe in patients with primary hyperaldosteronism than in 
patients with EH(276). Associations between Aldo and LV mass have been reported in 
various subgroups, predominantly with hypertension. The following studies utilised 
echocardiography.  203 
Utilising the Framingham cohort, Vasan et al(299) demonstrated that PAC was 
independently associated LV wall thickness, but only in women. Similarly, in the 
MONICA cohort (300) PAC was correlated with LVMI in hypertensive women, but not 
normotensive women or men. 
Mule et al compared PAC and echo-determined LV mass in Caucasian hypertensives with 
and without the metabolic syndrome(301). Patients with the metabolic syndrome had a 
higher baseline PAC (due to obesity on multivariate analysis), higher SBP and LV mass. In 
both groups, PAC was significantly associated with LV mass (adjusted for height) but in 
the group with metabolic syndrome, PAC was independently associated with LV mass 
after adjustment for blood pressure, gender and BMI. This relationship was much weaker 
in patients without the metabolic syndrome. 
El-Gharbawy et al(302) found PAC to be associated with LVMI, but only in black 
hypertensive patients with a BMI >27. Malmqvist et al(303) reported PRA was an 
independent predictor of LVMI in hypertensive patients with LVH, but not PAC. In a 
small study, Duprez et al(210) demonstrated that PAC was significantly associated with 
LVMI in patients with hypertension, even after adjustment for BP. Utilising urinary 
aldosterone measurement, Delles et al(304) assessed healthy Caucasian men and found 
urinary aldosterone to be associated with LV mass, but this was not subject to adjustment 
for body surface area and therefore was not left ventricular mass index. Contrary to this, 
Schlaich et al(305) assessed 76 healthy white men and found that baseline urinary 
aldosterone levels were not associated with LV structure or function. 
In this current comparison of patients with EH, PAC was a significant independent 
predictor of LVMI, which supports the studies documented above and expands the findings 
to include males and findings were independent of BMI. Due to small numbers of females 
with EH in the study (n=5), subgroup analysis was not performed. 
In patients with ESRD on haemodialysis, Sato et al(306) assessed the relationship between 
PAC and LVMI and found a significant association in non-diabetic patients but not in 
diabetics, although numbers were small.  
There have been no previous studies assessing the relationship between Aldo and LVMI in 
patients with CKD. Our findings that Aldo was not significantly associated with LVMI but 
that THDOC was a significant independent predictor, suggests that different mechanisms 204 
of increasing left ventricular mass may be seen in CKD as compared with EH. DOC is 
largely produced in response to ACTH, unlike aldosterone which responds to changes in 
electrolyte and fluid status. Despite this, there was no association between cortisol 
metabolites and LVMI in CKD, suggesting that ACTH is not the primary driver of this 
finding. An alternative explanation is that DOC binds and activates the cardiac MR in 
patients with CKD, but not EH, leading to myocyte hypertrophy and LVH. Why DOC 
should preferentially bind the MR over the traditional ligands of aldosterone or cortisol is 
unclear.  
Inhibition of the MR is, however, the only pharmaceutical intervention demonstrated to 
regress LVH in patients with CKD(131). Edwards et al demonstrated that in 112 patients 
with non-diabetic CKD 3, randomised to spironolactone 25mg or placebo for 40 weeks in 
addition to ACE or ARB, spironolactone significantly reduced LV mass independent of 
reductions in SBP. Similar findings were seen in patients with EH in a separate study(307). 
Blockade of the MR is not, however, ligand specific and it may be that the beneficial 
effects seen may relate to blockade of DOC, not aldosterone (or cortisol in tissues devoid 
of 11βHSD2) as previously presumed.  
No association was seen between a polymorphism of the aldosterone synthase gene (-
344C/T) and LVMI, which mirrors previous findings(308). 
 
5.4.2.7  LVMI and cortisol 
 
A high prevalence of LVH is reported in patients with Cushing’s syndrome(211). In a 
small group of patients with EH, urinary free cortisol and cortisone correlated significantly 
with LVMI, but not in controls. No adjustment was made for blood pressure or other 
potential correlates(309). In this study, no association was seen between cortisol 
metabolites, urinary free cortisol (F), urinary free cortisone (E) and LVMI in patients with 
CKD or patients with EH. 
 
5.4.3   Interaction between steroids and sodium 
 
Experimental data from animal models suggests a high sodium environment has a 
permissive effect on mineralocorticoids in terms of the development of ventricular 205 
hypertrophy and fibrosis(139;141). In this study there was a non-significant trend towards 
an association between high urinary sodium excretion, high urinary steroid excretion and 
high LVMI. Larger numbers may be required to demonstrate an association. 
The interaction between sodium, aldosterone and LV mass was studied in a hypertensive 
Belgian population(281) using echocardiography and urinary aldosterone excretion (from a 
24h sample, measured using RIA). LVMI independently increased with the 24-hour 
urinary excretion of both sodium and aldosterone. 
The mechanism by which a high sodium intake promotes mineralocorticoid mediated 
damage is uncertain but may relate to increased oxidative stress resulting in increased 
activation of the MR. 
5.4.4  LVMI in patients with EH 
The prevalence of LVH in the cohort of patients with EH is higher than would be expected 
for a general hypertensive cohort, where a prevalence of 15-20% by echo would be 
expected(310). It may be that the patients examined were not representative of a typical 
hypertensive cohort as they were recruited from a hospital blood pressure clinic, where, by 
definition, they have difficult to control blood pressure and might be more prone to 
developing end organ complications. The strong predictive nature of plasma aldosterone on 
LVMI differs from that seen in the CKD cohort but is in keeping with published data.  
5.4.5  Limitations  
 
As a cross-sectional analysis, this study cannot assume causality. Using estimated GFR 
rather than direct measurement will introduce some inaccuracy, although the MDRD6 
formula is well validated in patients with CKD. There are baseline differences between the 
different groups of renal diseases, reflecting their primary medical conditions, but the 
baseline differences are unlikely to have influenced the study findings. Small patient 
numbers limit individual disease subgroup analysis and therefore differences between 
diseases must be interpreted with caution as they may reflect under-powering of the study 
or differences between EH, CKD and different renal diseases. Direct measurement of 
albumin excretion was not available in this cohort and would have been interesting to 
compare with total proteinuria, as one would expect albuminuria to be more closely 
correlated if the association with LVMI was mediated by endothelial dysfunction. It would 206 
also be interesting to expand the study to include patients with milder CKD as increases in 
LVMI have been seen in patients with preserved renal function and biopsy proven 
GN(311) or APKD(312). Including larger numbers of patients would increase confidence 
in the existence of a relationship between steroids, sodium and LVMI in patients with 
CKD. 
5.5  Conclusion 
 
Although the identified predictors of LVMI are largely traditional and account for 68% of 
the variation in LVMI in patients with CKD, it remains unexplained why DOC should 
predict LVMI in patients with chronic kidney disease. This finding is not seen in patients 
with EH and suggests that DOC and possibly MR binding may have a role in explaining 
the excess cardiovascular morbidity and mortality seen in patients with CKD, independent 
of the effects of blood pressure.  
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6  Chapter Six: A study of the association between 
mineralocorticoids, sodium and vascular function in 
patients with chronic kidney disease  208 
6.1  Introduction  
 
In patients with CKD and ESRD, pulse wave velocity is independently associated with an 
increased risk of renal progression(242) and death(235;243). The main determinants of 
vascular function in patients with CKD are blood pressure and age however these do not 
fully explain the increased vascular stiffness seen. Endothelial function is also dysregulated 
in CKD(313) and may contribute to the increased vascular risk seen in these patients.  
Spironolactone treatment was shown to reduce vascular stiffness in patients with 
CKD(131), however whether levels of mineralocorticoids and sodium intake are directly 
associated with large and small vessel function in CKD has not been studied.  
The aims of this study were: 
1.  To assess which factors were associated with vascular stiffness and endothelial 
function in CKD, and to compare this with patients with EH. 
2.  To determine whether steroid status impacts upon vascular and endothelial function 
in patients with CKD and patients with EH, and whether sodium has a modulatory 
role in this situation. 
6.2  Methods 
 
Patients with CKD and hypertensive controls were recruited and the augmentation index 
(AIx), carotid-femoral pulse wave velocity (PWV) and endothelial reactive hyperaemia 
index (RHI) were assessed according to the protocol in chapter 2. The AIx was normalised 
to a heart rate of 75bpm due to the close correlation between AIx and heart rate – 
AIx@75bpm. Unless specified, this is the measure which will be assessed. 
 
6.2.1  Statistical analysis 
 
Differences between groups were compared using Student’s T-test, Mann Whitney U test, 
one-way ANOVA or Kruskall Wallis test as appropriate. Pearson’s and Spearman’s 
correlation coefficients were calculated for normally and non-normally distributed data, 
respectively. P≤0.01 was deemed significant due to multiple calculations. PWV and RHI 209 
were logarithmically transformed to achieve normality. Linear regression was used to 
determine which significant correlates were significant univariate predictors of the 
dependent variable. Significant univariate predictors were then were entered into 
multivariate linear regression models. 
6.3  Results 
6.3.1  Patient demographics 
 
Patient demographics are described in detail in chapter 4 (Table 4-1). Briefly, the mean age 
was 57.4 (SD 11.9) years, 78% of patients were male, mean SBP was 149 (SD 22) mmHg 
and mean DBP was 86 (SD 13) mmHg and mean BMI was 29.3 (SD 5.5) g/m2. Mean 
calculated augmentation index was 22.8 (SD 10.3) %, median PWV 8.9 (7.0-11.6) m/s and 
median RHI 1.8 (1.7-2.4).  
Within the CKD cohort, patients with IgAN were significantly younger and had 
significantly lower SBP. Diabetic patients had significantly lower levels of renal function.  
Drug therapies were varied across the whole cohort (Table 4-6). EH patients were 
significantly more likely to be prescribed thiazide diuretics (56% vs. 6%) and significantly 
less likely to be prescribed a statin (43% vs. 69%) or ACEi (37% vs. 64%). 
Biochemical differences between the hypertensive and CKD cohorts are as would be 
expected. Renal patients had significantly lower eGFR, higher urate, higher CRP, lower 
serum albumin, higher phosphate, higher PTH, lower vitamin D, lower haemoglobin and 
had higher levels of proteinuria. They also had significantly lower levels of urinary 
potassium excretion (tables 4-2 and 4-3). 
Mean AIx@75bpm was 22.8 (SD 10.3), median PWV 8.9 (IQR 7.0-11.6) m/s and median 
RHI 1.8 (1.7-2.4). Pulse wave velocity was significantly higher in the CKD group than the 
EH group. There was no significant difference between groups in terms of augmentation 
index or reactive hyperaemia index measurements. Within the CKD group, patients with 
DMN had a significantly higher PWV (table 6-1). 210 
 
Variable  EH 
controls 
 
N=30 
CKD 
patients 
 
N=70 
p  DMN 
 
 
N=34 
IgAN 
 
 
N=27 
MGN 
 
 
N=9 
p 
AIx  26.4 (11.6)  23.7 (10.3)  NS  24.6 (10.7)  21.1 (9.7)  27.9 (10.1)  NS 
AIx@75bpm  24.9 (10.8)  22.1 (10.1)  NS  23.7 (10.0)  19.1 (10.4)  24.7 (8.8)  NS 
PWV (m/s)  7.9 (6.7-
9.1) 
9.4 (7.3-13.5)  0.006  11.8 (9.3-
15.3) 
7.0 (5.8-
9.4) 
7.7 (6.3-
10.3) 
<0.001 
RHI  1.9 (1.7-
2.4) 
1.8 (1.5-2.4)  NS  1.6 (1.4-2.2)  2.0 (1.6-
2.5) 
1.8 (1.5-2.7)  NS 
Table 6-1: Baseline vascular function, stratified by group.  
Data expressed as mean (SD) or median (IQR). Comparison by t-test, Mann Whitney U test, one-way 
ANOVA or Kruskall Wallis test as appropriate. 
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6.3.2  Correlations between markers of vessel function and potential 
determinants 
   
Table 6-2 illustrates the correlation matrix between vascular function and demographics, 
prescribed medications, plasma and urine variables and left ventricular findings in patients 
with chronic kidney disease. Table 6-3 shows the same correlation matrix in patients with 
essential hypertension.  
 
 212 
Table 6-2: Correlation matrix in renal patients. 
 
Pearson’s or Spearman’s correlation coefficient as appropriate. P≤0.01 deemed significant (highlighted in 
bold). 
  Log RHI 
r, p 
AIx 
r,p 
AIx@75bpm 
r,p 
Log PWV 
r,p 
Age  -0.289, 0.02  0.305, 0.01  0.262, 0.03  0.602, <0.001 
Sex (male=0)  0.174, 0.15  0.29, 0.02  0.4, <0.001  -0.087, 0.50 
Weight  -0.187, 0.12  -0.312, 0.01  -0.481, <0.001  0.141, 0.27 
BMI  -0.199, 0.12  -0.064, 0.66  -0.171, 0.24  0.158, 0.28 
Height  -0.077, 0.52  -0.302, 0.01  -0.355, 0.003  0.014, 0.92 
Waist 
circumference 
-0.222, 0.04  -0.296, 0.007  -0.389, <0.001  0.286, 0.008 
IHD  -0.064, 0.53  0.119, 0.27  -0.033, 0.76  0.231, 0.03 
ECG abnormality  -0.174, 0.09  0.088, 0.42  0.056, 0.61  0.286, 0.007 
SBP  0.232, 0.05  0.396, 0.001  0.407, 0.001  0.373, 0.002 
DBP  0.336, 0.004  0.002, 0.99  0.127, 0.31  -0.127, 0.317 
PP  0.07, 0.57  0.475, <0.001  0.411, 0.001  0.516, <0.001 
Drugs (1=yes) 
-ACEi 
-ARB 
-BBlocker 
-Diuretic (loop) 
-Statin 
 
0.014, 0.91 
0.188, 0.12 
0.205, 0.09 
-0.054, 0.66 
-0.143, 0.17 
 
-0.26, 0.03 
0.03, 0.81 
0.197, 0.11 
-0.15, 0.22  
-0.011, 0.92 
 
-0.121, 0.33 
-0.07, 0.58 
0.009, 0.94 
-0.159, 0.20 
-0.128, 0.24 
 
0.121, 0.34 
-0.051, 0.69 
0.167, 0.19 
0.139, 0.28 
0.273, 0.03 
Log RHI  -  0.074, 0.55  0.128, 0.31  -0.234, 0.07 
AIx  0.074, 0.56  -  0.832, <0.001  0.199, 0.12 
AIx@75bpm  0.128, 0.31  0.832, <0.001  -  0.284, 0.03 
Log PWV  -0.234, 0.07  0.199, 0.12  0.284, 0.03  - 
EF  -0.003, 0.98  0.078, 0.57  -0.012, 0.93   0.086, 0.54 
LVMI  0.03, 0.83  0.134, 0.32  0.09, 0.51  0.273, 0.05 
EDV  0.121, 0.37  -0.096, 0.48  -0.099, 0.47  -0.113, 0.42 
ESV  0.009, 0.95  -0.032, 0.82  -0.02, 0.88  -0.175, 0.21 
eGFR (6v)  0.133, 0.27  0.044, 0.72  -0.008, 0.95  -0.468, <0.001 
Cholesterol  0.13, 0.28  0.001, 0.99  0.024, 0.85  -0.298, 0.02 
Cholesterol/HDL  -0.046, 0.71  0.005, 0.97  -0.095, 0.44  -0.02, 0.88 
PTH  -0.112, 0.37  0.025, 0.85  0.01, 0.94  0.251, 0.05 
PO4  -0.145, 0.24  0.126, 0.31  0.157, 0.21  0.297, 0.02 
CRP  0.151, 0.22  0.001, 0.99  0.215, 0.09  0.03, 0.819 
Hb  -0.011, 0.93  -0.134, 0.27  -0.273, 0.03  -0.337, 0.007 
Vit D   0.107, 0.38  0.187, 0.13  0.152, 0.22  -0.177, 0.16 
Glucose  -0.167, 0.18  0.306, 0.02  0.237, 0.06  0.347, 0.006 
Urate  -0.029, 0.82  -0.149, 0.12  -0.201, 0.12    0.12, 0.36 
PCR  -0.037, 0.76  0.139, 0.27  0.004, 0.97  0.197, 0.12 
Log24h QP  -0.034, 0.78  -0.173, 0.16  -0.116, 0.36  0.194, 0.13 
24h USod  -0.349, 0.004  -0.077, 0.49  -0.162, 0.14  0.221, 0.04 
24h USod/U Pot  -0.218, 0.08  -0.036, 0.78  0.007, 0.96  0.37, 0.003 
THALDO  -0.222, 0.08  -0.225, 0.08  -0.245, 0.06  -0.03, 0.82 
THDOC  -0.228, 0.07  -0.201, 0.12  -0.165, 0.2  0.015, 0.91 
Cortisol metabs  0.005, 0.97  -0.29, 0.02  -0.388, 0.002  -0.082, 0.53 
Log Plasma aldo  -0.131, 0.29  -0.101, 0.42  -0.123, 0.33  -0.139, 0.27 
PRC  -0.245, 0.04  -0.462, <0.001  -0.389, 0.001  -0.149, 0.24 
ARR  0.18, 0.14  0.366, 0.002  0.291, 0.02  0.073, 0.56 213 
 
Table 6-3: Correlation matrix in essential hypertensives. 
Pearson’s or Spearman’s correlation coefficient as appropriate. P≤0.01 deemed significant (highlighted in 
bold). 
 
 
 
 
 
  Log RHI 
r, p 
AIx 
r, p 
AIx@75bpm 
r, p 
Log PWV 
r, p 
Age  -0.084, 0.67  0.403, 0.06  0.343, 0.10  -0.03, 0.89 
Sex (male=0)  0.435, 0.02  0.291, 0.18  0.624, 0.001  -0.118, 0.53 
Weight  -0.216, 0.26  -0.223, 0.31  -0.331, 0.11  0.07, 0.71 
BMI  -0.294, 0.12  -0.007, 0.97  0.107, 0.62  0.067, 0.72 
Height  0.096, 0.62  -0.452, 0.03  -0.715, <0.001  -0.003, 0.99 
Waist 
circumference 
-0.145, 0.46  -0.124, 0.57  -0.172, 0.42  0.148, 0.44 
SBP  0.031, 0.87  0.159, 0.46  0.159, 0.46  0.12, 0.53 
DBP  0.259, 0.17  0.207, 0.34  0.059, 0.78  0.098, 0.61 
PP  -0.174, 0.37  -0.004, 0.99  0.168, 0.43  0.093, 0.63 
IHD  -0.105, 0.58  0.168, 0.44  -0.011, 0.96  0.188, 0.32 
ECG abnormality  -0.086, 0.66  -0.054, 0.81  0.036, 0.86  -0.245, 0.19 
Drugs (1=yes) 
-ACEi 
-ARB 
-BBlocker 
-Diuretic (loop) 
-Statin 
 
-0.054, 0.78 
0.262, 0.17 
-0.121, 0.53 
-0.174, 0.42 
-0.184, 0.34 
 
0.089, 0.69 
-0.229, 0.29 
0.009, 0.97 
-0.573, 0.01 
-0.068, 0.76 
 
-0.058, 0.79 
-0.238, 0.26 
0.226, 0.29 
-0.429, 0.07 
-0.035, 0.87 
 
-0.146, 0.44 
-0.347, 0.06 
0.015, 0.94 
0.402, 0.05 
-0.141, 0.46 
Log RHI  1  -0.02, 0.92  -0.067, 0.76  -0.122, 0.53 
AIx  -0.02, 0.93  1  0.881, <0.001  0.049, 0.82 
AIx@75bpm  -0.067, 0.76  0.881, <0.001  1  0.029, 0.89 
Log PWV  -0.122, 0.53  0.049, 0.82  0.029, 0.89  1 
EF  0.038, 0.85  0.26, 0.24  0.082, 0.71  -0.249, 0.2 
LVMI  -0.118, 0.55  -0.269, 0.23  -0.55, 0.007  -0.053, 0.79 
cEDV  -0.139, 0.48  -0.162, 0.47  -0.148, 0.44  -0.063, 0.75 
cESV  -0.098, 0.62  -0.258, 0.25  0.394, 0.03  -0.394, 0.03 
eGFR (6v)  0.119, 0.54  0.096, 0.66  -0.237, 0.27  -0.008, 0.96 
Cholesterol  -0.076, 0.69  0.319, 0.14  0.419, 0.04  0.251, 0.18 
Cholesterol/HDL  -0.117, 0.55  0.004, 0.99  0.106, 0.62  0.044, 0.82 
PTH  -0.171, 0.40  -0.186, 0.42  -0.059, 0.80  -0.308, 0.12 
PO4  0.009, 0.96  -0.01, 0.96  0.084, 0.70  -0.073, 0.71 
CRP  -0.194, 0.31  -0.103, 0.64  -0.072, 0.74  0.09, 0.64 
Hb  -0.071, 0.71  -0.118, 0.59  -0.313, 0.18  0.193, 0.31 
25-vit D  -0.283, 0.14  0.678, <0.001  0.404, 0.05  0.438, 0.02 
Glucose  -0.296, 0.11  -0.282, 0.14  -0.062, 0.74  0.297, 0.11 
Urate   -0.197, 0.31  0.016, 0.94  -0.172, 0.37  0.126, 0.52 
PCR  -0.17, 0.38  -0.366, 0.09  -0.222, 0.30  0.068, 0.72 
Log 24h QP  0.12, 0.55  -0.43, 0.04  -0.162, 0.46  0.316, 0.10 
24h USod  -0.154, 0.42  0.033, 0.88  -0.074, 0.73  0.566, 0.001 
24h USod/U Pot  -0.19, 0.31  -0.17, 0.37  -0.091, 0.63  0.376, 0.04 
THALDO  0.164, 0.39  -0.029, 0.88  -0.002, 0.99  0.118, 0.54 
THDOC  0.117, 0.54  -0.008, 0.97  0.059, 0.76  0.071, 0.72 
Cortisol metabs  0.067, 0.72  0.003, 0.99  -0.259, 0.17  -0.009, 0.96 
Log Plasma aldo  -0.405, 0.03  -0.702, 0.71  -0.127, 0.51  -0.126, 0.51 
PRC  -0.073, 0.71  0.076, 0.73  0.029, 0.89  -0.25, 0.19 
ARR  0.002, 0.99  -0.26, 0.23  -0.213, 0.32  0.23, 0.23 214 
6.3.3  Reactive hyperaemia index (RHI) 
6.3.3.1  RHI in different patient groups 
There was no significant difference in RHI between patients with CKD and hypertensives, 
or between different primary renal diseases (Figure 6-1).  
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Figure 6-1: Mean (SD) RHI values by patient group.  
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6.3.3.2  Correlations between demographic factors and RHI 
Factors which correlated significantly with a higher RHI in CKD patients (reflecting better 
endothelial function) (Tables 6-2 and 6-3) were a lower 24h urinary sodium excretion and 
a higher DBP. Factors approaching significance were lower age (r -0.289, p=0.02), lower 
PRC (-0.245, p=0.04), lower THALDO (-0.222, p=0.08) and lower THDOC (-0.228, 
p=0.07) excretion rates. 
In EH patients, RHI was lower in females (Table 6-4) and was inversely proportional to 
PAC. 
6.3.3.3  Linear regression of predictors of RHI in patients with CKD 
 
Significant correlates with RHI were entered in a univariate linear regression model to 
establish significant predictors. Significant univariate predictors of RHI in patients with 
CKD were DBP and 24h urinary sodium. Both remained significant independent predictors 
on multivariate analysis. (Table 6-5) 
6.3.3.4  Linear regression of predictors of RHI in patients with EH 
Female gender (B=0.148 (95% CI 0.029-0.268), β 0.432, p=0.017) and log PAC (B= -
0.168 (95% CI -0.315 - -0.021), β -0.405, p=0.026) were significant univariate predictors 
of log RHI. When both factors were entered into a multivariate linear regression model, 
neither factor remained significant. PAC was significantly higher in females (p=0.04) with 
EH than in males. 
 
6.3.3.5  Comparison of CKD patients with RHI > 1.6 compared with <1.6  
 
A cut-off of RHI <1.6 has been previously shown to correlate with increased vascular risk 
and coronary endothelial dysfunction(255). When this cut-off is applied to patients with 
CKD the only factor which differs significantly between patient groups is the level of 
urinary sodium excretion (p=0.002), (Figure 6-2). Therefore, patients with CKD and a 
higher sodium intake have a greater degree of endothelial dysfunction. Only three patients 
with EH had a RHI less than 1.6, precluding further analysis. 
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  EH 
r 
 
p 
CKD 
R 
 
P 
Female gender  0.432  0.02     
Log PAC  -0.405  0.03     
DBP      0.336  0.004 
24h USod      -0.349  0.004 
Table 6-4: Significant correlates with the reactive hyperaemia index by patient group. 
 
 
Variable  Univariate 
B 
 
95% CI 
B 
 
β 
 
P 
Multivariate 
B 
 
95% CI 
B 
 
β 
 
p 
DBP(mmHg)  0.004  0.001-
0.006 
0.334  0.005  0.003  0.001-
0.006 
0.298  0.013 
24h USod 
(mmol/24h) 
-0.001  -0.001-
0.000 
-0.35  0.004  -0.001  -0.001-
0.000 
-
0.269 
0.038 
Table 6-5: Significant univariate and multivariate predictors of logRHI in patients with CKD.  
R-squared for multivariate model 0.226. 217 
 
>1.6 <1.6
0
100
200
300 p=0.002
n=42
n=28
Group of RHI
U
S
o
d
 
(
m
m
o
l
/
2
4
h
)
 
Figure 6-2: Urinary sodium excretion by RHI group. 
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6.3.3.6  Utility of the reactive hyperaemia index as a measure of endothelial function. 
As the reactive hyperaemia index is an index calculated from the degree of increase in 
signal amplitude in the occluded arm after release of the blood pressure cuff compared 
with baseline signal amplitude, normalised to the control arm, there is concern that the RHI 
will be falsely influenced by baseline vasodilatation. In this cohort, the baseline average 
amplitude on the occluded or control arm did correlate negatively with the RHI i.e. if the 
average baseline amplitude is high (suggesting vasodilation) the calculated RHI is low 
(Figure 6-3A). There was however no difference between arms in terms of degree of 
baseline vasodilatation (Figure 6-3B). 
There was no difference between different groups of the cohort in terms of baseline blood 
flow (one-way ANOVA p=NS) therefore, although the level of baseline vasodilatation is a 
limitation of the technique it affected all patients similarly. 
A possible solution to correct for this limitation, calculating the RHI then multiplying by 
baseline amplitude in the intervention arm, was carried out but did not alter the study 
findings. 219 
 
 
 
 
Figure 6-3: A - Scatterplot of baseline flow in the occluded arm versus the derived log reactive 
hyperaemia index. B -  Scatterplot of baseline flow in the occluded arm versus the control arm. 
Fitted linear regression line and estimate of significance.  
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6.3.4  Pulse wave analysis  
6.3.4.1  PWA - Comparison between groups. 
 
The augmentation index was significantly higher in patients with EH than in patients with 
CKD (p=0.02), with the main difference being between patients with EH and patients with 
IgAN (p=0.03) (Figure 6-4). However, after adjusting for a heart rate of 75bpm, these 
differences were no longer significant.  
6.3.4.2  Correlation between demographic factors and augmentation index in 
patients with CKD and EH 
A correlation matrix was constructed to determine variables which correlated significantly 
with the AIx@75bpm. There was no significant correlation between AIx@75bpm and 
level of renal function or different drug treatments (Tables 6-3 and 6-6). 
Correlates of AIx@75bpm differed between patients with renal disease and patients with 
EH (Table 6-6). As expected, in both EH and CKD patients, AIx@75bpm increased with 
female sex and shorter height.  
In CKD patients however there was also a significant correlation between higher 
AIx@75bpm and lower PRC (p=0.001), lower cortisol metabolites (p=0.002), increased 
SBP (p=0.001) and PP (p=0.001) and smaller waist circumference (p<0.001). There was 
also a trend towards lower THALDO excretion and higher AIx@75bpm (p=0.06). 
In EH patients, higher AIx@75bpm correlated with a lower LVMI (p=0.007), which may 
relate to the lower left ventricular mass in women. There was a trend towards higher 
AIx@75bpm with higher vitamin D levels (p=0.05).  
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Figure 6-4: Barcharts demonstrating mean (+SD) augmentation index (AIx) and augmentation index 
@75bpm.  
A & B – cohort separated into essential hypertensives and patients with CKD. C & D – cohort separated 
further by primary renal disease. Comparison by Student’s T Test or one-Way ANOVA with Tukey’s post-
hoc analysis. 
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  EH 
r 
 
p 
CKD 
r 
 
p 
Female sex  0.624  0.001  0.4  <0.001 
Height (cm)  -0.715  <0.001  -0.355  0.003 
LVMI (g/m2)  -0.55  0.007     
Weight (Kg)      -0.481  <0.001 
Waist circ (cm)      -0.389  <0.001 
SBP (mmHg)      0.407  0.001 
Pulse pressure (mmHg)      0.411  0.001 
Plasma renin concentration (uIU/ml)      -0.389  0.001 
Cortisol metabolites (mcg/24h)      -0.388  0.002 
Table 6-6: Significant correlations with AIx@75bpm in hypertensive and CKD patients.  
P<0.01 = significant. 
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6.3.4.3  Linear regression of predictors of AIx in patients with CKD  
 
Significant correlates with AIx@75bpm in patients with CKD were entered into a 
univariate linear regression model to predict AIx@75bpm. Significant univariate predictors 
of AIx@75bpm in patients with CKD were female gender, height, SBP, pulse pressure, 
weight, waist circumference, plasma renin concentration and urinary cortisol metabolites 
(Table 6-7).  
Significant univariate predictors were entered together into a multivariate linear regression 
model. One measure of blood pressure (PP) was entered due to collinearity. Higher pulse 
pressure, smaller waist circumference and lower PRC remained significant independent 
predictors of AIx@75bpm. 224 
 
Variable  Univariate 
B 
 
95% CI 
 
β 
 
P 
Multivariate 
B 
 
95% CI 
 
β 
 
p 
PP (mmHg)  0.192  0.068-
0.316 
0.36  0.003  0.158  0.04-
0.27 
0.30  0.009 
Waist circ (cm)  -0.333  -0.506- -
0.106 
-
0.445 
<0.001  -0.298  -0.46- -
0.14 
-
0.40 
<0.001 
√ PRC  -0.548  -0.904- -
0.192 
-
0.359 
0.003  -0.37  -0.703- -
0.04 
-
0.24 
0.03 
Female gender  7.33  1.76-12.9  0.312  0.011         
Height (cm)  -0.34  -0.576- -
0.104 
-
0.339 
0.005  -  -  -  - 
SBP (mmHg)  0.152  0.048-
0.255 
0.345  0.005  -  -  -  - 
Weight (Kg)  -0.246  -0.359- -
0.134 
-
0.479 
<0.001  -  -  -  - 
Cortisol 
metabolites 
(mcg/24h) 
-0.001  -0.001-
0.000 
-
0.388 
0.002  -  -  -  - 
Table 6-7: Univariate and multivariate linear regression models of predictors of AIx@75bpm in 
patients with CKD.  
R-squared for multivariate model = 0.49. 
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6.3.4.4  Multivariate analysis of the significant predictors of AIx in essential 
hypertensives 
Gender, height and logLVMI correlated significantly with AIx@75bpm in patients with 
EH and were entered into a univariate linear regression model, whereby only gender and 
height remained significant univariate predictors. On multivariate analysis only height 
(cm) remained a significant independent predictor of AIx@75bpm (B=-0.651, 95% CI -
1.17- -0.14, p=0.016) in patients with EH. 
In patients with EH, AIx@75bpm is a univariate predictor of LVMI on linear regression – 
the lower the AIx@75bpm, the higher the LVMI (B= -0.005 (95% CI -0.008 - -0.001), 
p=0.015). However, when gender is added to the model, neither is a significant 
independent predictor. 
6.3.5  Carotid-femoral pulse wave velocity 
6.3.5.1   Levels and correlations with patient demographics 
PWV was significantly higher in patients with CKD compared with EH (p=0.006), with 
highest levels in patients with diabetic nephropathy (p<0.001) (Figure 6-5), although they 
had lower levels of renal function. In all patients PWV was associated with eGFR (figure 
6-6). 
Significant correlations between PWV and demographic factors differed between patients 
with CKD and patients with EH (Table 6-9). In CKD patients, higher PWV correlated 
significantly with older age, higher SBP, higher pulse pressure, lower eGFR, higher serum 
glucose, higher 24h USod:UPot ratio, larger waist circumference, lower haemoglobin and 
also correlated with the presence of ECG abnormalities. There was a trend towards higher 
PWV and higher LVMI (p=0.05), lower serum cholesterol (p=0.02), higher PTH (0.05), 
higher serum phosphate (0.02) and higher 24h urinary sodium excretion (0.04). 
In EH patients, a higher PWV correlated significantly with higher urinary sodium 
excretion. There was also a trend towards higher PWV with higher vitamin D levels 
(p=0.02) in these patients. 
There was a significant relationship on linear regression analysis between number of 
antihypertensive medications and PWV (p=0.014).  226 
 
 
 
 
Figure 6-5: Bar chart of PWV by patient group. 
Data expressed as mean (SD). Comparison by Student’s T-test (A) or one-way ANOVA (B). 
 
 
 
Figure 6-6: Scatterplot with fitted linear regression line demonstrating association between eGFR and 
PWV. 
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6.3.5.2  Linear regression of predictors of PWV in patients with CKD 
Factors which correlated significantly with PWV in patients with CKD were entered into a 
univariate linear regression model. From this, significant univariate predictors of PWV 
were age, waist circumference, SBP, pulse pressure and eGFR. On multivariate analysis, 
when all significant univariate predictors were entered into a multivariate linear regression 
model (including only one measure of blood pressure, PP), only pulse pressure, waist 
circumference and age remained significant independent predictors (Table 6-9). 228 
 
  EH 
r 
 
p 
CKD 
r 
 
P 
24h USod  0.566  0.001     
Age      0.602  <0.001 
Waist circumference      0.286  0.008 
SBP      0.373  0.002 
Pulse pressure      0.516   <0.001 
eGFR      -0.468  <0.001 
24h USod/UPot      0.37  0.003 
ECG abnormality      0.286  0.007 
Serum glucose      0.347  0.006 
Haemoglobin      -0.337  0.007 
Table 6-8: Correlations with logPWV reported by patient group.  
 
 
Variable  Univariate 
B 
 
95% CI 
 
β 
 
P 
Multivariate 
B 
 
95% CI 
 
β 
 
P 
Age (y)  0.008  0.005-
0.010 
0.602  <0.001  0.005  0.003-
0.008 
0.432  <0.001 
Waist circ (cm)  0.004  0.001-
0.007 
0.349  0.006  0.003  0.001-
0.005 
0.241  0.015 
Pulse pressure 
(mmHg) 
0.004  0.002-
0.006 
0.516  <0.001  0.002  0.000-
0.004 
2.55  0.012 
Systolic BP 
(mmHg) 
0.002  0.001-
0.004 
0.373  0.002         
eGFR 
(ml/min/1.73m
2) 
-0.003  -0.005-
0.002 
-
0.468 
<0.001         
Haemoglobin 
(g/dl) 
-0.031  -0.053-
0.009 
-
0.337 
0.007         
Table 6-9: Significant univariate and multivariate predictors of logPWV in patients with CKD. 
Only pulse pressure, not SBP, was entered into the multivariate model due to its higher predictive value 
and collinearity between the two variables. R-square value for the multivariate model was 0.59. 229 
6.3.5.3  Linear regression of predictors of logPWV in patients with EH 
24h urinary sodium excretion was the only significant correlate with PWV in patients with 
EH. On linear regression analysis it remained a significant predictor (B=0.001, (95% CI 
0.0-0.001), p=0.001, R2=0.32). 
6.3.6  Endothelial function, pulse wave velocity and augmentation index - 
association with proteinuria and left ventricular abnormalities  
 
RHI, PWV and AIx@75bpm measures did not correlate with levels of proteinuria, 
ventricular mass, left ventricular ejection fraction or left ventricular volume in patients 
with CKD. PWV correlated significantly with the presence of ECG abnormalities in 
patients with CKD. Using binary logistic regression with ECG abnormalities as the 
predicted variable, logPWV was a significant univariate predictor (B=4.57, p=0.016).  
In patients with EH, AIx@75bpm correlated significantly with LVMI, however was not a 
significant multivariate predictor. RHI, PWV and AIx measures did not correlate with left 
ventricular ejection fraction or left ventricular volume. 
6.4  Discussion 
 
6.4.1  Key findings  
 
In this study it has been demonstrated that : 
  The determinants of markers of vascular function differ between patients with EH 
and CKD.  
  Urinary steroid excretion was not associated with vascular function measures.  
  Urinary sodium excretion was the only significant determinant of PWV in patients 
with EH and an independent predictor of RHI in patients with CKD.  
  Plasma aldosterone concentration was a univariate predictor of RHI in patients with 
EH, but not a multivariate predictor.  230 
  None of the three vascular or endothelial function methods tested were 
independently associated with left ventricular abnormalities or proteinuria excretion 
in patients with CKD. 
6.4.2  Carotid-femoral PWV 
Carotid-femoral pulse wave velocity is the gold standard measure of vascular stiffness. In 
this CKD cohort, the significant independent predictors of PWV were : 
  Increasing age 
  Increasing waist circumference  
  Higher pulse pressure 
Although PWV was higher in patients with reduced renal function, this was not an 
independent association once adjustments were made for other demographic factors. There 
was no significant association between THALDO, THDOC or urinary sodium excretion 
and PWV. In patients with CKD, PWV predicted the presence of ECG abnormalities but 
was not associated with cardiac MRI determined LV mass, function or volume. Nor was it 
associated with the level of proteinuria excretion.  
In patients with EH, PWV was independently determined by 24h urinary sodium excretion, 
a reflection of dietary sodium intake.  
 
6.4.3  Augmentation index 
 
Augmentation index is an integrated measure of vascular stiffness, with a higher value 
being an indicator of poor prognosis. In both groups AIx@75bpm increased with 
increasing height and was higher in females, which are recognised associations.  
In CKD patients however, the following were significant independent predictors, removing 
the association with height and gender : 
  Increasing pulse pressure 231 
  Smaller waist circumference  
  Lower plasma renin concentration  
It may be in renal patients that intravascular volume expansion suppresses PRC and raises 
pulse pressure, resulting in a higher AIx.  
In EH patients, AIx@75bpm was independently predicted by height, with the time taken 
for the reflective wave to return being longer with the further distance to travel. 
AIx@75bpm was a significant negative predictor of LVMI in these patients, although this 
was likely due to AIx being higher in women, who have a lower LVMI.  
6.4.4  Reactive hyperaemia index 
 
The reactive hyperaemia index is a nitric oxide mediated measure of endothelial function. 
The RHI falls as the endothelium becomes dysfunctional. In patients with CKD, high 
urinary sodium excretion was independently associated with a lower RHI. Diastolic blood 
pressure was also a significant multivariate predictor of the RHI – the higher the DBP, the 
higher the RHI, which is contrary to what one would expect, but may be explained by 
peripheral vasoconstriction, increasing DBP and RHI.  
In patients with EH, univariate (but not multivariate) predictors of low RHI were :  
  Male gender 
  Increasing PAC 232 
 
Table 6-10: Significant multivariate independent predictors of measures of vascular function in 
patients with CKD and patients with EH. 
 
6.4.5  Comparison with previous studies 
 
In normal subjects, PWV increases with age and blood pressure(314) and is higher in 
patients with diabetes(315). Increasing PWV with increasing waist circumference has also 
previously been reported in normal individuals(316). Similarly, augmentation index relates 
to diastolic blood pressure, height and gender(317) – being higher in women for reasons 
that are unclear(318). Endothelial function, measured as the RHI, has been shown to be 
independently associated with male gender, BMI, cholesterol, diabetes, age and 
smoking(256).  
The most comprehensive CKD cohort with which to compare our findings is from 
America. Townsend et al assessed determinants of aortic PWV using Sphygmocor carotid-
femoral PWV in a CRIC substudy(319), utilising measurements in 2564 patients with 
CKD. Similar to our findings, independent predictors of PWV  were increasing age, blood 
pressure and waist circumference, as well as serum glucose, black race and male gender. 
They found each 10ml/min/1.73m
2 loss in eGFR to be associated with a 0.4m/s increase in 
PWV, although eGFR was not a significant independent predictor. There was also no 
significant independent relationship between PWV and proteinuria.  233 
Covic et al(238) assessed independent predictors of arterial stiffness parameters in patients 
with CKD. Similar to our cohort, age predicted PWV and MAP independently predicted 
AIx. Toussaint et al(320) reported an association between PWV and age in patients with 
CKD, but also found triglyceride levels to be significant independent predictors. We found 
no association with lipids, but did not assess triglycerides directly. 
Using the radial augmentation index in non-diabetic patients with CKD 3, Takenaka et 
al(244) found the independent predictors of AIx to be increasing age and weight, shorter 
height and lower heart rate. These findings are contrary to our own, perhaps reflecting a 
differing case mix. They also found increasing AIx was associated with LVMI (on echo) in 
male patients, which we did not; and showed AIx to be a significant independent predictor 
of slope decline in eGFR. 
There are no published data assessing RHI in patients with CKD with which to compare 
our findings, however we were unable to demonstrate the independent associations seen in 
the Framingham cohort (male sex, BMI, waist circumference, SBP, DBP and lipids). The 
RHI is an attractive operator independent method of measuring NO dependent endothelial 
function. It is however limited by baseline vasodilation. Alternative ways of measuring 
endothelial function such as the gold standard brachial flow mediated dilatation (FMD) 
have not been directly compared with EndoPAT in patients with CKD, to confirm that it is 
a valid measurement.  
We found 24h USod excretion to be an independent predictor of PWV in patients with EH. 
In a heterogenous normotensive and hypertensive Portugese population, carotid-femoral 
PWV was independently determined by age, SBP and urinary sodium excretion(321). In a 
black South African cohort, urinary sodium alone was not associated with PWV or AIx, 
but when corrected for urinary potassium excretion, it was an independent predictor of 
AIx(322).  
The finding that urinary sodium excretion was a strong predictor of RHI in patients with 
CKD is novel. The findings support the notion that elevated sodium intake contributes to 
endothelial and vascular dysfunction, potentially leading to increased risk of mortality. The 
mechanisms by which sodium has a detrimental effect are not clear but are likely to 
include oxidative stress or volume overload.  234 
An Australian cross-over study in normotensive individuals demonstrated that a low salt 
diet can significantly improve endothelial function (measured using FMD) independent of 
blood pressure, but had no effect on augmentation index or pulse wave velocity (323). The 
trial lasted only 2 weeks and it may be that to have an effect on larger arteries, a longer 
trial period would be required. 
The finding that urinary steroid excretion and PAC are not related to measures of vascular 
function is surprising. The MCR is known to be expressed on vascular endothelium and 
indeed local systems are thought to exist which mediate vasoconstriction. Similarly, it is 
unclear why treatment with spironolactone should reduce PWV in patients with CKD(131), 
when urinary steroid excretion was not associated with the measure. Perhaps local RAAS 
systems are not reflected in serum or urine measurements of steroids. 
Alternatively, reduction in blood pressure is the dominant mechanism of benefit. 
6.4.6  Limitations  
The number of patients assessed in the EH cohort was small, meaning that weaker 
correlations would not be identified. Small sub-groups within the CKD cohort mean 
further analysis was limited. All patients included in the study were prescribed anti-
hypertensive medications, including ACEi, which modify PWV(324) and endothelial 
function and beta blockers which reduce augmentation index, meaning that some 
associations may be masked. As a cross-sectional analysis, implications regarding the 
utility of these measures in prognosis cannot be made. Similarly, causation and 
directionality cannot be implied by the reported associations. 
 
6.5  Conclusions 
 
The determinants of vascular and endothelial function in patients with EH and CKD differ. 
We have confirmed previously reported associations between measures. The role of renal 
function in determining the measures of vascular function appears to be indirect and 
explained by other factors such as obesity and blood pressure, as eGFR was not an 
independent predictor on multivariate analysis. Urinary sodium excretion is an independent 
predictor of endothelial dysfunction but urinary steroid excretion was not associated with 
any of the three measures. 235 
7  Chapter Seven: An in vitro study of the effects of 
aldosterone and sodium on proximal tubular cells  236 
7.1  Introduction 
In addition to its traditional physiological role of sodium retention, aldosterone has also 
been shown to have pro-inflammatory and pro-fibrotic effects in rats, in the context of a 
high sodium environment, leading to glomerulosclerosis and interstitial fibrosis (141;146). 
Fibrosis involves the accumulation of extracellular matrix, usually collagen, in response to 
injury or inflammation. In renal disease, tubulointerstitial fibrosis has consistently been 
shown to be the predominant histological marker of the risk of renal progression(25). 
Renal fibrosis is mediated via mesenchymal cells (the interstitial fibroblast or glomerular 
mesangial cell), cells which migrate from the vasculature or via epithelial-mesenchymal 
transition (325). 
Proximal tubular cells are also thought to be important in the development of interstitial 
fibrosis. HK-2 cells are an immortalized human proximal tubular cell line, known to 
express the MR (187), however the pro-inflammatory and pro-fibrotic effects of Aldo on 
proximal tubular cells, a non-traditional mineralocorticoid target, have not been 
determined. Similarly, despite the in vivo studies where a high sodium environment is 
necessary for pathological effects, the combined effects of Aldo and sodium on renal cells 
have also not been studied. Evidence from cardiomyocytes suggests Aldo inhibits the 
hyperosmolar cell shrinkage of a high sodium environment, leading to cell 
hypertrophy(177). 
The aims of this study were therefore  
1.  To confirm that HK-2 cells respond to Aldo.  
2.  To ascertain whether HK-2 cells produce pro-inflammatory cytokines in response 
to Aldo, and whether this is modified by a high sodium environment.  
3.  To establish whether there is evidence of a pro-fibrotic response to Aldo by HK-2 
cells in terms of collagen production, and whether this effect is a generic MR effect 
or ligand specific. 237 
7.2  Methods 
The laboratory techniques, chemicals and immunobiological agents used in this chapter are 
described in detail in chapter 2. 
7.2.1  Statistical analysis 
Differences between groups were assessed using one-way analysis of variance or Student’s 
t-test as appropriate. Analyses were conducted using SPSS (Illinois) v.15.0. 
7.3  Results 
7.3.1  HK-2 cells express the mineralocorticoid receptor  
 
To confirm that HK-2 cells express the MR reverse transcription PCR was performed 
using cDNA synthesised from untreated HK-2 cells as described in the Methods chapter. 
The PCR product was then run on an agarose gel and analysed qualitatively under UV 
light. This confirmed that HK-2 cells express the MR by the presence of an appropriately 
sized band (Figure 7-1).  238 
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Figure 7-1: Ethidium bromide stained agarose gel viewed under UV light. 
 Amplification of the MCR cDNA fragment (amplicon size 73bp) and Beta actin amplicon 97bp.  
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7.3.2  HK-2 cells phosphorylate ERK in response to Aldo treatment 
In order to confirm that HK-2 cells were responsive to Aldo treatment (see section 1.4.4, 
non-genomic signalling) an ERK phosphorylation assay was performed. HK-2 cells were 
serum starved overnight and treated with Aldo (10
-6M) for 1, 5, 10 and 15 minutes. One 
control well was stimulated with fetal bovine serum (FBS) for 15 minutes. Western blot 
was performed in triplicate which confirmed that HK-2 cells responded in a time-
dependent manner to Aldo stimulation by phosphorylating ERK, maximally at 5 minutes. 
A representative plot is shown (figure 7-2).  240 
 
 
 
Figure 7-2: Representative immunoblot demonstrating time dependent ERK phosphorylation after 
treatment with FBS (serum stimulation). 
 Aldo (10
-6M) treatment for 1 minute, 5minutes, 10 minutes and 15 minutes. GAPDH was used to 
demonstrate equal loading. 
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7.3.3  Aldosterone or angiotensin II treatment alone or in combination with 
sodium does not result in an increase in IL-6, IL-8, GM-CSF or TGF-
β1  production measured using ELISA 
 
To ascertain whether treatment of HK-2 cells with Aldo and or sodium resulted in a pro-
inflammatory response, ELISA was performed on cell culture supernatant. HK-2 cells 
were seeded at a density of 2x10
5 and incubated for 1, 24 or 48 hours in predetermined 
culture conditions. The 1h time point was chosen to ascertain whether any detected effect 
was genomic or non-genomic (see section 1.4.4).  
Cells were cultured with sodium alone (Na) (additional 50mmol/l - total media 
concentration 150mmol/l), Aldo alone at differing concentrations (Aldo 10
-6 M or Aldo 10
-
8 M) or both. The concentration of sodium was chosen as it was thought that the sodium 
content of the proximal tubule would be higher than normal serum concentration (135-
145mmol/l). The Aldo concentration was chosen to reflect physiological levels (10
-8) and 
supraphysiological levels. Commencing Aldo treatment at a 1nM concentration is 
reasonable as this is consistent with the reported Kd for Aldo-MR binding (326).  
Control cells were stimulated with lipopolysaccharide (LPS). ELISA was then performed 
on cell culture supernatant and results were normalised to untreated cells (negative 
control). Experiments were repeated 6 times. There was no significant difference in IL-6, 
IL-8 or GM-CSF production from baseline in response to Aldo or sodium at 1hour, 24 
hours or 48 hours (Figure 7-3). GM-CSF was not detectable at 1h. HK-2 cells did not 
excrete TGF-β1 at 24 or 48 hours either basally or in response to LPS, Aldo or sodium at 
the above concentrations and is therefore not included in the figure.  
Cells were also treated with angiotensin II at a concentration of 10
-6M alone and in 
combination with Aldo 10
-8 M and sodium to assess whether there was a synergistic or 
permissive effect of AgII. No response was seen in terms of IL-6, IL-8 or GM-CSF 
production at 48 hours (Figure 7-4).  242 
 
Figure 7-3:  Mean fold change from baseline in cytokine production by HK-2 cells measured using 
ELISA.  
7.3a: IL6. 7.3b: IL8. 7.3c: GM-CSF. Results normalised to negative control. See text for definitions of cell 
culture conditions. Comparisons made using one-way ANOVA, not including LPS stimulation. 
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Figure 7-4: Mean fold change in cytokine production (detected by ELISA) by HK-2 cells after 
angiotensin II treatment.  
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7.3.4  Transforming growth factor beta gene expression is not influenced by 
aldosterone or sodium treatment.  
 
As the dominant inflammatory cytokine associated with interstitial fibrosis(160), this 
mediator was explored further, as cell culture studies suggested it was not released by HK-
2 cells. To ascertain whether TGF-β1 was being synthesised but not secreted, or whether 
TGF- β2 or β3 were being synthesised rather than TGF- β1, real time PCR was undertaken 
using HK-2 cells treated with Aldo (Aldo 10
-6 M or Aldo 10
-8 M) alone or in combination 
with sodium (additional 50mmol/l, total concentration 150mmol/l) for 24 and 48 hours. 
Beta actin was amplified as the house-keeping gene to which results were normalised and 
each experiment was replicated six times. There was no significant change in TGF-β1, 2 or 
3 gene expression with experimental conditions (Figure 7-5). 245 
 
Figure 7-5: Mean fold change in TGFβ gene expression by HK-2 cells relative to baseline in response to 
sodium and aldosterone treatment.  
a: TGF β1; b: TGF β2, c: TGF β3. Results compared by 0ne-way ANOVA for 24h and 48h treatment. 
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7.3.5  Collagen 1 gene expression is up-regulated in a high sodium and 
aldosterone / cortisol environment – an effect which is blocked with 
canrenone. 
 
To ascertain whether HK-2 cells mounted a pro-fibrotic response to treatment with Aldo 
and sodium, real time PCR was undertaken for collagen 1 and collagen 4 (C1 and C4) gene 
expression. HK-2 cells were treated with Aldo (Aldo 10
-6 M or Aldo 10
-8 M) alone or in 
combination with sodium (additional 50mmol/l, total concentration 150mmol/l) for 24 and 
48 hours. C1 and C4 were chosen because these are the primary constituents of renal 
interstitial fibrosis.  
There was no significant difference in C4 relative gene expression under differing 
experimental conditions (Figure 7-6). 
Aldo or sodium alone did not result in a significant increase in C1 gene expression at 24h 
or 48h. However, at 48h, compared with Aldo10
-6 alone (p=0.002) or Na alone (p=0.007), 
Aldo10
-6 and Na together significantly increased gene expression 2.2 fold (SD1.03). 
Aldo10
-8 and Na resulted in a 2.54 fold (SD 0.83) increase, which was significantly higher 
than Aldo10
-8 alone (p=0.016) and Na alone (p=0.009) at 48h (Figure 7-7).  
Similar results were seen at 24h, with Aldo10
-6 and Na significantly increasing collagen 1 
gene expression 2.85 fold (SD 1.4); and Aldo10
-8 and Na significantly increasing collagen 
1 gene expression 1.79 fold (SD 0.31) (p<0.05 for all comparisons) (Figure 7-7).  
The addition of canrenone significantly abrogated this synergistic response at 24h and 48h 
with both Aldo10
-8 and Na and Aldo10
-6 and Na (Figure 7-7). 
To ascertain whether this was a specific Aldo effect or due to ligand binding to the MR, 
HK-2 cells were incubated for 48h with cortisol 10
-9M alone (dose utilised in previous 
studies (152)) and in combination with sodium (media concentration 150mmol/l). Again, 
cortisol alone did not result in a relative increase in C1 gene expression but the 
combination of cortisol and sodium increased relative C1 gene expression 3.02 fold (SD 
0.39). This effect was significantly inhibited by the addition of canrenone (10
-6M) 
(p=0.005), but not back to baseline (Figure 7-8). Co-culture of cells with lower dose 
cortisol (10
-11M) and sodium resulted in a similar increase in relative C1 gene expression 
2.65 fold (SD 0.16).   247 
Therefore, collagen 1 gene upregulation is a generic effect seen secondary to binding of the 
MR in HK-2 cells and is not a ligand specific effect. 248 
 
 
Figure 7-6: Fold change in collagen 4 production from baseline at 24h and 48h in response to 
treatment with aldosterone and sodium.  
Mean (SD). Comparison by one-way ANOVA. 
 
 
Figure 7-7: Change in collagen 1 gene expression in HK-2 cells treated with Aldo, sodium and 
canrenone for 24h and 48h.  
Mean (SD). Comparison by one-way ANOVA.249 
 
 
Figure 7-8: Relative change in collagen 1 gene expression after 48h treatment of HK-2 cells.  
Comparison by t-test. Data expressed as mean (SD). 
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7.3.6  11-beta hydroxysteroid dehydrogenase type 2 is expressed by HK-2 
cells 
 
To ascertain whether the effect of cortisol seen at the MCR in HK-2 cells was secondary to 
an absence of the 11βHSD2 enzyme, which usually protects the MCR from non-Aldo 
steroid binding, reverse transcription was performed and PCR was undertaken for the 
11βHSD2 enzyme and the product run on an ethidium bromide stained gel. An 
appropriately sized band was seen under UV light, demonstrating that HK-2 cells do 
express the 11βHSD2 enzyme gene (Figure 7.9). 251 
 
50bp 
ladder
B Actin
Blank
11BHSD2 
Blank
B Actin 11BHSD2
50bp
100bp
150bp
200bp
250bp
300bp
350bp
400bp
450bp
500bp
550bp
600bp
650bp
700bp
750bp
800bp
 
Figure 7-9: HK-2 cells express 11BHSD2.  
Unstimulated HK-2 cell cDNA amplified using primers specific for the 11βHSD2 enzyme and run on an 
ethidium bromide gel. 11βHSD2 enzyme amplicon size 65bp. BActin control amplicon 97bp.  
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7.3.7  Western blot analysis of collagen 1 expression 
 
Attempts were made to quantify collagen 1 protein expression using Western blot analysis. 
Two different antibodies were tried under differing assay conditions but the assay could 
not be accurately reproduced.  
7.4   Discussion 
 
It can be seen that HK-2 cells, traditionally viewed as a proximal tubular cell line, have a 
mixed phenotype and express the MR, allowing them to respond to Aldo, as evidenced by 
time-dependent ERK phosphorylation. They also express the enzyme 11-beta 
hydroxysteroid dehydrogenase type 2 (11-BHSD2). This mixture of phenotype enables the 
study of the effects of Aldo treatment and MR activation on renal cells.  
The following are the key findings of this study on the effects of aldosterone and sodium 
on human proximal tubular cells: 
1.  Collagen 1 gene expression increases in response to treatment with Aldo or cortisol 
at physiological concentrations, but only in a high sodium environment.  
2.  Blockade of these effects using canrenone, an MR antagonist, confirms that this is a 
MR-mediated effect. Collagen 1 is the main component of renal interstitial fibrosis 
and this novel finding provides further evidence for the synergistic role of 
aldosterone and sodium in the development of fibrosis. 
That Aldo has renal effects beyond its traditional distal tubular role is further supported in 
the literature by the localisation of the MR to sites out with the distal nephron, including 
mesangial cells(327) and podocytes(193). It has also been localised to the (renal) vascular 
endothelium(328) and vascular smooth muscle cells(329), where it is protected by the 
enzyme 11BHSD2.   
The findings in this study support in vivo evidence that mineralocorticoids have a direct 
pro-fibrogenic effect on the rat kidneys and heart, in the context of a high sodium 
environment. These studies are described in section 1.7. The convincing in vivo findings 
have led to more focused in vitro attempts to clarify the exact molecular in intracellular 
pathways involved in this pro-inflammatory pro-fibrotic response. 253 
The effects of Aldo have been studied in a number of different renal cell types including 
fibroblasts, mesangial cells, human kidney cortex cells and inner medullary collecting duct 
cells, with evidence for an increase in inflammatory mediators and collagen production in 
response. These studies are described in section 1.8.7.  
There are however no studies demonstrating a direct pro-inflammatory effect of Aldo on 
HK-2 cells. In the studies reported here, there was no evidence that Aldo directly 
influences IL6, IL8, TGFβ1 or GM-CSF production. It may be that effects are mediated via 
other cytokines which were not tested e.g. IL-1 or PAI-1, or it may be that additional cells 
are required for Aldo to have pro-inflammatory effects e.g. fibroblasts in the interstitium. 
Similarly, sodium alone or in combination with Aldo had no direct effect on a pro-
inflammatory phenotype. 
Therefore there is a large body of evidence suggesting a direct pathological role for Aldo 
in the kidney. These effects appear to be mediated via the MR, with subsequent ERK 
phosphorylation and intracellular signalling. This study has confirmed that activation of the 
MR in cells of renal origin, in a high sodium environment, can result in a pro-fibrotic 
phenotype. Mineralocorticoids alone do not induce a proinflammatory or profibrotic 
response in human proximal tubular cells unless co-incubated in a high sodium 
environment, suggesting the requirement of a specific co-factor or alteration in the cell 
status is required. 
It may be that the high sodium environment promotes intracellular oxidative stress as the 
cell attempts to respond to the increased osmotic load, potentially via increased expression 
and activation of the NHE3 receptor.  
To expand upon these findings there are a number of additional studies I would perform to 
confirm my findings and focus on the mechanisms of effect. Firstly, I would measure the 
osmolarity of the media serially over time after the addition of sodium in order to ascertain 
how quickly the cells adapt and I would also add a control well with an alternative osmotic 
agent e.g. dextrin. Secondly I would perform proliferation and apoptosis assays at each of 
the time points, in order to control for the effects of cell number. Thirdly I would attempt 
to quantify collagen 1 production via sonicated Sirius Red assays, as Western blotting has 
proven unreliable. Next, I would ascertain the effects of adding an ERK inhibitor (U0126) 
to the assay to confirm whether ERK signalling is involved. It would also be interesting to 
measure superoxide activity as a measure of oxidative stress and assess the effects of N-254 
acetylcysteine or tempol on collagen 1 gene expression in Aldo/sodium treated cells. It 
would be useful to study the role of intracellular regulatory pathways including SGK1. 
SGK1 promotes ENaC phosphorylation and increases the probability of ENaC being open, 
promoting sodium retention. It also promotes Nedd 4-2 phosphorylation, inhibiting Nedd 
4-2:ENaC binding, thus preventing channel internalisation and degradation.  
There are a number of limitations to this study. It would have been optimal to quantify the 
production of the collagen 1 protein, in order to confirm that increased gene expression 
was translated into protein formation. Also, whilst HK-2 cells respond to Aldo, it would be 
useful to confirm these findings in a more traditional Aldo target cell i.e. the distal tubular 
epithelium. Studies are however limited by the lack of an appropriate human distal tubular 
cell line or available primary renal tissue. The lack of a pro-inflammatory response seen 
may simply reflect the cytokines measured and perhaps a panel approach to cytokine 
measurement, allowing a wider array of cytokines to be tested, might have been of use. 
Also, the ELISAs used required quite substantial dilutions of cell culture supernatant 
which might have introduced error. The lack of a positive control for TGFB1 production 
by HK-2 cells means that it cannot be excluded that these cells simply do not produce 
TGFB1. Lastly, studies have shown conflicting effects of Aldo on cell proliferation and 
apoptosis and it would have been beneficial to determine its effects, and indeed those of 
sodium, on HK-2 cells under my study conditions. 255 
8  Chapter Eight: General discussion  256 
8.1  Summary of findings 
The aims of this thesis were to assess mineralocorticoid status in patients with chronic 
kidney disease and ascertain whether levels of these molecules, in association with sodium 
status, were associated with negative prognostic features. The main findings were: 
  A novel relationship exists between urinary sodium and urinary mineralocorticoid 
excretion in patients with CKD. High levels of urinary THDOC and THALDO 
excretion are associated with high urinary sodium excretion.  
  Urinary THDOC excretion is independently associated with LVMI and THALDO 
excretion is independently associated with proteinuria in patients with CKD. 
  Factors associated with LV mass differ between patients with CKD and patients 
with EH. 
  Vascular function is not directly associated with mineralocorticoid status in patients 
with CKD. 
  Excretion of urinary sodium, normalised to urinary creatinine, is associated with an 
increased mortality risk but not RRT risk in patients with CKD. 
  Human proximal tubular cells in a high sodium environment respond to steroid 
stimulation by increasing collagen 1 gene transcription, a response which is 
inhibited by blockade of the mineralocorticoid receptor. 
8.2  Strengths of these studies 
Patients recruited to the clinical studies were very closely phenotyped. The usage of CMR 
enabled the most accurate determination of left ventricular mass available. Measurement of 
urinary steroid metabolites is the most accurate reflection of 24h steroid status, removing 
the inaccuracies of a spot plasma sample, and has not previously been reported in patients 
with CKD. The usage of these two methods in particular and a comparator group of 
patients with EH, provide a unique opportunity to study the regulation of MC production 
and interactions between steroids, the kidney, the heart and vasculature in patients with 
CKD. This, in the context of the laboratory and retrospective cohort studies, has resulted in 
a number of novel findings which deserve further attention.  257 
8.3  Sodium excretion in CKD 
In order to understand the interaction between mineralocorticoids and sodium in patients 
with CKD, it was important to study sodium excretion in these patients. Historically 
patients with uraemia have been shown to have elevated total body sodium. Chapter 3 
demonstrated in a large cohort with extensive prospective follow-up a number of key 
findings. Firstly, urinary sodium excretion falls with advancing renal failure, but only once 
patients reach CKD 5. The kidney compensates for declining nephron mass by increasing 
fractional excretion of sodium, presumably via increased single nephron GFR. Whether 
patients reduce dietary sodium intake with advancing renal disease or whether the kidney 
loses its ability to excrete the sodium load, resulting in increased total body sodium is 
unclear. What was shown however is that urinary sodium excretion, when normalised to 
urinary creatinine, was an independent predictor of mortality but not of requirement for 
RRT, suggesting that the negative effects of sodium may be more related to cardiac or 
vascular effects rather than direct renal effects. Adjustment for urinary creatinine likely 
compensates for muscle mass and loss of tubular secretion with advancing CKD. This 
association with mortality has not previously been shown in a CKD population and lends 
support to the need for long-term trials assessing the benefits of dietary sodium reduction 
in CKD.  
8.4  Mineralocorticoids in CKD 
Chapter 4 describes a number of novel associations which address the ambiguity regarding 
mineralocorticoid status in CKD. Absolute levels of mineralocorticoid excretion did not 
differ between patients with EH and patients with CKD. It had previously been thought 
that aldosterone levels increase in CKD, for reasons that remain inadequately explained. 
This assumption largely derives from historical cohorts and relates to very low levels of 
renal function, rather than patients with CKD 3 or 4. It has however been shown in this 
thesis that in a cross-sectional cohort of patients with CKD3 or 4, aldosterone levels do not 
correlate with level of renal function. Similarly, levels were not higher in patients with 
diabetes. It should be noted however that CKD patients are presumed to have intravascular 
volume expansion and had significantly higher plasma potassium, therefore although 
steroid levels are not increased, this may be inappropriate as they should perhaps be 
suppressed if normal physiological principles applied. 258 
Despite similar levels of plasma and urinary steroids in EH and CKD, physiological 
principles appear to be unexpectedly altered in patients with CKD. Strikingly, the strongest 
determinant of urinary THALDO and THDOC excretion in these patients was urinary 
sodium excretion, a reflection of dietary sodium intake. This relationship was not seen in 
patients with EH. Furthermore, plasma renin concentration (a surrogate for angiotensin II), 
cortisol metabolite excretion (a surrogate for ACTH) and serum potassium, all traditional 
regulators of mineralocorticoid synthesis and excretion, were not significantly associated 
with urinary steroid excretion in CKD. 
Sodium and aldosterone are intrinsically linked – sodium is responsible for intravascular 
volume status. Reduced intravascular volume stimulates aldosterone production via the 
renin-angiotensin system. In the distal tubule aldosterone acts via the MR to stimulate 
ENaC opening, promoting sodium retention; and to a lesser degree via the NaH exchanger, 
with hydrogen ion loss and sodium retention.  Concurrently the ROMK channels extrude 
potassium. Are the findings described in chapter 4 a reflection of altered aldosterone action 
in the distal tubule of CKD, or is steroid production by the adrenal cortex altered in CKD? 
Deeming the relationship to be a factitious reflection of renal leak seems unlikely and the 
size of the THALDO molecule means it should be freely filtered at the glomerulus. 
Our studies show that high THALDO excretion is associated with high urinary potassium 
excretion, supporting the idea that aldosterone is still acting in the distal tubule in its 
traditional role. Alteration of ENaC function, resulting in sodium being excreted rather 
than retained in response to aldosterone, would seem unlikely, in that this would affect the 
electrochemical gradient in the tubule. It therefore seems more likely that the abnormality 
relates to the adrenal cortex and the stimuli or environment for aldosterone production.  
It is possible that dietary sodium intake overwhelms renal sodium excretion in patients 
with CKD. Even a very small excess of intake would over time result in very significant 
sodium overload. Non-osmotic storage in the lymphatics is possible, however the 
likelihood is that sodium overload promotes intravascular volume overload, impaired 
baroreceptor sensitivity and loss of sympathetic inhibition of aldosterone release. Sodium 
overload also likely promotes oxidative stress. This, in the context of a uraemic milieu and 
mild acidosis, may alter sensitivity of the adrenal cortex to its usual stimuli, promoting 
aldosterone release perhaps in an attempt to normalise pH or potassium.  259 
An alternative is that other stimuli such as endothelin take on a more prominent role in 
CKD. ANP is an inhibitor of aldosterone secretion, but levels of ANP increase in CKD. Or 
perhaps aldosterone and deoxycorticosterone production from extra-adrenal sites (such as 
the heart and kidney) increases in CKD and is regulated differently, but plasma aldosterone 
levels fall to almost zero post-adrenalectomy, so it is unlikely that we are detecting extra-
adrenal synthesis. Therefore this is a novel relationship which remains unexplained and 
deserves further study (Figure 8-1). 260 
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Figure 8-1: Potential relationship between sodium, steroids and negative effects (highlighted in red). 
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8.5  Adverse effects of mineralocorticoids 
Regardless of the determinants of mineralocorticoid synthesis, we demonstrated that 
absolute levels of tetrahydrodeoxycorticosterone excretion were independently associated 
with LVMI (chapter 5) and tetrahydroaldosterone excretion with proteinuria excretion 
(chapter 4) – both significant predictors of mortality in the CKD population. These 
associations have not previously been reported. A synergistic interaction between steroids 
and sodium, such as has been reported in animal studies, was seen. This is of importance in 
that present methods of addressing cardiovascular risk and the elevated mortality 
associated with chronic kidney disease are inadequate. These findings support the usage of 
MR blockade, the only intervention found to reduce LV mass in CKD, in patients with 
CKD to reduce cardiovascular and renal risk and this should be the subject of large clinical 
trials. 
Chapter 6 demonstrated that mineralocorticoids do not appear to be directly associated 
with vascular function in patients with CKD or patients with EH. This is surprising given 
that the vascular endothelium expresses the MR, that aldosterone is known to have direct 
effects including vasoconstriction and that MR blockade was shown to reduce pulse wave 
velocity. It may be that due to the ‘real world’ conditions of the study, the influence of 
mineralocorticoids on the vasculature (large or small vessel) could not be seen due to 
concomitant medications. An association was seen between high urinary sodium and poor 
endothelial function in patients with CKD, strengthening the evidence of an independent 
negative effect of sodium.  
Chapter 7 extends the extensive work done demonstrating pathological effects of 
aldosterone. In human proximal tubular cells, MR binding, regardless of ligand, resulted in 
increased collagen 1 gene expression, but  and only in a high sodium environment. The 
effects were blocked by an inhibitor of the MR, confirming the involvement of the MR. 
This finding supports previous studies highlighting a profibrotic role for aldosterone and 
MR receptor binding, whilst extending these findings to include a novel cell line under 
differing sodium conditions. 
8.6  Limitations of these studies 
There are limitations in these studies. Cross-sectional studies cannot assume causality and 
associations can only be reported as such. The small patient groups limit extensive 262 
subgroup analysis and limit identification of relationships such as that between steroids, 
sodium and LV mass. Patients were not advised to discontinue their usual medications and 
as such drug effects may alter or disguise relationships. Urinary sodium intake was 
determined by 24h excretion. This is widely accepted as the gold standard measure of 
dietary sodium intake, however it is not a measure of whole body sodium. 24h blood 
pressure monitoring was undertaken in a minority and was closely related to clinic blood 
pressures, however the majority of patients were reluctant to undertake this investigation in 
addition to the 24h urine collection. GFR was estimated using validated equations, 
however measurement of true GFR would have been useful. Similarly, we measured total 
proteinuria rather than albuminuria and this additional information may have provided 
further insight.  263 
8.7  Future studies 
A physiological study of adrenal aldosterone response to traditional stimuli of AgII, ACTH 
and potassium infusion in patients with CKD off medication would be beneficial. It would 
also be interesting to confirm whether or not the normal diurnal variation in aldosterone 
levels, a reflection of ACTH, exists in patients with CKD.  
In order to interpret the steroid abnormalities further, it would be useful to have an 
objective assessment of body fluid status, for example utilising bioelectrical impedence 
analysis. A measure of total body sodium, for example via MRI 
23Na spectroscopy or 
24Na 
exchangeable sodium, would also inform the interpretation of whether patients with CKD 
are chronically sodium overloaded and whether this relates to adrenal steroid release in the 
same way that urinary sodium excretion does. Assessment of markers of oxidative stress 
and WNK production and correlation with measures of sodium status and aldosterone 
production would also be of interest.  
The finding that determinants of LV mass differ between patients with CKD and patients 
with EH suggest that it would be worthwhile expanding the cohort to include patients with 
less advanced renal impairment to establish at what stage these differences develop. DOC 
excretion associated more closely with LVMI than Aldo in patients with CKD, suggesting 
that further study of this mineralocorticoid, which has been largely overlooked until now, 
is warranted. What effects does DOC have on the myocardium?   
A comparison of EndoPAT and brachial artery flow mediated dilatation in patients with 
CKD would be useful in order to validate the technique more thoroughly in patients with 
CKD.  
All patients recruited into the study consented to longitudinal follow-up and it will be of 
interest to determine whether steroid excretion rates correlate with renal and patient 
survival and cardiovascular events. 
Follow-up studies to the laboratory work are extensively discussed in chapter 8. Further to 
this, in vitro assessment of adrenal cortical cells cultured in a high sodium ‘uraemic’ milieu 
would be of interest in terms of aldosterone and deoxycorticosterone production.  264 
8.8  Conclusions 
  Urinary steroid excretion, an integrated measure of steroid status, is not elevated in 
moderate CKD as compared with patients with EH. 
  Patients with diabetic nephropathy do not exhibit RAAS overactivation, compared 
with primary renal diseases. 
  Determinants of urinary steroid excretion differ between patients with CKD and 
patients with EH, suggesting that stimulation of aldosterone production differs in 
the context of uraemia. 
  Around half of patients with CKD 3/4 have left ventricular hypertrophy despite 
reasonable blood pressure control. 
  Urinary tetrahydrodeoxycorticosterone excretion, in addition to male gender and 
systolic blood pressure, is significantly associated with LVMI, unlike in EH where 
plasma aldosterone concentration is the significant independent predictor. 
  Urinary tetrahydroaldosterone excretion is independently associated with 
proteinuria excretion in patients with CKD. 
  An interaction was seen between high urinary steroid excretion, high urinary 
sodium excretion and proteinuria and LVMI. 
  Pulse wave velocity is higher in patients with diabetic nephropathy and is 
predominantly determined in CKD by pulse pressure, age and waist circumference.  
  Urinary sodium excretion was associated with endothelial dysfunction in patients 
with CKD and pulse wave velocity in patients with EH, supporting a negative role 
for sodium in the vasculature. 
  A high urinary sodium:creatinine ratio is independently associated with risk of 
death in patients with CKD. 265 
  Co-culture of human proximal tubular cells with aldosterone and sodium is 
associated with upregulation of collagen 1 gene synthesis, an effect which is 
inhibited by blockade of the mineralocorticoid receptor. 
  These studies support a role for mineralocorticoids in the adverse phenotype seen in 
CKD and suggest that further study of MR ligands and blockade should be 
undertaken. 
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9.2  Supplementary material 
1.  Patient consent form 
2.  Patient information sheet 
3.  GP letter regarding patient participation. 
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CONSENT FORM 
 
          Please initial each box to show that you have read and understood each 
point. 
 
1.  I confirm that I have read and understand the information sheet dated 17.11.2008, version 2.0, 
for the above study, that I have had the opportunity to ask questions and that I have received 
satisfactory answers to the questions that I have asked 
 
2.  I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected. 
 
3.  I  understand  that  sections  of  any  of  my  medical  notes  may  be  looked  at  by  responsible 
individuals from the North Glasgow NHS University Trust where it is relevant to my taking part 
in research.  I give permission for these individuals to have access to my records. 
 
4.  I understand that personal information about me including information about my health will be 
collected and processed as part of the study and I consent to this. 
 
5.  I understand that data about me as collected for this study including information about my 
health may be passed to other members of the Study team. I understand that information that 
may identify me will be removed before any data leaves the (Western Infirmary, Glasgow). I 
give my consent for this to happen. 
 
6.  I understand that blood and urine will be frozen and stored in Glasgow as required for further 
analysis in relation to this study and I give my consent for this to happen. 
 
7.  I consent to my blood being stored for genetic testing. This will be anonymous and I will not be 
identified. 
 
8.  I understand that my G.P will be informed that I am taking part in this study. I give my consent 
for this to happen. 
 
9.  I agree to take part in the above study. 
 
 
 
________________________  _________________________ 
  _______________ 
Name of Patient  Signature    Date   
 
 
_________________________  _________________________ 
  _______________ 
Name of Person taking consent  Signature    Date 
(if different from researcher) 
 
 
_________________________  ___________________________
  _______________ 
Researcher  Signature    Date     
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Patient information sheet 
 
Renal Research Group 
British Heart Foundation Cardiovascular Research Centre /  
Western Infirmary 
University of Glasgow, G12 8TA 
 
You are being invited to take part in a research study. Before you decide, it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully. Talk to others 
about the study if you wish. 
  Part 1 tells you the purpose of this study and what will happen to you if 
you decide to take part. 
  Part  2  gives  you  more  detailed  information  about  the  conduct  of  the 
study. 
Ask us if there is anything that is not clear or if you would like more information. 
Please take your time to decide whether or not you wish to take part. 
 
Part 1 
What is the purpose of the study? 
Factors  which  predict  the  progression  of  kidney  disease  include  high  blood 
pressure  (hypertension)  and  protein  in  the  urine  (proteinuria).  The  role  of 
aldosterone (a hormone produced by the adrenal gland) in hypertension has 
become  appreciated  in  the  last  decade.  Our  principal  research  question  is 
whether  the  level  of  aldosterone  produced  by  the  body  influences  kidney 
damage and hence progression of kidney disease, and whether this influence 
is via mechanisms related to salt intake and proteinuria. We would also like to 
study  the  relationship  between  the  stiffness  of  the  blood  vessels  in  the 
circulation and aldosterone levels, proteinuria and outcome. 
 
Why have I been chosen? 
You have high blood pressure and normal kidney function or you have kidney 
disease secondary to diabetes, IgA nephropathy or membranous nephropathy. 
 
Do I have to take part? 270 
No. It is up to you to decide whether or not to take part. If you do, you will be 
given this information sheet to keep and be asked to sign a consent form. You 
will  still  be  free  to  withdraw  at  any  time  in  the  future  and  without  giving  a 
reason. A decision to withdraw at any time, or a decision not to take part, will 
not affect the standard of care that you receive. 
 
What will happen to me if I take part? 
If you take part, you will be asked to undertake a series of tests. These all take 
place  on  the  one  study  visit.  Following  this  study  visit  no  further  tests  are 
required but we will study your progress during your usual follow up visits via 
the renal clinic electronic patient record (EPR) which is already routinely used 
for standard out patient appointments.  The detailed study visit takes about 2 
hours in total. If required we will provide transport to and from your home for 
the visit.  
 
What do I have to do? 
Study Visit 
You will be asked to have the following tests:  Blood pressure measurement, 
weight, height and waist measurement, a physical examination and a blood 
test (this will be taken from your arm in the usual fashion).  Approximately 40 
mL of blood will be taken equating to three tablespoons. These blood samples 
will be for analysis of aldosterone and related hormones in the blood. Like any 
other blood test this may cause a little discomfort and occasionally bruising. 
You will be asked questions about the drugs you are currently taking and your 
medical history. We will perform an electrocardiograph to look at your heart. 
This will take 5 minutes and involves stickers being placed on your chest and 
arms and a recording taken. 
 
  We would like to examine the stiffness of your arteries.   
For this purpose we will measure how fast the pulse travels through your 
body from the heart to the groin. This involves measurement of the pulse 
with a pencil-like probe which is placed to your neck and to your groin for 
each about 1 minute. In parallel we will look at the electrical activity of your 
heart with an electrocardiograph. 271 
  We would like to examine the consequences of stiff arteries for your heart.  
This examination again involves assessment of your pulse with a pencil-like 
probe. It is carried out at the artery at your wrist and takes 1 to 2 minutes. 
At the same time we will measure your blood pressure with a cuff as known 
to you from your GP. We can then calculate the pulse waveform and the 
blood pressure in the large arteries close to your heart. 
  We would like to examine the function of your arteries.   
For this test we use again the pencil-like probe to measure the pulse at your 
wrist. We will perform a few readings to make sure that the signal is stable. 
You would then receive two puffs of glycerol trinitrate (GTN) spray under 
your  tongue.  This  spray  makes  blood  vessels  wider  and  is  therefore 
commonly used to treat chest pain. We will measure changes in the pulse 
waveform  in  response  to  this  test.  You  would  then  inhale  two  puffs  of 
salbutamol spray which may be known to you as a spray against asthma 
and chronic bronchitis. GTN spray can cause a headache after it is given, 
and lower the blood pressure. Salbutamol can cause a temporary tremor. 
Again we will measure the pulse waveform. Because we must be sure to 
have stable signals both before and after administration of the sprays this 
part of the study may take up to 30 minutes.   
Alternatively  we  may  examine  blood  flow  in  your  fingers. We  will  use  a 
standard blood pressure cuff to block the blood flow to your forearm for 5 
minutes.  This  may  cause  some  numbness  of  your  forearm  which 
disappears shortly after release of pressure of the cuff. Blood flow in your 
fingers will be measured before, during and after the 5-minutes block with 
probes on your left and right index finger. This test takes about 25 minutes 
in total. In patients with blood vessel disease of their arms (e.g. Raynaud's 
disease) we would not perform the test involving blocking blood flow to the 
arm for 5 minutes. 
  We would like to assess your heart function with a MRI scanner - CMR 
Scan – this involves lying on a table as it passes through a large circular 
magnetic resonance scanner.  This does not involve any X-rays.  However, 
the scan may be noisy and may rarely cause claustrophobia.  Your blood 
pressure will be measured during the scan which will take approximately 25 
mins in total.   272 
  Both before and following these tests we will ask you to perform a 24 hour 
collection  of  urine.  You  will  receive  containers  to  collect  your  urine 
specimens and can leave to return the following day with the sample. 
  We  will  also  ask  you  to  wear  a  blood  pressure  monitor  for  24  hours  at 
home. This involves wearing a blood pressure cuff around your arm and a 
small  portable  recorder  on  your  belt.  You  should  go  about  your  daily 
activities as normal, except showering or taking a bath whilst wearing it. 
The  monitor  takes  your  blood  pressure  every  20  minutes  and  hourly 
overnight. Your sleep may be disrupted as the cuff inflates. This method 
gives us a very accurate measure of your normal blood pressure. 
  Following this visit no further specific study visits are required but we will 
continue to monitor you blood pressure, weight and kidney function when 
you routinely attend the out patient clinic. 
 
Your doctor will be informed of your participation in this study.  
 
What are the possible disadvantages and risks of taking part? 
We have taken every step in the design of this study to minimise any possible 
disadvantages and risks.  We will take blood samples and perform intravenous 
cannulation which can cause bruising and swelling and may be slightly painful. 
We will do our utmost to ensure that the urine collection is collected at a time 
that is most convenient for you  
 
What are the possible benefits of taking part? 
The study may not benefit you directly, but the information we receive may help 
us to understand mechanisms involved in progression of kidney disease. 
 
What happens when the research study stops? 
We  would  ask  your  permission  to  store  your  blood  and  urine  samples  (in 
anonymised form) in the University of Glasgow so that we can consider them 
for use in future research studies that we may carry out. (Any future use of the 
samples would require the approval of a Research Ethics Committee for that 
project).  
 
Part 2 273 
What if relevant new information becomes available? 
If  any  clinically  significant  information  comes  to  light  as  a  consequence  of 
taking part in this study, we will inform your GP (with your permission). 
 
What will happen if I don’t want to carry on with the study? 
You can withdraw from the study at any time without having to give a reason.  
However,  we  would  ask  your  permission  to  use  any  information  collected 
during the time of your participation for research purposes. Any stored blood or 
urine samples that can be identified as yours will be destroyed if you wish. 
 
What if there is a problem? 
Complaints: If you have a concern about any aspect of this study, you should 
ask  to  speak  with  the  researchers  who  will  do  their  best  to  answer  your 
questions. If you remain unhappy and wish to complain formally, you can do 
this  through  the  NHS  Complaints  Procedure.  In  the  event  of  a  complaint 
contact the NHS: 
Complaints Office, 
Western Infirmary, 
Dumbarton Road, 
Glasgow G11 6NT 
Tel: 0141 211 2257 or 2926  
Harm: In the event that something does go wrong and you are harmed during 
the research study, there are no special compensation arrangements. If you 
are  harmed  and  this  is  due  to  someone’s  negligence,  then  you  may  have 
grounds for a legal action for compensation against the University of Glasgow 
or NHS Research and Development, but you may have to pay for your legal 
costs. The normal National Health Service complaints mechanism will still be 
available to you. 
 
Will my taking part in this study be kept confidential? 
Yes. All information which is collected about you during the course of the 
research will be kept strictly confidential.  It may have been your GP who 
contacted you about this study initially, but if we contacted you directly throught 
the hospital clinic, we would like to inform your GP of your involvement in the 274 
study and will ask for your permission to do this.  All other information about 
you which leaves the hospital will have your name, address and date of birth 
removed so that you cannot be recognised from it.  
 
What will happen to any samples I give? 
A portion of the blood samples will be analysed immediately by the Department 
of Biochemistry at Gartnavel Hospital. The remainder of the  blood samples, 
along with the urine samples, will be transferred to the University of Glasgow 
for  analysis. The  samples  will be  analysed in  the  University  of Glasgow  by 
various  biochemical  techniques  in  order  to  measure  the  levels  of  certain 
‘markers’. The samples will be anonymised so that you will not be identifiable 
from them.  
 
Will any genetic tests be done on the samples that I give? 
Yes we will use some of your blood sample for genetic testing.  Following this 
current study, we would ask your permission to store any remaining samples 
so that we may consider them for use in future research studies that we may 
carry out (if a local Ethics Committee deems the study appropriate). Genetic 
samples will be stored in a coded fashion, to prevent identification of samples 
by third parties.  Genetic samples will not identify individual patients.    Any 
results from the planned or future genetic studies will not have any healthcare 
implications for you and hence we would not normally feed these results back 
to you. 
 
What will happen to the results of the current research study?  
The  results  of  this  study  will  be  published  in  medical  journals,  reports  and 
textbooks. You will not be identifiable in any publication or report. The reports 
will be stored for 6 years at The University of Glasgow. 
 
Who is organising and funding the research? 
The research is being organised and sponsored by the University of Glasgow.  
 
 
Who has reviewed the study? 
This study has been given a favourable ethical opinion for conduct in the NHS 
by West Glasgow Research Ethics Committee.  275 
 
Contact details 
You may contact me (one of the Principal Researchers) directly by telephoning 
0141  211  1867  for  further  information  at  any  time.  Alternatively,  you  may 
contact Dr Neal Padmanabhan, Consultant Nephrologist who is acting as an 
independent advisor – contact 0141 211 2178. 
Many thanks for taking the time to read this information. 
Dr Patrick Mark 
Department of Medicine 
The University of Glasgow 276 
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Investigators – Prof J Connell, Prof A Jardine 
 
                British Heart 
Foundation Cardiovascular Research Centre 
126 University Place 
Glasgow 
G12 8TA 
Dear Doctor, 
Re: 
Name 
Date of Birth 
Your patient attended today to take part in a study to evaluate markers of 
progression of renal disease. They were recruited from the renal clinic at the 
Western Infirmary. The study involves taking basic anthropometry, urine and blood 
samples. These are for baseline biochemistry and novel markers. Blood is taken for  
DNA analysis, which is anonymised. They also underwent tests to look at 
endothelial function, pulse wave analysis and cardiac MR scanning.  
As these tests are predominantly for research purposes we do not plan to send a 
report of these. However, should you wish to obtain further information please do 
not hesitate to contact myself, Professor Jardine or Professor Connell on 0141 330 
2723. 
Yours sincerely, 
  Dr. Emily McQuarrie 
  Clinical Research Fellow 
  BHF CVRC 
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